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 Growth hormone (GH) regulates overall body growth and metabolism and is used 
therapeutically for a variety of clinical applications.  GH binding to its receptor activates 
the tyrosine kinase, JAK2.  Active JAK2 initiates multiple cellular responses to GH, 
including regulation of the cytoskeleton, that lead to cellular proliferation, differentiation 
and migration.  Recent studies questioned whether JAK2 is the primary kinase 
responsible for transducing all GH signals.  This thesis establishes that JAK2 is the 
primary kinase responsible for GH-mediated activation of Stat1, Stat3, Stat5, ERK1/2 
and Akt in two established models of GH signaling, 3T3-F442A preadipocytes and H4IIE 
hepatoma cells.  This work also characterizes two novel mechanisms by which the 
adaptor protein, SH2B1, may modulate GH-induced regulation of the actin 
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cytoskeleton.  The cytoskeleton scaffolding protein, II-spectrin, was identified as an 
SH2B1 interacting protein.  JAK2 was found to phosphorylate II-spectrin in an 
SH2B1-dependent manner.  GH induced formation of a II-spectrin/SH2B1/JAK2 
complex in 3T3-F442A cells and induced a shift in II-spectrin subcellular localization in 
H4IIE cells.  These results suggest that GH may regulate the cytoskeleton through an 
SH2B1/II-spectrin interaction.  SH2B1 was also found to localize to focal adhesions, 
which are cytoskeletal structures that regulate cell anchorage and motility.  GH 
increased the dynamic cycling of SH2B1 into and out of focal adhesions.  In addition, 
PMA induced redistribution of SH2B1 out of focal adhesions.  Two serines within 
SH2B1 (serines 161 and 165) were implicated in regulating this PMA effect as well as 
the dynamic cycling of SH2B1 into and out of focal adhesions.  Mutation of SH2B1 
serine 165 to glutamate also increased the overall focal adhesion number in cells.  
These results implicate SH2B1 as a novel focal adhesion protein and suggest that 
stimuli that induce phosphorylation of SH2B1 at serines 161 and/or 165 regulate 
SH2B1 dynamics at focal adhesions and may contribute to the regulation of overall 
focal adhesion number.  Taken together, the work in this thesis demonstrates that GH 
activates downstream signaling through JAK2 in 3T3-F442A and H4IIE cells.  This work 
also provides evidence that GH regulates the cytoskeleton through an SH2B1/II-










Growth hormone (GH) is a major regulatory factor of overall body growth as 
evidenced by the height extremes in people with abnormal circulating GH levels or GH 
receptor (GHR) disruptions.  GH also affects metabolism, cardiac and immune function, 
mental agility and aging.  Currently, GH is being used therapeutically for a variety of 
clinical conditions including promotion of growth in short statured children, treatment of 
adults with GH deficiency and HIV-associated wasting.  At the cellular level, GH either 
directly or indirectly elicits a variety of responses depending on cell type and context.  
These responses include cellular differentiation of epiphyseal prechondrocytes into 
chondrocytes and 3T3-F442A preadipocytes into mature adipocytes, chemotaxis of 
monocytes, and migration and proliferation of models of breast and endometrial cancer.  
To help reveal previous unrecognized functions of GH, better understand the known 
functions of GH, and avoid adverse consequences that are often associated with 
exogenous GH administration, careful delineation of the molecular mechanisms whereby 
GH induces its diverse effects is needed.  
 
Growth Hormone Signal Transduction 
GH is a peptide hormone that is secreted into the circulation by the anterior 
pituitary and acts upon various target tissues expressing GHR.  GH binding to GHR 
activates the tyrosine kinase Janus kinase 2 (JAK2), thus initiating a multitude of 
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signaling cascades that result in a variety of biological responses including cellular 
proliferation, differentiation and migration, prevention of apoptosis, cytoskeletal 
reorganization and regulation of metabolic pathways.  A number of signaling proteins 
and pathways activated by GH have been identified, including JAKs, signal transducers 
and activators of transcription (Stats), the mitogen activated protein kinase (MAPK) 
pathway, and the phosphatidylinositol 3’-kinase (PI3K) pathway.  Although these signal 
transduction pathways have been well characterized, the manner by which GH activates 
these pathways, the downstream signals induced by these pathways, and the cross-talk 
with other pathways are not completely understood. 
 
GH receptor dimerization and activation 
The downstream signaling pathways mediated by the GHR are initiated upon the 
binding of GH to the extracellular domain of the GHR (Fig. 1.1A).  Early analysis of the 
extracellular domain of GHR in association with GH indicated that one GH molecule 
binds sequentially to two GHR molecules (1).  Formation of this GH-GHR2 trimer 
complex was thought to be necessary and sufficient for GH responses (1).  However, 
other studies indicated that dimerization of the GHR was insufficient for activation of GH-
mediated signaling (2) and that preformed GHR dimers exist prior to GH binding (3).  
These findings, along with newer results from tests of GHR activation, lay the 
groundwork for a revised model of GHR activation.  A recent study (4) confirmed that 
unliganded GHR exists as a dimer, using co-immunoprecipitation, fluorescence 
resonance energy transfer (FRET), bioluminescence resonance energy transfer (BRET), 
and X-ray crystallography of the extracellular domain of GHR.  Only minor differences 
were observed between the crystal structures of the liganded and unliganded GHR 
extracellular domain dimers.  However, inducing a nominal 40° clockwise rotation in the 
lower -helical transmembrane sequence by insertion of alanine residues or a nominal 
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100° clockwise rotation in the juxtamembrane helix of GHR just N-terminal of the Box 1 
domain containing the JAK2 binding site resulted in constitutive activation of JAK2 and 
Stat5.  From these and other findings, Brown et al. (4) suggested a model whereby GH 
binding asymmetrically at the receptor binding sites of preformed GHR dimers causes 
the intracellular domains of the GHR to undergo relative rotation.  Because the 
cytoplasmic domain of each GHR molecule is thought to bind a single JAK2 molecule, 
this rotation is postulated to bring two JAK2 molecules into sufficient proximity to allow 
each JAK2 molecule to phosphorylate the activating tyrosine residue in the kinase 
domain on the other JAK2 molecule, thereby activating JAK2.  Since GH binding has 
also been reported to increase the co-immunoprecipitation of JAK2 with GHR (5), the 
GH-induced conformational change in GHR may also increase the stability of the GHR-
JAK2 interaction.  More recently, Yang et. al  (6) provided evidence using GHR 
truncation and point mutants and GHR-low density lipoprotein receptor (LDLR) chimera 
receptors suggesting that the dimerization interface is the main contributor to GHR 
predimerization rather than the length of the receptor transmembrane domain.  However, 
they also found that GHR-LDLR receptor chimeras were less sensitive to inhibition of 
GH signaling by a GHR antibody and less sensitive to induced receptor metalloprotease 
cleavage.  Therefore, they concluded that the longer transmembrane domain of the GHR 
compared to the GHR-LDLR receptor chimera does provide added sensitivity to GH-
induced JAK2 activation and presumably, downstream signaling.  Finally, in a 
subsequent study, this group presented data in opposition to the prevailing theory that 
one GH molecule containing two asymmetric binding sites binds one GHR dimer (6).  
Here, Yang et. al showed GHR and JAK2 activation in response to recombinantly 
produced GH-GH and G120R-G120R dimers.  G120R is a naturally occurring GH 
mutant lacking one GHR binding site, rendering the molecule unable to activate GHR-
mediated signaling (Reviewed in (7)).  This study showed that even though G120R-
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G120R molecules contain only one of the two known GHR asymmetric binding sites, the 
dimer molecule was still able to activate JAK2 and Stat5.  While the physiological 
significance of this study remains in question, these results, along with the studies 
describing new models of GHR dimerization and activation, are suitable reminders that 




Figure 1.1 Signal transduction pathways induced by growth hormone.   
(A) GH binds a GHR dimer, inducing a conformational change that activates two JAK2 
molecules.  (B) JAK2 activation induces JAK2 autophosphorylation and JAK2 
phosphorylation on multiple GHR tyrosines.  GH-activated JAK2 also phosphorylates 
and activates multiple signaling proteins and pathways including  (C) Stats,  (D) IRS and 
PI-3 kinase and  (E) MAPK.  (F) The binding of GH to GHR may also activate Src 




GH signal transduction via JAK2 
Activation of JAK2 is thought to be the key step in initiating GH signaling (5). The 
FERM domain of JAK2 is thought to mediate JAK2 binding to the cytoplasmic Box 1 
region of GHR (8-10).  Following GH activation of JAK2, JAK2 autophosphorylates 
multiple tyrosines (11, 12) and subsequently phosphorylates multiple tyrosine residues in 
GHR (13, 14) (Fig. 1A).  Based upon JAK2 overexpression systems, some of the 
autophosphorylation sites in JAK2 appear to be regulatory sites since mutating them has 
been shown to either stimulate (e.g. tyrosine 119, 570) or decrease (e.g. tyrosines 221, 
972, 1007) JAK2 activity (11, 15-18).  For some of those tyrosines, phosphorylation is 
thought to cause a conformational change in JAK2 that alters JAK2 activity.  For 
example, phosphorylation of tyrosine 1007 is thought to expose the substrate and/or 
ATP binding sites (15) whereas phosphorylation of tyrosine 119 is thought to promote 
dissociation of JAK2 from its associated cytokine family receptor (18).  
Autophosphorylation of some tyrosines are alternatively or additionally thought to 
regulate JAK2 activity indirectly by recruiting regulatory proteins to JAK2.  For example, 
phosphorylated tyrosine 1007 has also been shown to bind the negative regulators of 
cytokine signaling SOCS1 (19), SOCS3 (20) and the phosphatase PTP1B (21) 
(discussed in more detail below).  Autophosphorylation of tyrosine 813 appears to 
enhance JAK2 activity as a consequence of recruiting the adaptor protein, SH2B1 (also 
known as SH2-B or PSM1) (12).  SH2B1 has been hypothesized to either stabilize the 
active conformation of JAK2 (22) or promote the dimerization of JAK2 (23).  Some of the 
autophosphorylation sites in JAK2 (e.g. tyrosine 966 (24)) as well as the phosphorylated 
tyrosines in GHR, are thought to serve as docking sites for signaling molecules 
containing Src homology 2 (SH2) or phosphotyrosine binding (PTB) domains.  Based on 
mutational studies, 7 different tyrosines within the cytoplasmic domain of the GHR have 
been implicated in at least one downstream GH response (reviewed in (25)).  For 
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example, 5 or 6 phosphorylated tyrosines in GHR have been hypothesized to bind 
Stat5a and Stat5b, based upon decreased GH-dependent Stat5 tyrosyl phosphorylation 
or Stat5-dependent responses in cells expressing mutated or truncated GHR (13, 14, 
26-28).  Recruitment of these signaling molecules to GHR-JAK2 complexes and their 
activation allows GH to elicit diverse biological and physiological effects.  A number of 
signaling proteins and pathways are thought to be initiated at least in part as a 
consequence of binding to activated GHR-JAK2 complexes (reviewed in (25, 29)). 
Examples include pathways involving Stats 1, 3, 5a and 5b, the MAPK pathway, and the 
phosphatidylinositol 3’-kinase (PI3K) pathway (Fig. 1.1B and C). 
 
GH signal transduction via Src tyrosine kinase 
One of the more interesting recent developments in GH signaling is support for 
the hypothesis that not all GH signaling events lie downstream of JAK2.  Zhu et al. (30) 
provide evidence using both pharmacological inhibitors and kinase inactive proteins in 
NIH3T3 cells that the tyrosine kinase Src is activated by GH independent of JAK2.   
Using the same reagents, the same group reported that full activation of the Ras-like 
small GTPases RalA, RalB, Rap1 and Rap2 by GH requires both c-Src and JAK2 (30, 
31) (Fig. 1.1C) whereas activation of Stat5 requires only JAK2.  Activation of RalA by GH 
was linked to increased phospholipase D activity and the formation of its metabolite, 
phosphatidic acid, which were in turn linked to GH-activation of extracellular regulated 
kinases (ERKs) 1 and 2 and subsequent Elk-1-mediated transcription (30), suggesting 
that GH activation of ERKs 1 and 2 is at least partially dependent upon GH activation of 
Src and independent of JAK2.  GH-dependent Rap1 activity appears to be dependent on 
CrkII-C3G activation and capable of mediating CrkII enhancement of GH-stimulated 
JNK/SAPK activity.  Rap1 was also implicated as an inhibitor of GH activation of RalA 
and its subsequent stimulation of ERKs 1 and 2 (31).  The latter suggests that the 
 
 7 
balance between Ral and Rap protein activation by GH would affect the relative levels of 
activation of ERKs 1/2 versus JNK/SAPK (Fig. 1.1C).  Using a COS7 cell overexpression 
system, Manabe et al. (32) also found GH to modestly stimulate Src activity.  They 
showed that Src can bind to and phosphorylate GHR and used Src inhibitor or anti-
sense to implicate Src in GH-dependent tyrosyl phosphorylation of GHR and Stat5a/b 
but not JAK2 in F-36P human leukemia cells (Fig. 1.1C).  Cell type specificity was one 
hypothesis put forward to explain the apparent discrepancy between these two groups 
regarding the role of Src in Stat5b phosphorylation (32).  Previous studies in IM-9 and 
CHO cells based upon truncated and mutated GHR and JAK2 inhibitors had suggested 
that regulation of cellular [Ca2+] by GH may also be JAK2 independent (reviewed in (25), 
raising the possibility that this function might also be mediated by Src.   Although recent 
inhibitor studies by Zhang et al. (33) found that human GH-induced increases in 
cytosolic free Ca2+ in, and insulin secretion from, BRIN-BD11 beta cells appeared to be 
dependent upon activation of both JAK2 and Src, these actions were not mediated via 
the GHR but rather the prolactin receptor, which can also bind human GH.  In contrast, 
the rise in cytosolic free Ca2+ elicited by bovine GH, which binds only to the GHR, was 
not blocked by inhibitors of either JAK2 or Src.  Thus, these data support the GHR-
mediated increase in cytosolic free Ca2+ being independent of JAK2.  They also suggest 
that GH binding to the GHR activates an as yet unidentified, early signaling protein in 
addition to JAK2 and Src.  Most recently, in an elegant study by Rowlinson et al. (34), a 
GH-induced conformational change in a loop (F’G’ loop) of one of two -sandwich 
modules in the extracellular domain of GHR was found to be responsible for activating 
the Src family kinase, Lyn, but not JAK2 in FDC-P1 cells.  In combination with a second 
published report, this group also found that liver samples from mice harboring GHR 
mutations rendering the receptor unable to bind JAK2 still displayed Src and ERK1/2 
activation in response to GH treatment (35).  The conclusion from these studies was that 
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GH-induced activation of ERK1/2 is mediated through Src family kinase while STAT5 
activation is mediated through JAK2, and that movement of the F’G’ loop within the GHR 
dictates which signaling pathway will be activated.  Collectively, these results indicate 
that both Src family kinases and JAK2 may transduce the GH signal.  However it is not 
currently clear if both kinases are utilized in all cells, or whether the relative abundance 
of a particular kinase defines utilization.  Therefore, a more complete understanding of 
the relative contribution of each kinase in different cell types remains an important 
question. 
 
GH regulation of Stat transcription factors 
A number of the responses to GH involve transcription factors and gene 
expression.  Among these transcription factors, members of the SH2 domain-containing 
signal transducers and activators of transcription (Stat) family of proteins have been 
shown to be particularly important for JAK2-mediated GH signaling (36) and will be 
discussed below.  The regulation of other transcription factors is outside the scope of 
this thesis, and is described elsewhere in detail (36, 37).  Activation of Stat proteins is 
known to require tyrosine phosphorylation-dependent homo or heterodimerization, a 
process that is facilitated by the GH-dependent creation of Stat binding sites on the 
activated GHR-JAK2 complex (Fig. 1.1B).  Once bound to these sites on the activated 
GHR-JAK2 complex, Stats 1, 3, 5a and 5b are thought to be phosphorylated by JAK2 
after which they dimerize, translocate to the nucleus and act as transcription factors for 
many important GH-regulated genes (36, 38, 39).  Many past and recent studies have 
shown that activation of Stat5a and Stat5b is critical for a variety of GH functions, 
including changes in metabolism, body growth and sex-dependent liver gene regulation 
(reviewed in (36, 39)).   
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Although Stat5a and Stat5b have been implicated in body growth via mouse 
gene deletion studies, only recently have Stat5b binding sites in the IGF-1 gene 
promoter elements been identified and shown to regulate IGF-1 transcription in a GH-
dependent manner through Stat5b (40, 41).  In support of Stat5 being important for GH-
dependent IGF-I levels in serum and body growth, a patient with severe growth 
retardation and immunodeficiency has been found to have a mutation in the Stat5b gene 





Figure 1.2.  Diseases and disorders associated with abnormal GH-induced JAK-
Stat signaling.   
(A) A patient has recently been identified who has severe growth retardation and 
immunodeficiency as a result of a mutation in the Stat5b gene that abrogates JAK2-
dependent phosphorylation and nuclear localization of Stat5b.  (B) EVB-transformed 
lymphocytes from X-SCID patients lacking the common cytokine receptor (-chain exhibit 
decreased GH-induced JAK2-dependent phosphorylation and nuclear localization of 
Stat5b.  (C) Fibroblasts from several patients exhibiting idiopathic short stature exhibit 
attenuated GH-induced JAK2-dependent phosphorylation and nuclear translocation of 
Stat3, increases in the cell cycle inhibtor, p21, and decreases in cyclins. 
 
 
Recently, an exciting mechanism was proposed whereby Stat5 and the 
transcriptional repressor, B cell lymphoma 6 (Bcl6), interact to regulate GH-induced 
gene expression (43, 44).  Using gene set enrichment analysis to identify novel GH-
regulated genes at time points matching important physiological actions, Chen et. al 
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identified Bcl6 as being strongly inhibited by GH.  They further found that upon GH 
stimulation, there was an increase in Stat5 occupancy on the highly GH-responsive 
gene, SOCS2 (see below for more on SOCS2).  Concomitant with this, Chen et. al found 
a decrease in Bcl6 occupancy of the SOCS2 gene.  Therefore, the results of this study 
for the first time identified GH-regulation of a powerful transcriptional repressor (Bcl6) 
and suggested that Stat5 and Bcl6 compete for regulation of the SOCS2 gene. 
Although current dogma dictates that JAK2 phosphorylates Stat5 through direct 
interactions between GHR, JAK2 and Stat5, Adriani et al. (45) have recently 
demonstrated a requirement for the common cytokine receptor -chain (c) for proper 
GH-mediated Stat5b activation in B cell lines.  These investigators found that in EBV-
transformed lymphocytes from c negative X-SCID patients, GH was able to normally 
activate JAK2, but GH-dependent Stat5b phosphorylation and nuclear localization were 
significantly suppressed. These cells exhibited a total loss of GH-induced proliferation.  
Reconstitution of X-SCID patient lymphoblastoid cell lines with wild-type c resulted in 
normal GH-induced phosphorylation of Stat5b and nuclear localization.  This study 
suggests a novel dependence of GH signaling on the common cytokine receptor -chain 
in certain cell types, consistent with the presence of -chains in non-hematopoietic 
tissues and short stature of X-SCID patients (Fig. 1.2B).  Whether this effect of -chain 
on GHR signaling is a direct or indirect effect remains to be determined. 
Another clinical report in 2006 describes patients diagnosed with idiopathic short 
stature whose fibroblasts exhibit normal activation of Stats 5a and 5b but impaired 
activation of Stat3 (46) (Fig. 1.2C).  Idiopathic short stature is characterized by a normal 
birth weight and no endocrine abnormalities but a retarded growth velocity and a height 
more than two standard deviations below the mean.  In fibroblasts taken from these 
patients, GH-induced Stat3 activation was attenuated, cyclin levels were reduced and 
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levels of p21WAF/CIPI (a negative regulator of the cell cycle) were elevated (46).  The 
idiopathic short stature phenotype and high p21WAF/CIPI levels in the human fibroblasts 
were reversed by treatment of patients with exogenous GH.  Further studies are needed 
to know whether the elevated levels of p21WAF/CIPI and/or suppressed Stat3 activation are 
responsible for the short stature. 
 
GH signal transduction via MAPK and PI3-kinase pathways 
The Ras/MAPK pathway has also been shown to be activated by GH (reviewed 
in (25, 29)).  GH has been shown to stimulate the binding of the adapter protein Shc to 
GHR-JAK2 complexes; the tyrosyl phosphorylation of Shc and its binding to Grb2 and 
the guanine nucleotide exchange factor, SOS; and the activity of Ras, Raf, mitogen-
activated protein kinase/extracellular-regulated protein kinase (MEK) and finally ERKs 1 
and 2 (47-50) (Fig. 1.1D).  Although several groups have linked GH activation of ERKs 1 
and 2 to JAK2, the Lobie laboratory have data suggesting that GH might also regulate 
ERKs 1 and 2 by a Src-dependent, JAK2-independent pathway that involves 
phospholipase D and RalA and RalB (30) or by a c-Src-FAK-Grb2 complex (reviewed in 
(29)).   Alternatively, Yamauchi et al. (51) propose that GH activates the MAPK pathway 
by stimulating tyrosyl phosphorylation of a Grb2 binding site in the epidermal growth 
factor receptor.  GH activation of the Ras/ERK pathway has been linked to GH activation 
of a variety of proteins (reviewed in (29)).  Examples include phospholipase A2, which 
has been linked to GH-induced P450-catalyzed formation of an active arachidonic acid 
metabolite and expression of CYP2C12; and the transcription factor Elk1 whose 
phosphorylation by ERK1/2 is required for transcription via the c-fos serum response 
element (SRE).   More recently, GH-induced ERK1/2 has been shown to phosphorylate 
the transcription factor CEBP, an event that has been implicated in CEBP nuclear 
translocation (52, 53)  (Fig. 1.1C) and differentiation of 3T3-F442A preadipocytes into 
 
 13 
adipocytes (54).   Although Stat5b has been thought largely responsible for sex-
dependent liver gene expression, including regulation of expression of the CYP2C11 
gene (39), Verma et al. (55) raise the possibility that ERK1/2 may also regulate 
expression of CYP2C11 gene, based upon correlative data using different doses of 
pulsatile GH replacement therapy in mice (Fig 1.1C).   
Recent results from Yang et al. (56) indicate that in 3T3-F442A cells, GHR is 
selectively enriched in caveolar and lipid raft domains of the plasma membrane.  GH 
stimulation induced in this fraction accumulation and activation of Ras/MAPK, but not 
Stat signaling molecules.  Disruption of these fractions using methyl--cycoldextrin 
inhibited GH-induced ERK1/2 activation, but had no effect on GH-stimulated Stat5 
activation.  These findings imply that GHR membrane localization may be important for 
the initiation of different GH-induced signal transduction pathways and that GH induction 
of ERKs 1/2 and Stat5 may require GHR in different cellular compartments.   
In addition to activating the Ras/MAP kinase pathway, GH has also been shown 
to stimulate the PI-3 kinase pathway (reviewed in (29), Fig. 1.1B).  One possible 
mechanism whereby GH activates PI-3 kinase is through tyrosyl phosphorylation of the 
large adaptor proteins designated insulin receptor substrate (IRS) proteins because of 
their known role in insulin signaling.  GH stimulates the tyrosine phosphorylation of IRS-
1, IRS-2 and IRS-3, and phosphorylation of these IRS proteins is known to lead to their 
association with multiple signaling molecules including the p85 subunit of PI-3 kinase.  
Other data suggest that GH might activate PI-3 kinase through a CrkII-IRS-1 interaction 
(57) or through binding of the p85 and p85 subunits of PI-3 kinase (58). Activation of 
PI3 kinase has been linked by inhibitor studies to GH stimulation of glucose transport 
(59) and the anti-apoptotic serine kinase Akt (60).  This GH-dependent activation of Akt 
has been shown to be dependent on the presence of the JAK2 binding region of GHR, 
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and implicated in GH promotion of cell survival, possibly through inhibition of the pro-
apoptotic caspase-3 protein (61).  GH-induced activation of p70S6K, a kinase involved in 
the control of cell proliferation and differentiation, has also been shown to be activated in 
PI-3 kinase-dependent and PKC-dependent manners (62-64). 
 
Negative regulators of GH signaling 
GH is secreted episodically and GH responses are transient.  In contrast, 
prolonged activation of JAK2 has been associated with cell transformation and cancer.  
Thus, precise regulation of GH signaling is vitally important for the proper maintenance 
of body growth and metabolism, with down-regulation of GH signaling being an 
important aspect of proper GH signaling.  Current knowledge of down-regulation of the 
GH signal reviewed here includes blockage or removal of SH2 and PTB binding sites by 
inhibitory molecules or dephosphorylation, and ubiquitin-dependent GHR endocytosis. 
 
Suppressor of cytokine signaling proteins 
The suppressor of cytokine signaling (SOCS) family of proteins plays an 
important role in the negative regulation of GH signaling.  There are eight members of 
the SOCS family, of which GH has been reported to induce the expression of four, 
namely, SOCS-1, -2, -3 and CIS (cytokine-inducible SH2-containing protein) (reviewed 
in (65)).  SOCS proteins share a centrally located SH2 domain and a motif termed the 
SOCS box, which resides in the carboxy-terminus.  Although it has been known for 
some time that the SOCS family is involved in negatively regulating GH signaling, more 
recent studies continue to shed light on the mechanisms of this regulation (Fig. 1.3). 
SOCS-1 is thought to bind the activating tyrosine in the kinase domain of JAK2 and 
inhibit JAK2 activity (19) (Fig. 1.3A).  SOCS-3 has been shown to bind this residue in 
JAK2 as well as to phosphorylated residues in GHR (20, 66, 67).  SOCS-3’s mechanism 
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of GH signaling inhibition is thought to be by inhibition of JAK2 kinase activity through a 
mechanism dependent on SOCS-3 binding to GHR (Fig. 1.3A). SOCS-2 has been 
shown to bind phosphorylated GHR GST fusion proteins and peptides (66-68). CIS has 
also been shown to bind phosphorylated GST-GHR fusion proteins (66, 67).  The 
SOCS-2 and CIS binding sites in GHR were subsequently mapped to tyrosines 487 and 
595 using a mammalian 2-hybrid system (14). The mechanism of SOCS-2 and CIS 
inhibition of GH signaling may be through inhibiting Stat5b binding of GHR, however, in 
SOCS overexpression studies, SOCS-2 and CIS inhibition of GH signaling seems to be 
less effective than that of SOCS-1 and SOCS-3 (66) (Fig 1.3A).  Additionally, while 
SOCS-2 and CIS bound GHR tyrosines 487 and 595 in the mammalian 2-hybrid system, 
Stat5a and Stat5b were found to bind GHR tyrosines 534, 566 and 627 (14).  These 
results suggest that Stat5 does not compete with SOCS-2 or CIS for binding sites on 
GHR.  SOCS-1, and possibly SOCS-2 and SOCS-3, also appear to be involved in the 
ubiquitination of the GHR-JAK2 complex as each have been shown to be associated 
with ubiquitin ligase activity (reviewed in (65), Fig. 1.3B).  Results using pharmacological 
inhibitors of proteasomes and dominant negative forms of CIS indicate that CIS 
negatively regulates GHR signaling at least in part by stimulating GHR internalization 
and proteasomal degradation (69) (Fig 1.3B). New evidence indicates that SOCS-2 may 
also inhibit GH responses in the animal indirectly by antagonizing IGF-1 signaling (70).  
Mice lacking SOCS-2 are large (71), suggesting physiological relevance of SOCS-2 as a 
negative regulator of GHR.  Although at high concentrations, SOCS-3 is able to down-
regulate GH-induced JAK2 activity and has been shown to be associated with ubiquitin 
ligase activity, the physiological significance of SOCS-3 action on GH signaling is 
currently unclear because liver-specific SOCS-3-/- mice do not differ in size from wild-
type littermates (72).  Similarly, CIS-/- and SOCS-1-/- mice are not bigger than normal (73, 
74).  It is always possible that these SOCS proteins share some redundancy in function, 
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and that increased body size would be observed if they were deleted in combination.  
Because SOCS proteins are synthesized in response to other ligands, a number of 
recent studies have investigated whether GH insensitivity is a consequence of elevated 
levels SOCS protein.   In that regard, Leung et al. (75) have implicated SOCS-2 
upregulation in the known ability of estrogen to inhibit GH signaling.  Similarly, increases 
in SOCS 1 and 3 have been implicated in the ability of sepsis to inhibit GH signaling in 
liver (76, 77), and increases in SOCS 2 and 3 in the negative effect of uremia on hepatic 




Figure 3. Negative regulation of GH signaling. 
(A) SOCS-1 binds JAK2 and inhibits JAK2 kinase activity. SOCS-3 is thought to bind 
phosphorylated GHR and inhibit JAK2 kinase activity. SOCS-2 and CIS bind 
phosphorylated GHR and may compete with Stat5B for GHR binding sites.  (B) 
Internalization and degredation of activated GHR may be facilitated by CIS and the 
ubiquitin ligase activity associated with SOCS proteins.  (C) Protein tyrosine 
phosphatases negative regulate GH signaling by binding the activated receptor complex 
and presumably dephosphorylating phosphotyrosines on JAK2, GHR or associates 
signaling proteins.  SHP2 has been hypothesized to be both a positive and negative 





Protein tyrosine phosphatases 
Another important mechanism whereby GH signaling is thought to be negatively 
regulated is through protein tyrosine phosphatases (PTPs).  A number of phosphatases 
have been reported to down-regulate GH signaling, including SH2 domain-containing 
protein-tyrosine phosphatase (SHP-1), SHP-2, protein-tyrosine phosphatase (PTP)-H1, 
PTP1, TC-PTP and PTP1b (reviewed in (65), Fig. 1.3C).  SHP-1 has been implicated as 
a negative regulator of GH signaling based upon the observation that GH-dependent 
tyrosyl phosphorylation of JAK2 and DNA binding of Stat5b are prolonged in liver 
extracts from motheaten mice deficient in SHP-1 (79).  SHP-2 is reported to both 
positively and negatively regulate GH signaling.  Based upon phosphatase inactive 
forms of SHP-2, Frank and colleagues (80) observed that overexpression of a 
catalytically inactive form of SHP-2 inhibited GH stimulation of c-fos enhancer-driven 
luciferase reporter, leading them to conclude that SHP-2 is a positive regulator of GH 
signaling.  In contrast, Stofega et al. (81) reported that mutating the SHP-2 binding sites 
in GHR (Y595 and Y487) enhanced and prolonged GH-dependent tyrosyl 
phosphorylation of JAK2, GHR, and Stat5b, leading them to propose that SHP-2 is a 
negative inhibitor of GHR signaling.  However, SOCS-2 and CIS are also reported to 
bind Y595 and Y487 (14).  This raises the possibility that mutating these tyrosines in 
GHR prolongs GH-dependent tyrosyl phosphorylation of JAK2, GHR, and Stat5b due to 
the inability of SOCS-2 and CIS to inhibit signaling.  Because the dominant negative 
forms of SHP-2 could affect multiple steps in GH signaling, not just JAK2 activity, and 
mutation of GHR binding sites for SHP-2 could also affect binding of other proteins to 
GHR, definitive resolution of the role of SHP-2 in GH signaling awaits further studies.  
Interestingly, Stofega et al (82) have also shown that GH stimulates the tyrosyl 
phosphorylation of the JAK2-associated membrane protein SIRP- (signal regulatory 
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protein alpha).  The phosphorylated tyrosines in SIRP- recruit SHP-2 (Fig. 1.3C).  
Mutation of those tyrosines enhances GH signaling, suggesting that recruitment of SHP-
2 to SIRP in response to GH may also contribute to the attenuation of GH signaling 
(82).  Pasquali et al. (83) have recently shown that PTP-H1, PTP1, TC-PTP, and PTP1b 
are all able to dephosphorylate GHR.  PTP1b knockout mice also display increased 
JAK2, Stat5 and Stat3 phosphorylation in response to GH compared to wild type mice 
(84).  Interestingly, Choi and colleagues (85) have recently demonstrated that 
phospholipase C1 provides a physical link between JAK2 and PTP1b in a GH-
dependent manner, leading to attenuation of GH-induced signaling.  Why phospholipase 
C1 would serve as an adapter protein for PTP1b is unclear. 
 
Receptor internalization 
The Strous laboratory has elucidated mechanisms whereby GHR is internalized 
in both ubiquitin-dependent and independent manners.  They have identified a motif in 
the cytosolic domain of GHR that recruits the ubiquitin conjugation system to GHR (86). 
The recruitment of the ubiquitin conjugation system, as well as the activity of the 
proteasome, seem to be necessary for GHR internalization (87, 88).  Although both an 
intact ubiquitin conjugation system and full proteasome activity seem to be required for 
subsequent proteasome-specific degradation of GHR, actual conjugation of ubiquitin to 
GHR does not seem to be necessary.  The ubiquitination, internalization and 
degradation of the GHR/JAK2 complex have also recently been reported by Rico-
Bautista et al. (89) to depend on an intact actin cytoskeleton. 
 
Receptor processing and subcellular localization 
 
 19 
Like amyloid precursor protein, Notch, and ErbB4, GHR appears to undergo 
“regulated intramembrane processing”, or RIP (90).  Following the same RIP program as 
the three receptors above, the extracellular domain of GHR is initially cleaved by the 
metalloprotease, tumor necrosis factor-(converting enzyme (TACE or ADAM-17), which 
results in shedding of the GHR extracellular domain (91).  The remaining membrane-
bound GHR is clipped within the lipid bi-layer, releasing the intracellular portion of GHR 
into the cytosol (92).  The exact functional significance of the releasing of this domain of 
GHR into the cytosol is currently unknown.  However, studies of other receptors 
undergoing RIP and those classically thought to be membrane-bound that are now being 
found in the cytosol may give hints as to the function of cytosolic GHR domain.  
Following RIP, ErbB4 has been shown to translocate to the nucleus where it plays a role 
in regulating transcription (93).   
It is interesting to note that full-length GHR has been reported in the nucleus of 
various cell types.  Using monoclonal antibodies specific for GHR, Lincoln et al. (94) 
identified GHR in the nucleus of a variety of normal and neoplastic cell types.  Gevers et 
al. (95) found GHR present in the nucleus of both germinal and proliferating 
chondrocytes in the rat growth plate and Vespasiani Gentilucci et al. (88) found GHR in 
the nucleus of hepatocytes from patients in the later stages of chronic liver disease.  
Finally, Conway-Campbell found GHR to localize to the nucleus in response to GH 
stimulation in CHO-K1 cells and found nuclear GHR to be correlated with proliferation in 
a model of liver regenration (96).  It will be interesting to see if the -secretase-processed 
intracellular domain of GHR also translocates to the nucleus and to determine the 
function of nuclear GHR.   
Along with being targeted to the nucleus, GH and GHR have been reported in the 
mitochondria (97, 98).  Perret-Vivancos et al. (99) recently reported that GH and GHR 
internalization through the caveolar pathway was essential for their targeting to the 
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mitochondria, and hypothesized that mitochondrial targeting was required for the 
observed GH stimulation of cellular oxygen consumption. 
 
One outstanding question that remains in the field of GH signal transduction is, 
how are events downstream of GH-induced activation of the GHR/JAK2 complex 
precisely regulated so that the appropriate response can be achieved in differing cell 
types and physiological contexts?  The ability of adaptor molecules to modulate signal 
transduction pathways may be one answer to this question.  Adaptor proteins lack 
intrinsic enzymatic activity but generally contain multiple protein-protein interaction 
domains, serving to recruit additional signaling molecules to the region of activation, 
allowing for specific activation or modification of those signaling molecules.  Additionally, 
some adaptor proteins can be targeted to different subcellular locations, providing an 
added level of specificity to the signaling system.  The adaptor protein, SH2B1, was 
identified as a JAK2 binding protein that is recruited to JAK2 in response to GH (100).  
Subsequent studies have revealed SH2B1 to be a key modulator of GH signaling 
(Reviewed in (101)). 
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SH2B1 in GH Signal Transduction 
 
The SH2B family of adaptor proteins includes SH2B1 (formerly SH2-B for SH2 
domain containing protein B, or PSM for proline rich, pleckstrin homology (PH) and SH2 
domain-containing signaling modulator), SH2B2 (formerly APS for adaptor protein with 
PH and SH2 domains) and SH2B3 (formerly Lnk).  Each SH2B1 family member was first 
described as a signaling molecule in immune cell activation (102-104) and each contains 
a domain structure consisting of a dimerization domain (DD), a PH domain, an SH2 
domain and several proline rich regions.  These proteins are able to homo and SH2B1 
and SH2B2 are able to heterodimerize through their DD domains, presumably allowing 
for tailored responses to particular signals depending on the relative abundance and 
subcellular location of SH2B1 and SH2B2.  The SH2B1 message undergoes alternative 
splicing at the 3’ end that results in four SH2B1 proteins (, , , ) (105).  All four 
isoforms share an N-terminal DD, nuclear localization sequence (NLS) (106) and nuclear 
export sequence (NES) (107) as well as C-terminal PH and SH2 domains.  The isoforms 
differ C-terminal to the SH2 domain, and the variation in the C-terminal sequence is 
known to alter subcellular localization in at least the  isoform (108).  SH2B1 isoforms 
have been implicated in modulating signals from numerous hormones and growth 
factors to enhance kinase activity, recruit additional signaling molecules, regulate gene 
transcription and/or modulate cytoskeletal dynamics (Reviewed in (101)).  These 
multiple functions of SH2B1 allow SH2B1 isoforms to regulate neuronal differentiation 
(109, 110), energy and glucose homeostasis (111), cell motility (112, 113) and 
proliferation (105).  While it is possible that several SH2B1 isoforms modulate GH signal 
transduction, the majority of evidence to date has characterized involvement of SH2B1 







Figure 1.4. Schematic of SH2B1. 
Abbreviations used are DD for dimerization domain, NLS for nuclear localization 
sequence, NES for nuclear export sequence, PH for pleckstrin homology domain and 
SH2 for SH2 domain.  Tyrosines 439 and 494, which are sites of GH-induced 
phosphorylation, are represented. 
 
 
SH2B1 as a JAK2 binding protein 
 The first indication that SH2B1 might be involved in GH signaling came when 
the C-terminus of SH2B1 containing the SH2 domain was identified as a binding 
partner of active, but not kinase-dead, JAK2 in a yeast-2-hybrid assay (100).  
Subsequent experiments in this study found SH2B1 to co-immunoprecipitate with and 
be phosphorylated by wild type, but not kinase dead JAK2 when both proteins were 
exogenously expressed in COS cells.  Additionally, Rui et al. found endogenous SH2B1 
to co-immunoprecipitate with and be phosphorylated by JAK2 in response GH 
stimulation of 3T3-F442A cells.  Later, SH2B1 was found to enhance JAK2 kinase 
activity, a function that is dependent on the SH2 domain of SH2B1, as well as enhance 
GH-mediated activation of Stat5B (114).  Tyrosine (Tyr) 813 of JAK2 was identified as 
both a GH-induced JAK2 autophosphorylation site and the binding site for the SH2 
domain of SH2B1 (12), indicating that GH- or other cytokine-induced phosphorylation of 
JAK2 is required for SH2 domain-mediated SH2B1 binding to JAK2.  Interestingly, a 
second SH2B1 site that lies outside the SH2 domain was found to be responsible for a 
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lower-affinity interaction with both active and inactive JAK2 (115), perhaps acting as a 
“pre-loading” mechanism to facilitate more efficient signaling upon JAK2 activation.  
Finally JAK2 mediated tyrosyl phosphorylation of SH2B1 was mapped to Tyr439 and 
494 (116), both of which were found to be functionally relevant to GH-induced cellular 
responses (see below). 
 
 SH2B1 in GH-induced regulation of the actin cytoskeleton 
Some cellular responses to GH stimulation include chondrocyte differentiation 
(117), monocyte chemotaxis (118), and proliferation and migration of models of 
epithelial-derived cancer (reviewed in (119)).  An essential aspect of each of these 
responses is a change in cellular morphology, a process that requires regulation of the 
actin cytoskeleton (Reviewed in (120, 121)), see below). 
 
Regulation of the actin cytoskeleton  
 The eukaryotic cytoskeleton is a dynamic structure consisting of microfilaments 
(or actin filaments), intermediate filaments and microtubules.  The cytoskeleton is closely 
linked to the plasma membrane and facilitates cellular motility and division, participates 
in intracellular transport, and provides structural integrity to give the cell its shape.  Actin 
monomers (G-actin) polymerize to form actin filaments (F-actin), which can then be 
organized into higher-order functional structures (e.g. stress fibers, filopodia, 
lamellipodial actin dendritic branches and microspikes).  Therefore, regulation of actin 
polymerization and organization is essential to each of these processes (122).  Because 
intermediate filaments seem to be non-essential for cell shape and microtubules appear 
to have an indirect (although important) effect on cell shape, it is thought that regulation 
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of the actin-based cytoskeleton is of principle importance for proper control of the 
processes mentioned above (reviewed in (123, 124)). 
 An abundance of proteins are known to bind actin to regulate actin 
polymerization, depolymerization, organization and localization, resulting in a complex 
network of regulation (Reviewed in (125)).  Actin nucleating proteins, such as Arp2 and 
Arp3, promote F-actin formation by forming a heterotrimer with G-actin and facilitating 
rapid growth of the filament (reviewed in (126)).  Other proteins, such as the 
WASP/WAVE family of proteins seem to be necessary for Arp2/3-mediated actin 
polymerization (reviewed in (127)).  Rho GTPases (Rac, Rho and Cdc42) have 
historically been known to be among the most potent activators of actin polymerization.  
In recent years, this potent ability to induce formation of F-actin structures such as stress 
fibers, lamellipodia and filopodia, has been shown to be mediated through Rho GTPase 
activation of WASP/WAVE proteins.  Actin depolymerizing factor (ADF) appears to 
promote actin depolymerization by binding to the end of F-actin and facilitating 
dissociation of subunits into G-actin (127).  In addition to the regulation of actin-filament 
dynamics, regulation of higher-order actin filament structures is important for proper 
cellular function.  Actin bundling proteins align F-actin into parallel or anti-parallel linear 
arrays to form structures such as stress fibers, while actin crosslinking proteins organize 
F-actin into more perpendicular arrays to form structures such as the actin meshwork 
that make up lamellipodia (125).  
 These higher-order actin filaments are tethered to the plasma membrane by a 
multitude of structural, scaffolding, and transmembrane proteins.  Actin stress fibers 
terminate at focal adhesions, which are integrin-based macromolecular complexes that 
mediate cell-extracellular matrix (ECM) attachment and facilitate direct signaling 
between the ECM and the cell (reviewed in (128)) (Fig. 1.5B).  Several proteins within 
focal adhesions bind F-actin, and in this way the cytoskeleton becomes a key 
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component of cell adhesion sites. In addition to actin-binding proteins, several adaptor, 
scaffolding and enzymatic proteins are found in focal adhesions.  The formation of new 
adhesion complexes at the leading edge of a cell and the dissolution of focal adhesions 
complexes at the rear of a cell and the base of cell protrusions (together termed “focal 
adhesion turnover”) are important events that facilitate cellular motility.  Changes in the 
protein composition of focal adhesions and the activation status of proteins within focal 
adhesions are two mechanisms by which focal adhesion turnover, and therefore cell 
motility, is regulated (129). 
 
 
Figure 1.5. Components of the actin cytoskeleton. 
(A) Membrane-bound scaffolding proteins such as spectrins form complexes with F-actin 
to provide structural integrity for a cell.  (B) Actin stress fibers are incorporated into 




 The actin cytoskeleton can also be integrated into the structural framework of the 
cell by binding scaffolding proteins such as spectrins, which represent a class of actin-
binding and crosslinking proteins that also bind the plasma membrane (Figure 1.5A).  
Many of these proteins, like spectrins, are especially large proteins (> 2000 amino acids) 
that interact with dozens of other proteins to form a complex network of scaffolding, 
adaptor and signaling proteins in close association with F-actin and the plasma 
membrane (reviewed in (130, 131)).  Many of these membrane-associated actin-binding 
proteins are phosphorylated or otherwise modified in response to extracellular and 
intracellular stimuli.  These modifications can alter their localization and/or alter their 
affinity for F-actin, resulting in attachment or detachment of F-actin to the plasma 
membrane.  Modulation of both actin polymerization dynamics and F-actin attachment to 
the plasma membrane/cell adhesion sites are the major mechanisms by which cell 
morphology and motility are regulated. 
 
SH2B1 is required for GH-induced changes in cell morphology 
 The observation that GH drives processes that require regulation of the actin 
cytoskeleton, combined with the finding that SH2B1 is required for neuron growth factor 
(NGF)-induced neurite outgrowth (109, 110)} prompted Herrington et al. (132) to 
investigate the possibility that SH2B1 is involved in GH-mediated regulation of the actin 
cytoskeleton.  Here, it was demonstrated that SH2B1 co-localizes with actin in GH-
induced cell ruffles.  This study further showed SH2B1 to enhance both GH- and 
platelet-derived growth factor (PDGF)-induced ruffling and pinocytosis.  However, 
SH2B1 truncation and point mutants that functionally inactivate the SH2 domain acted 
as dominant negative proteins in these assays even though GH-induced JAK2 activity 
was unaffected.  These results suggested both that the SH2 domain of SH2B1 is 
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necessary for ligand-induced cytoskeletal regulation and that a region N-terminal to the 
SH2 domain interacts with one or more regulators of the actin cytoskeleton.   In addition 
to the SH2 domain, Tyr439/494 were also found to be relevant.  Mutation of these Tyr to 
phenylalanine inhibited GH-induced cell ruffling (116), linking JAK2-mediated 
phosphorylation of SH2B1 to GH-induced cytoskeletal regulation.  These results also 
raise the possibility that proteins containing SH2 or phosphotyrosine binding domains 
(PTB) bind SH2B1 to facilitate this function. 
 The above findings were extended when it was shown that SH2B1 enhances 
GH-mediated lamellipodia activity and cell migration while SH2 domain mutants again 
acted as dominant negative proteins (112).  In this study, additional C-terminal truncation 
mutants were found to act in a dominant negative fashion, again suggesting that the N-
terminus of SH2B1 interacts with a protein or proteins that regulate the cytoskeleton. 
Evidence for the involvement of SH2B1 in cytoskeleton regulation was further 
demonstrated when it was shown that 1) GH activated endogenous Rac, 2) SH2B1 
SH2 domain mutants inhibit constitutively active Rac-induced cell ruffling, and 3) 
SH2B1 amino acids 85-106 bind Rac (112).  As Rac is known to be a major regulator of 
the cytoskeleton (reviewed in (133)), the results of this study provided one mechanism 
wherein GH can regulate the cytoskeleton.  SH2B1 may recruit Rac into the 
appropriate location to be activated by GH and/or GH may induce a SH2B1/active Rac 
complex to localize to ruffles. 
 In addition to its involvement in NGF, PDGF and GH-induced responses, 
SH2B1 is able to cross-link actin filaments in vitro, an action that requires two proposed 
actin-binding domains (a.a. 150-200 and 615-670) (113).  In the prokaryotic system, 
SH2B1 promotes bacterial actin-based motility through an interaction with the bacterial 
actin binding protein, ActA (a functional homologue of eukaryotic WASP) (134).  In 
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addition to SH2B1, other SH2B family members have been implicated in regulating the 
cytoskeleton.  SH2B2 co-localizes with actin in B cells (135), is thought to modulate actin 
dynamics in mast cells (136), and interacts with the cytoskeleton regulatory proteins, 
Vav3 (137) and Enigma (138).  SH2B3 is a binding partner of the actin binding and focal 
adhesion protein, filamin (139).  From the above studies, it can be concluded that 
SH2B1 is an important mediator of GH-induced cytoskeleton regulation, and likely of 
cytoskeletal regulation in general. 
 
Further actions of GH on the cytoskeleton 
In addition to the studies mentioned above, studies specifically investigating GH 
action on the cytoskeleton found GH stimulation of CHO cells to result in a rapid 
depolymerization of actin stress fibers, followed by the formation of focal, filamentous, 
actin-containing complexes (140), as well as alterations in cellular microtubule 
physiology (141).  This latter effect may be due to GH-induced JAK2 phosphorylation of 
tubulin (142).  The Lobie lab has also reported GH to stimulate the formation of a 
p130cas/CrkII/Src complex that also contains the p85 subunit of PI-3 kinase.  They have 
implicated the formation of this complex in the control of cytoskeletal dynamics (143), as 
their data indicate that PI-3 kinase regulates GH-stimulated reorganization of the actin 
cytoskeleton (140) and others have shown that formation of the p130cas-CrkII complex 
is sufficient for cell migration (144).  They also provide evidence for an interaction 
between JAK2 and FAK (focal adhesion kinase, an important regulator of focal 
adhesions and cytoskeletal rearrangement) that results in tyrosyl phosphorylation of FAK 
and two of its focal adhesion substrates, paxillin and tensin (145).  More recently, this 
group has implicated p38 MAPK as being important for GH-induced cytoskeletal 
rearrangements (146).  Interestingly, p130cas, CrkII, Src and FAK are all components of 
focal adhesions.  Mechanistically, as discussed above, the ability of SH2B1 to bind 
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active Rac seems necessary for GH-induced cell ruffling.  It remains to be determined if 
this interaction is sufficient for all of the processes requiring actin cytoskeleton regulation 
that SH2B1 has been shown to modulate, or whether SH2B1 interacts with additional 





Many of the gross events initiated by GH have been delineated.  As presented 
above, the GH-induced activation of JAK2, ERK1/2 and Stat proteins has been well 
documented across almost all cell and tissue types tested.  In addition, many groups 
have described cellular events such as cytoskeletal reorganization to be a consequence 
of GH administration.  There are also a growing number of studies revealing some of the 
finer aspects of GH action, such as which genes are transcribed in response to GH-
induced Stat activation as opposed to GH-induced ERK1/2 activation (37).  Yet, as these 
aspects of GH action are revealed, further questions arise regarding the specific 
mechanism of a GH-induced response, along with, how well observations represent GH-
induced responses between cell and tissue types.  Within the field of GH signaling, there 
have been an increasing number of reports implicating the Src family kinase proteins as 
transducers of the GH signal in parallel with or in lieu of JAK2.  However, the relative 
importance of JAK2 and SFKs in two well-established models of GH signaling (3T3-
F442A fibroblasts and H4IIE hepatoma cells) had not been assessed.  In addition to this 
question of the primary kinase responsible for GH signaling, the accumulating evidence 
implicating the downstream signaling molecule, SH2B1, as a major channel through 
which GH regulates the cytoskeleton raises the possibility that SH2B1 interacts with 
several actin-regulating molecules and/or is localized to actin cytoskeletal structures. 
Therefore, the objective of this thesis work was to 1) determine the relative contribution 
of JAK2 and Src family kinases to GH-signaling in well-established models of GH signal 
transduction and 2) more fully characterize the mechanism by which SH2B1 modulates 
GH-induced regulation of the cytoskeleton. 
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In Chapter 2, I present data where I, in collaboration with Dr. Hui Jin, utilize 
pharmacological inhibitors, RNA interference and genetic ablation to investigate the role 
of JAK2 and Src family kinases to GH signaling in 3T3-F442A and H4IIE cells.  Multiple 
labs have used both cell lines over several years to delineate numerous actions of GH, 
and therefore, we found it of great importance to determine which kinase(s) were 
responsible for these actions.  We first used antibodies that specifically detect the 
activated forms of Src family kinases or JAK2 to assess the activation status of these 
kinases in response to GH.  While Src family kinases are active even in the serum-
deprived basal state and showed no detectable increase in activation upon GH 
administration, JAK2 is robustly activated in response to GH in both cell types.  To rule 
out the possibility that increases in Src family kinase activity were below the level of 
detection by the antibody that we were using or that GH stimulation recruited active 
SFKs to substrates, we use SFK pharmacological inhibitors to block activation of Src 
family kinases prior to GH treatment.  Compared to control cells, we show that GH is still 
able to activate ERK1/2 and Stat proteins in the presence of the Src family kinase 
inhibitors, although we found Akt activation to be decreased compared to control cells.  
Interestingly, basal Akt activation was also reduced, indicating that the effect of the 
inhibitors on Akt activation may not be directly related to GH stimulation. 
To more fully characterize the contribution of JAK2 to GH signaling in these cells, 
we created 3T3-F442A and H4IIE cells stably expressing control shRNA or shRNA 
against JAK2.  We found that compared to control cells, JAK2 knockdown cells exhibited 
an almost complete inhibition of GH activation of Stat3, ERK1/2 and Akt in 3T3-F442A 
cells and Stat1, Stat5, ERK1/2 and Akt in H4IIE cells.  However, although GH-induced 
Stat5 activation was measurably reduced in knockdown versus control 3T3-F442A cells, 
the level of reduction is less than the level of JAK2 protein reduction, indicating that 
some other kinase may be partially responsible for Stat5 activation in 3T3-F442A cells.  
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To test this possibility, we next assessed Stat5 activation in murine embryonic fibroblasts 
(MEFs) derived from JAK2 knockout mice.  GH treatment of these cells did not result in 
any detectable activation of Stat5, while WT control MEFs exhibited substantial Stat5 
activation.  In addition, transient transfection of JAK2 knockout MEFs with JAK2 cDNA 
rescued the ability of GH to activate Stat5.  Taken together, we reasoned that JAK2 is, in 
fact, the primary kinase responsible for Stat5 activation in these cells.  Additionally, we 
concluded that some signaling molecules are more tightly coupled to the level of JAK2 
activation than others (e.g. when JAK2 levels are reduced by 80%, Stat3, ERK1/2 and 
Akt activation is almost completely abolished while Stat5 activation is reduced to a lesser 
extent, indicating that lower levels of active JAK2 fully activate Stat5 while full activation 
of other signaling molecules require higher levels of active JAK2).  Finally, we showed 
that GH-induces activation of Stat3, Stat5, ERK1/2 and Akt in MEFs derived from triple 
Src family kinase knockout mice, indicating that Src family kinases are dispensable for 
GH-induced activation of these downstream signaling molecules in these cells.  
Together, these results indicate that in 3T3-F442A, H4IIE and MEF cells, JAK2, and not 
Src family kinases, is the primary kinase responsible for Stat, ERK1/2 and Akt activation 
in response to GH. 
In Chapter 3, I further characterized the JAK2-binding protein, SH2B1, as a 
mediator of GH-mediated regulation of the actin cytoskeleton.  Steven Archer, a former 
graduate student in the Carter-Su laboratory, showed that amino acids 105-150 of 
SH2B1 interact with amino acids 2200-2358 of II1-spectrin through yeast-2-hybrid 
and co-immunoprecipitation assays.  Because of the perceived importance of SH2B1 to 
regulation of the actin cytoskeleton, and because spectrins are a major component of 
the actin cytoskeleton, I sought to further characterize the interaction between SH2B1 
and II1-spectrin.  
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II1-spectrin (2200-2358) localizes to the cytoplasm and nucleus in 293T cells.  
SH2B1 exhibits strong plasma membrane and moderate cytoplasmic localization in 
293T cells, and SH2B1 exhibits strong nucleolar localization in 293T cells.  Therefore, I 
first utilized the specific localization patterns of II1-spectrin (2200-2358), SH2B1 and 
SH2B1 in 293T cells to determine if the SH2B1/II1-spectrin interaction was robust 
enough to alter the localization of II1-spectrin (2200-2358).  I showed that SH2B1 
and SH2B1 both recruit II1-spectrin (2200-2358) to their respective subcellular 
locations.  II1-spectrin (2165-2358) localizes to the plasma membrane in 293T cells.  
SH2B1 (148-198) lacks a plasma membrane binding domain, and thus localizes to the 
cytoplasm in 293T cells.  I further showed that II1-spectrin (2165-2358) recruits 
SH2B1 (148-198) to the plasma membrane.  These results suggest that the 
interaction between SH2B1 and II1-spectrin is robust.  
I subsequently showed that SH2B1 and full-length II1-spectrin co-localize at 
the plasma membrane with the SH2B1-binding protein, JAK2, when all three are 
expressed in 293T cells.  Because phosphorylation of spectrins is a major mechanism of 
regulation of spectrin function, I next sought to determine whether JAK2 phosphorylates 
II1-spectrin.  Surprisingly, I found that when both are expressed in 293T cells, JAK2 
phosphorylates both II1-spectrin and its splice variant, II2-spectrin, but does so only 
in an SH2B1-dependent manner.  To further assess the relationship between these 
proteins in an endogenous setting and in the context of GH signaling, I turned to a 3T3-
F442A fibroblast model in which control shRNA or shRNA against SH2B1 is stably 
expressed.  GH stimulation of control cells resulted in formation of a complex of II-
spectrin, SH2B1 and JAK2, although no GH-induced phosphorylation of II-spectrin 
was observed at the 20 min time point tested.  However, GH stimulation of SH2B1 
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knockdown cells resulted in a significant reduction in the formation of the II-
spectrin/SH2B1/JAK2 complex.  These exciting results indicated both that GH treatment 
induces the formation of a novel complex of II-spectrin, SH2B1 and JAK2, and that 
formation of this complex is dependent on SH2B1.  Finally, I demonstrated a possible 
functional relevance to this relationship by showing that GH treatment of H4IIE cells 
results in the redistribution of II1-spectrin from cell-cell contacts into the cytoplasm.  
Together, the results suggest that GH stimulation may induce the formation of a II-
spectrin/SH2B1/JAK2 complex that results in JAK2 phosphorylation of II-spectrin and 
II-spectrin redistribution out of the plasma membrane.  II-spectrin redistribution out of 
the plasma membrane may contribute to cytoskeleton reorganization, and thus, the data 
presented in this Chapter identify a component of the actin cytoskeleton as a novel 
SH2B1-binding protein and suggest a novel mechanism whereby SH2B1 mediates 
GH-induced reorganization of the actin cytoskeleton. 
In Chapter 4, I characterize an additional novel role of SH2B1 in the actin 
cytoskeleton.  James Herrington, a former post-doctoral fellow in the Carter-Su lab, 
observed that GFP-tagged WT SH2B1, but not SH2B1 containing a nonfunctional 
SH2 domain, localized to focal adhesions in NIH 3T3 cells.  I extended these 
observations in 3T3-F442A cells by showing the SH2 domain of SH2B1 is necessary 
and sufficient for focal adhesion localization.  Further, I showed that GH stimulation 
significantly increases the dynamic cycling of SH2B1 into and out of focal adhesions 
(focal adhesion protein turnover).  I found that stimulation with phorbol 12-myristate 13-
acetate (PMA), a potent activator of protein kinase C (PKC), caused SH2B1 to leave 
focal adhesions.  In contrast, SH2B1 with two serines lying within a PKC substrate 
consensus motif (serines 161 and 165) mutated to alanine was not induced to leave 
focal adhesions by PMA stimulation.  I expanded these results by showing that the 
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dynamic turnover of SH2B1 (S161,165A) was significantly reduced and that of SH2B1 
(S165E) was slightly increased compared to WT SH2B1.   Finally, I presented evidence 
suggesting that phosphorylation of serine 165 is functionally relevant by showing that 
cells expressing SH2B1 (S165E) have significantly more focal adhesions than control 
cells.  Taken together, the results presented in Chapter 4 identify SH2B1 as a novel 
focal adhesion protein, whose dynamics at focal adhesions are regulated by GH and 
possibly by PKC-induced phosphorylation of serines 161 and/or 165.  In addition, these 
results suggest that phosphorylation of these serines and subsequent change in 
SH2B1 dynamics at focal adhesions contributes to the overall number of focal 
adhesions in cells.   
In summary, in this thesis, I demonstrate the primary importance of JAK2 to GH 
signal transduction in 3T3-F442A and H4IIE cells.  Additionally, I characterize II-
spectrin as a novel SH2B1-interacting protein and provide evidence suggesting that the 
SH2B1/II-spectrin interaction may play a role in GH-induced regulation of the 





Portions of Chapter 1 are found in my review of GH signaling published in Reviews in 
Endocrine and Metabolic Disorders (2006). 7:225-2358, under the title, “Recent 








JAK2, but not Src family kinases, is required for Stat, ERK, and Akt signaling in 





Janus kinase 2 (JAK2), a tyrosine kinase that associates with the growth hormone (GH) 
receptor and is activated by GH, has been implicated as a key mediator of GH signaling.  
Several published reports suggest that members of the Src family of tyrosine kinases 
may also participate in GH signaling.  We therefore investigated the extent to which 
JAK2 and Src family kinases mediate GH activation of STATs 1, 3, and 5a/b, ERKs 1 
and 2, and Akt, in the highly GH-responsive cell lines 3T3-F442A preadipocytes and 
H4IIE hepatoma cells.  GH activation of Src family kinases was not detected in either cell 
line.  Further, blocking basal activity of Src kinases with the Src inhibitors PP1 and PP2 
did not inhibit GH activation of STATs 1, 3 or 5a/b, or ERKs 1 and 2.  When levels of 
JAK2 were depressed by shRNA in 3T3-F442A and H4IIE cells, GH-stimulated 
activation of STATs 1, 3 and 5a/b, ERKs 1 and 2, and Akt were significantly reduced, 
however, basal activity of Src family kinases was unaffected.  These results were 
supported genetically by experiments showing that GH robustly activates JAK2, STATs 
3 and 5a/b, ERKs 1 and 2, and Akt in murine embryonic fibroblasts derived from 
Src/Yes/ Fyn (SYF) triple knock out embryos that lack known Src kinases.  These results 
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strongly suggest that JAK2, but not Src family kinases, is critical for transducing these 





Growth hormone (GH) is a peptide hormone that is secreted into the circulation by the 
anterior pituitary.  It is the primary hormone contributing to postnatal body growth (147, 148).  
It also regulates carbohydrate, fat and protein metabolism (147, 148), immune and cardiac 
function (149) and aging (150) and has been implicated in cellular proliferation, 
differentiation, and survival (29).  GH signaling pathways are initiated by GH binding to its 
receptor in the plasma membrane.  This binding activates the GH receptor-associated 
tyrosine kinase Janus kinase 2 (JAK2) which in turn phosphorylates multiple tyrosines within 
both itself and the GH receptor  (5, 25, 151).  Multiple signaling molecules have been shown 
to be recruited to the activated GH receptor-JAK2 complex, leading to the activation of a 
variety of signaling pathways.  Among these pathways are the signal transducer and 
activator of transcription (STAT), phosphoinositide 3-kinase (PI 3-kinase)/Akt, and 
MAPK/extracellular regulated kinase (ERK) signaling pathways (25, 29, 36).   
 Among the seven known mammalian STATs, STATs 1, 3, 5a and 5b have been 
implicated as GH signaling molecules.  In response to GH, these STATs become tyrosyl 
phosphorylated, dimerize and translocate to the nucleus where they regulate target genes 
(36, 38). STATs 5a and 5b are thought to be particularly important mediators of GH 
responses, including body growth, adipose tissue development, and the sexually dimorphic 
expression of a number of hepatocyte specific genes (42, 152-155).   
 GH activation of ERKs 1/2 and the PI3-kinase/Akt pathway has been observed both 
in cell culture (47, 156-160) and in animals (51, 161, 162).  Based upon in vitro studies using 
a number of cell types, several different mechanisms have been proposed by which GH 
activation of JAK2 leads to activation of ERKs 1 and 2.  One proposed mechanism involves 
Shc as the adapter protein linking Grb2 to the activated GH receptor-JAK2 complex, which 
in turn initiates a Grb2/SOS/Ras/Raf/MEK/ERK1/2 cascade (48-50).  GH-induced activation 
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of ERKs 1 and 2 has also been reported to involve JAK2 phosphorylation of the Grb2 
binding site (tyrosine 1068) in the epidermal growth factor receptor and recruitment of Grb2 
(51).  Others (62, 157, 163) suggest that protein kinase C and/or PI3-kinase activity are 
required for GH activation of ERKs 1 and 2.  
 Similarly, several mechanisms for GH activation of the PI3-kinase/Akt pathway have 
been suggested.  One proposed pathway involves JAK2 phosphorylating insulin receptor 
substrate (IRS) proteins which in turn recruit the p85 subunit of PI3-kinase, thereby 
activating PI3-kinase (29, 158, 159, 164).  Others have shown direct binding of the p85 
and  subunits of PI3-kinase to phosphorylated tyrosine residues in the C-terminus of the 
GH receptor, raising the possibility that GH may promote direct binding of p85 subunits to 
GH receptor (58).  
 Although JAK2 is generally believed to be the major tyrosine kinase initiating GH 
signaling pathways, several studies have suggested that Src family kinases are also 
capable of binding to the GH receptor and transducing GH signals.  There are 8 known 
members of the mammalian Src kinase family: c-Src, Yes, Fyn, Lyn, Lck, Hck, Fgr, and Blk 
(165).  Like JAK2, c-Src, Yes, and Fyn are expressed in most tissues whereas the other Src 
family members are expressed predominantly in hematopoietic cells (166).  Lck and Lyn are 
also expressed in neurons (165).  Zhu et al. showed that GH could activate Src and Fyn in 
NIH-3T3 cells (30) and Src in CHO cells ectopically expressing GH receptor (143).  Manabe 
et al. (32) showed that GH can increase Src activity in F-36 human leukemia cells.  Based 
on experiments using the Src family kinase inhibitor, PP2, and antisense c-Src 
oligonucleotides, Manabe et al. also suggest that in F-36 human leukemia cells, Src 
activates STAT5 in lieu of JAK2.  Similarly, Brown et al. (167) report that in FDC-P1 myeloid 
cells, GH activation of ERKs 1 and 2 is dependent on a Src family kinase.  Zhu et al. (30), 
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using NIH-3T3 cells, also concluded that GH-induced activation of ERKs 1 and 2 is 
mediated by a JAK2-independent pathway involving c-Src. 
 In this study, we have examined the relative roles played by endogenous JAK2 and 
Src family kinases in GH signaling in two well-characterized, GH-responsive cell lines, 3T3-
F442A preadipocytes and H4IIE hepatoma cells.  GH is required for differentiation of 3T3-
F442A preadipocytes into mature adipocytes (168) and regulates the actin cytoskeleton 
(132, 169).  In the differentiated, adipocyte form of 3T3-F442A cells, GH regulates lipolysis, 
hormone-sensitive lipase (170) and rates of glucose transport (171).  It also regulates the 
transcription of multiple genes, including insulin-like growth factor-1, a number of early 
response genes, and multiple genes encoding proteins that regulate carbohydrate and lipid 
metabolism (172).  Maximal expression of these genes involves a variety of signaling 
molecules, including STATs 1, 3 and 5a/b, ERKs 1 and 2, and Akt (5, 28, 37, 47, 156, 157, 
160, 173-176).  These signaling proteins have also been shown to be activated in H4IIE 
cells (177-179).  H4IIE cells have been used to study the effect of GH on protein synthesis 
(180) and insulin responsiveness (179, 181, 182). 
 Using an antibody specific to the activated form of Src family members, we provide 
evidence that GH does not detectably activate Src family kinases in 3T3-F442A or H4IIE 
cells.  Using Src family kinase inhibitors and shRNA to JAK2 in 3T3-F442A preadipocytes 
and H4IIE hepatoma cells, and mouse embryo fibroblasts (MEFs) from control, JAK2 
knockout, or Src/Yes/Fyn triple knockout mice, we provide strong evidence that GH 
activation of STATs 1, 3 and 5, ERKs 1 and 2, and Akt are dependent on JAK2 but not Src 
family kinases.  Our studies also reveal that moderate levels of activated JAK2 are sufficient 





 GH does not activate Src family kinases in 3T3-F442A preadipocytes or H4IIE 
hepatoma cells.  As an initial step in investigating whether Src family kinases mediate 
actions of GH, we examined whether Src family kinases are activated by GH in the GH-
responsive 3T3-F442A preadipocyte and H4IIE hepatoma cell lines.  3T3-F442A 
preadipocytes and H4IIE hepatoma cells were treated with vehicle alone or with GH 
(500ng/ml) for various times.  Lysates from these cells were subjected to SDS-PAGE and 
subsequent immunoblot analysis with anti-pY416-Src antibody (pY416-Src), which 
recognizes the activated form of the Src family members c-Src, Lyn, Fyn, Lck, Yes and Hck.  
Thus, it would be expected to recognize all forms of Src found in 3T3-F442A and H4IIE 
cells.  As shown in Figs. 2.1A and 2.1B (3rd panel, lane 1), Src family kinases were 
noticeably active in the basal state in both 3T3-F442A preadipocytes and H4IIE hepatoma 
cells, respectively.  However, GH treatment failed to increase Src family kinase activity 
above basal levels in either cell line (Figs. 2.1A and 2.1B, 3rd panel, lanes 2-5).  Levels of 
Src family proteins in cell lysates were also unchanged by GH, as judged by immunoblotting 




Figure 2.1. GH does not activate Src family member proteins.  A) 3T3-F442A 
preadipocytes were treated with either vehicle for 0 min (lane 1) or with GH (500 ng/ml) for 
the indicated times (lanes 2-5).  Cell lysates were immunoblotted with pY1007/1008-JAK2 
(reprobed with JAK2) and pY416-Src (reprobed with Src) as indicated (n=3).  B) H4IIE 
hepatoma cells were treated with either vehicle for 0 min (lane 1) or with GH (500 ng/ml) for 
the indicated times (lanes 2-5).  Proteins in an aliquot of H4IIE cell lysates were 
immunoprecipitated with JAK2 prior to blotting with pTyr and reprobing with JAK2 as 
indicated.  Proteins in aliquots of cell lysates were immunoblotted with pY416-Src and 
reprobed with Src as indicated (n=4). 
 
 
 To verify that these cells were responsive to GH, the ability of GH to activate JAK2 in 
3T3-F442A cells was assessed by blotting lysates with anti-pY1007/1008-JAK2 antibody 
(pY1007/1008-JAK2) (Fig. 2.1A, top panel).  This antibody recognizes the phosphorylated 
form of tyrosine(s) 1007 and/or 1008, the activating tyrosines in the kinase domain of JAK2.  
Phosphorylation of tyrosine 1007 is required for JAK2 activity (15) and generally mirrors 
overall tyrosyl phosphorylation of JAK2 assessed using an anti-phosphotyrosine antibody 
(pY) (12). In contrast to what was observed for Src family kinases, GH caused a rapid and 
transient phosphorylation of JAK2 on Tyr1007/1008.  Phosphorylation of JAK2 was 
observed as early as 5 min after GH addition, was maximal at 15 and 30 min, and started to 
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decline within 45 min after GH addition (Fig. 2.1A, top panel).  The ability of GH to activate 
JAK2 in the H4IIE hepatoma cells was assessed by immunoprecipitating JAK2 using JAK2 
and blotting with pY (Fig. 2.1B, top panel).  GH caused a similar rapid and transient tyrosyl 
phosphorylation of JAK2 in H4IIE cells.  A robust signal was evident within 5 min after GH 
addition, and returned to near basal levels by 60 minutes.   Blotting JAK2 
immunoprecipitates with pY1007/1008-JAK2 revealed a similar time course (see Fig. 2.4B, 
top panel, lanes 1-5).  Immunoblotting cell lysates with JAK2 (Figs. 2.1A and B, 2nd panels) 
indicated that endogenous levels of JAK2 were similar for all conditions for both cell types.  
Taken together, the data in Fig. 2.1 suggest that while GH rapidly and substantially activates 
JAK2, GH does not appreciably increase total Src family kinase activity in 3T3-F442A 
preadipocytes or H4IIE hepatoma cells. 
 Inhibition of Src family kinases does not affect GH activation of JAK2 or 
tyrosyl phosphorylation of STATs 1, 3 or 5.  Multiple Src family members exist in 3T3-
F442A preadipocytes and H4IIE hepatoma cells.  Because pY416-Src may detect different 
Src family members with different affinities and Src family kinases are basally active in these 
cells, it is possible that we were unable to detect a small GH-induced increase in kinase 
activity of one or more Src kinase family members that might be important for GH signal 
transduction.  Alternatively, GH might increase Src kinase-substrate interactions by altering 
the subcellular location of already active Src kinases or the availability of Src kinase 
substrates.  We therefore examined whether Src family inhibitors would inhibit GH activation 
of JAK2 or the activation of a variety of other GH signaling molecules.  3T3-F442A 
preadipocytes and H4IIE hepatoma cells were pretreated with vehicle (DMSO), the Src 
family inhibitors PP1 or PP2, or their inactive analogue, PP3 (183, 184), for 60 min before 
GH (500 ng/ml) was added for 15 min.  As predicted, PP1 and PP2, but not PP3, inhibited 
Src family kinase activity (assessed using pY416-Src) in both untreated (Figs. 2.2A and 
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2.2B, top panel, lanes 1-4) and GH-treated cells (Figs. 2.2A and 2.2B, top panel, lanes 5-8).  
In contrast, the number of JAK2 proteins activated in response to GH, assessed using 
pY1007/1008-JAK2 (Figs. 2.2A and 2.2B, 3rd panel, lanes 5-8) and normalized for the 
amount of JAK2 (Figs. 2.2A and 2.2B, 4th panel, lanes 5-8) present in each lane, was similar 
for cells pretreated with vehicle or inhibitors.  The lack of a change in JAK2 activation with 
the Src inhibitors suggests that Src family kinases do not play a role in GH activation of 





Figure 2.2. GH-stimulated activation of STATs is not blocked by Src kinase inhibitors.  
A) 3T3-F442A preadipocytes were treated with vehicle (DMSO) (-) or 100 M PP1, PP2, or 
PP3 for 60 min before addition of vehicle (-GH) or 500 ng/ml GH (+GH) for 15 min as 
indicated.  Proteins in cell lysates were immunoblotted with pY416-Src (reprobed with 
Src), pY1007/1008-JAK2, JAK2, pY705-STAT3, STAT3, pY694-STAT5, and 
STAT5 as indicated (n=3).  B) H4IIE hepatoma cells were treated with vehicle (DMSO) (-) 
or 100 M PP1, PP2, or PP3 for 60 min before addition of vehicle (-GH) or 500 ng/ml GH 
(+GH) for 15 min as indicated.  Proteins in an aliquot of H4IIE cell lysates were 
immunoprecipitated with JAK2 prior to blotting with pY1007/1008-JAK2 and reprobing 
with JAK2 as indicated.  Proteins in aliquots of cell lysates were immunoblotted with 
pY416-Src (reprobed with Src), pY701-STAT1 (reprobed with STAT1), pY694-





 The contribution of Src family kinase activity to GH-activation of STAT proteins was 
assessed using antibodies that recognize the tyrosyl phosphorylated, activated forms of 
STAT1 (pY701-STAT1), STAT3 (pY705-STAT3) or STATs 5a and 5b (pY694-STAT5).  
Phosphorylation of tyrosines 701 (185), 705 (186), and 694/699 (187, 188) is required for 
activation of STATs 1, 3, and 5a/5b, respectively. Because neither pY694-STAT5 nor 
STAT5 can distinguish between the very similar STAT5a and STAT5b, we shall use the 
term STAT5 to indicate both STAT5a and STAT5b.  Fig. 2.2A (lanes 5-8) reveals similar 
levels of GH-stimulated tyrosyl phosphorylation of STAT3 (5th panel) and similar levels of 
GH-stimulated tyrosyl phosphorylation of STAT5 (7th panel) in 3T3-F442A cells treated with 
or without the Src family inhibitors PP1 and PP2.  PP1 and PP2 also had no effect on the 
ability of GH to activate STAT1 (Fig. 2.2B, 5th panel, lanes 5-8) or STAT5 in H4IIE cells (Fig. 
2.2B, 7th panel, lanes 5-8) or levels of the different STATs in either 3T3-F442A or H4IIE cells 
(Figs. 2.2A and 2.2B, 6th and bottom panels).  Thus, Src family kinases appear not to play a 
significant mediator role in GH activation of STAT proteins in either 3T3-F442A 
preadipocytes or H4IIE hepatoma cells.  
 Effect of Src family inhibitors on GH activation of ERK 1, ERK 2 and Akt.  We 
next examined whether Src family kinases are important for GH activation of ERK1, ERK2 or 
Akt.  Dual phosphorylation of ERK1 on T202 and Y204 and ERK2 on T185 and Y187 
(numbering system of human ERKs) is required for their activation.  Proteins in aliquots of 
3T3-F442A and H4IIE cell lysates from Fig. 2.2 were blotted with an antibody that 
specifically recognizes ERKs 1 and 2 that are phosphorylated on both the activating Thr and 
Tyr (pT202/pY204-ERK1/2).  As seen in Fig. 2.3A and 2.3B (top panel, lanes 1 and 5), GH 
activated ERKs 1 and 2 in 3T3-F442A preadipocytes and H4IIE hepatoma cells.  In 3T3-
F442A cells, this activation was not reduced when cells were pretreated with PP1, PP2, or 
PP3 (Fig. 2.3A, top panel, lanes 5-8).  In H4IIE cells, PP1 and PP3 reduced GH activated 
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ERKs 1 and 2, whereas PP2 had no effect (Fig. 2.3B, lanes 5-8, 1st panel).   When 
comparing these results to the results seen in Fig. 2.2B (lanes 5-8, top panel), it becomes 
apparent that the effect of PP1 on ERK activation in H4IIE cells is not specific to inhibition of 
Src family kinases.  This comparison shows that when Src family kinase activity is 
undetectable due to pharmacological inhibition by PP2, GH is still able to fully activate ERKs 
1 and 2 (compare Fig. 2.2B, lane 7, top panel to Fig. 2.3B, lane 7, top panel).  Therefore, the 
ability of PP1 to inhibit GH-mediated ERK 1 and 2 activation in H4IIE cells cannot be 
ascribed to a lack of Src family kinase activity.  Taking this together with the observation that 
the negative control (PP3) also significantly inhibits GH-mediated activation of ERKs 1 and 2 
but not Src family kinase activity, the conclusion can be drawn that in rat hepatoma cells, 
PP1 and PP3 inhibit ERK 1 and 2 activation in a non-Src family kinase-specific manner.  
Thus, these inhibitor studies fail to implicate Src family kinases in GH-mediated activation of 
ERKs 1 and 2 in 3T3-F442A or H4IIE cells.  Whether the PP1/2/3 pattern of inhibition 
indicates the direct or indirect contribution of some other enzyme to the activation of ERKs 1 
and 2 in H4IIE cells but not 3T3-F442A cells is not known.  However, the pattern of inhibition 




Figure 2.3. Effect of Src kinase inhibitors on GH activation of Erks 1 and 2 and Akt.  
Proteins in aliquots of cell lysates from 3T3-F442A preadipocytes (A) and H4IIE hepatoma 
cells (B) used in Figure 2 were immunoblotted with pT202/pY204-ERK1/2 (reprobed with 




 Finally, we sought to determine whether Src family kinases are important for GH-
stimulated activation of PI3-kinase signaling.  Akt, a downstream signaling molecule of PI3-
kinase, requires phosphorylation on Ser 473 to be active (191).  As shown in Figs. 2.3A and 
2.3B (3rd panel, lane 1 vs 5) phosphorylation of Akt on Ser 473 was robust in both 3T3-
F442A preadipocytes and H4IIE hepatoma cells stimulated with GH.  In both cell types, this 
level of phosphorylation was substantially reduced in cells pretreated with PP1 and PP2 
(Figs. 2.3A and 2.3B, 3rd panel, lanes 5-8).  A more modest inhibition was observed in cells 
pretreated with PP3.  The ability of PP1 and PP2 to inhibit phosphorylation of Ser473 in Akt 
in response to GH raises the possibility that Src family kinases are important for GH 
activation of Akt.  However, PP1 and PP2 (and to a lesser extent PP3) were also found to 
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reduce basal levels of Akt phosphorylation in both 3T3-F442A and H4IIE cells (Figs. 2.3A 
and 2.3B, 3rd panel, lanes 1-4), indicating that Src family kinase activity may not mediate GH 
activation of Akt per sé.  Rather, GH activation of Akt may depend on basal priming of Akt 
by basally active Src. Taken together, the results of Figs. 2 and 3 in which Src family 
kinases were inhibited in 3T3-F442A preadipocytes and H4IIE hepatoma cells do not 
support the hypothesis that Src family kinases play a mediator role in the ability of GH to 
activate JAK2, STATs 1, 3 or 5, or ERKs 1 and 2.  However, they do suggest that GH 
activation of Akt may require basal Src family kinase activity.  Because of the inhibition of 
basal Akt activity by inhibitors of Src family kinases, these experiments are unable to 
address whether or not Src family kinases play a mediator role in GH activation of Akt. 
 GH-stimulated activation of STATs 1, 3 and 5, ERKs 1 and 2, and Akt is 
diminished when endogenous JAK2 levels are reduced in 3T3-F442A preadipocytes 
and H4IIE hepatoma cells.  To determine the degree to which JAK2 is required for GH-
mediated activation of STAT proteins, ERKs 1 and 2 and Akt, we examined the ability of GH 
to activate these signaling molecules when endogenous JAK2 levels were reduced in both 
3T3-F442A preadipocytes and H4IIE hepatoma cells.  3T3-F442A preadipocytes and H4IIE 
hepatoma cells stably expressing control shRNA (Figs. 2.4A and 2.4B, 2nd panel, lanes 1-5) 
or JAK2 shRNA (Figs. 2.4A and 2.4B, 2nd panel, lanes 6-10) were treated with vehicle or GH 
(500 ng/ml) for various times.  Immunoblotting cell lysates with JAK2 indicated at least an 
80% reduction of endogenous JAK2 protein levels in 3T3-F442A preadipocytes (83% ± 6%, 
n=3) and H4IIE hepatoma cells (89% ± 4%, n=3) as determined by quantification of JAK2 
bands. Immunoblotting with pY1007/1008-JAK2 confirmed that levels of activated JAK2 
are decreased to a similar extent as levels of total JAK2 in the JAK2 shRNA expressing 3T3-




Figure 2.4. GH-mediated STAT activation is significantly diminished when JAK2 levels 
are reduced using shRNA to JAK2.  A) 3T3-F442A preadipocytes stably expressing either 
control shRNA or JAK2 shRNA were treated with either vehicle for 0 min or with GH 
(500ng/ml) for the indicated times.  Cell lysates were immunoblotted with pY1007/1008-
JAK2, JAK2, pY705-STAT3, STAT3, pY694-STAT5, and STAT5 as indicated (n=3).  
B) H4IIE hepatoma cells stably expressing either control shRNA or JAK2 shRNA were 
treated with either vehicle for 0 min or with GH (500ng/ml) for the indicated times.  Proteins 
in aliquots of H4IIE cell lysates were immunoprecipitated with JAK2 prior to blotting with 
pY1007/1008-JAK2 and reprobing with JAK2 as indicated.  Aliquots of cell lysates were 





 In control shRNA 3T3-F442A cells, GH-stimulated phosphorylation of STAT3 on 
Y705 was detectable within 5 min and maximal at 30 min (Fig. 2.4A, 3rd panel, lanes 1-5).  
GH-stimulated tyrosyl phosphorylation of STAT5 on Y694 was also detectable within 5 min 
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but remained elevated even after 45 min (Fig. 2.4A, 5th panel, lanes 1-5).  Reduction of 
levels of endogenous JAK2 using shRNA resulted in a substantially reduced GH-dependent 
phosphorylation of both STAT3 (by 68% ± 4%, n=3) and STAT5 (by 47% ± 7%, n=3) (Fig. 
2.4A, 3rd and 5th panels, respectively).  Reduction of endogenous JAK2 did not alter levels of 
STAT3 or STAT5 (Fig. 2.4A, 4th and 6th panels, respectively).  In control shRNA expressing 
H4IIE cells, GH-stimulated phosphorylation of both STAT1 on Y701 and STAT5 on Y694 
was detectable within 5 min, was maximal at 15 min and returned to near basal values by 60 
min.  In the shRNA-JAK2 H4IIE cells, GH-dependent phosphorylation of both STAT1 and 
STAT5 was substantially reduced at all time points (Fig. 2.4B, 3rd and 5th panels 
respectively).  Reduction of endogenous JAK2 did not alter levels of STAT1 or STAT5 (Fig. 
2.4B, 4th and 6th panels, respectively).  Thus, reduction of endogenous JAK2 substantially 
reduces the ability of GH to activate STAT proteins in both 3T3-F442A preadipocytes and 
H4IIE hepatoma cells. 
 We next determined the importance of JAK2 for GH-mediated activation of ERKs 1 
and 2.  GH stimulation of control shRNA 3T3-F442A preadipocytes resulted in the transient 
activation of ERKs 1 and 2, which was evident within 5 min and over by 45 min (Fig. 2.5A, 
top panel, lanes 1-5).  Activation of ERKs 1 and 2 was almost eliminated in cells expressing 
JAK2 shRNA, being detectable above basal values only at the 5 min time point (Fig. 2.5A, 
top panel, lanes 6-10).  GH stimulation of control shRNA H4IIE hepatoma cells resulted in a 
relatively modest increase in activation of ERKs 1 and 2, visible in Fig. 2.5B (top panel, 
lanes 1-5) at the 15 and 30 min time points.  No GH stimulation of ERKs 1 and 2 was 
detectable in the JAK2 shRNA hepatoma cells (Fig. 2.5B, top panel, lanes 6-10).  Reduction 
of endogenous JAK2 did not alter levels of ERKs 1 or 2 in either cell line (Fig. 2.5A and 
2.5B, 2nd panels).  Thus, reduction of endogenous JAK2 substantially reduces the ability of 
GH to activate ERKs 1 and 2 in both 3T3-F442A preadipocytes and H4IIE hepatoma cells. 
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 For Akt, GH (500 ng/ml) caused a robust increase in phosphorylation of Ser473 
within 5 min in both control shRNA 3T3-F442A preadipocytes and H4IIE hepatoma cells 
(Figs. 2.5A and 2.5B, 3
rd
 panels, lanes 1-5).  Phosphorylation was sustained for 30 min in the 
3T3-F442A cells before declining whereas it started declining within 15 min in the H4IIE 
cells.  For both cell types, however, phosphorylation of Ser473 was reduced to barely 
detectable values at all time points by the reduction of JAK2 with shRNA JAK2 (Figs. 2.5A 
and 2.5B, 3
rd
 panels, lanes 6-10).  Akt levels were not similarly reduced in either control or 
shRNA JAK2 expressing cells (Figs. 2.5A and 2.5B, 4th panels).  The fact that reducing 
JAK2 is so effective in reducing levels of GH activation of Akt supports the hypothesis that 





Figure 2.5.  GH activation of Erk 1, Erk 2 and Akt is diminished substantially when 
JAK2 levels are reduced using shRNA to JAK2.  Proteins in aliquots of the lysates of (A) 
3T3-F442A preadipocytes stably expressing either control shRNA or JAK2 shRNA or (B) 
H4IIE hepatoma cells stably expressing either control shRNA or JAK2 shRNA used in Figure 




 To rule out the possibility that reduction of endogenous JAK2 reduces the level of 
Src family kinases, lysates from both 3T3-F442A and H4IIE cells were blotted with pY416-
Src and Src (Figs. 2.6A and 2.6B, panels 3 and 4).  No differences in levels of Src 
activation or Src protein were observed between control and JAK2 knock down cells, 
indicating that reducing the level of JAK2 does not affect basal Src family kinase activity.  
Thus, basal Src family kinase activity appears to be independent of JAK2.  To test whether 
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the decreased responsiveness to GH of the JAK2 shRNA cells compared to the control 
shRNA cells could be a result of reduced expression of the GH receptor, control and shRNA 
expressing 3T3-F442A cells were treated with GH for 15 min.  GH receptor levels were 
similar in control and JAK2 shRNA expressing cells as shown by blotting lysates with 
antibody to the intracellular domain of the GH receptor (Fig. 2.6C middle panel). When GH 
receptor was immunoprecipitated using antibody to the extracellular domain of the GH 
receptor and blotted with PY, tyrosyl phosphorylation of GH receptor was found to be 
reduced in JAK2 shRNA cells (Fig. 2.6C, bottom panel) compared to control shRNA cells, as 
one would predict from the decreased levels of JAK2.  Taken together, the data of Figs. 2.4-
2.6 indicate that JAK2 is required for maximal GH-mediated activation of STATs 1, 3 and 5, 




Figure 2.6.  Src family kinase activity is not affected by reducing levels of JAK2. A) 
Proteins in aliquots of the lysates from 3T3-F442A preadipocytes stably expressing either 
control shRNA or JAK2 shRNA used in Figure 4 were immunoblotted with pY1007/1008-
JAK2, JAK2, and pY416-Src (reprobed with Src) as indicated (n=3).  B) Proteins in 
aliquots of the lysates from H4IIE hepatoma cells stably expressing either control shRNA or 
JAK2 shRNA used in Figure 4 were immunoprecipitated with JAK2 prior to blotting with 
pY1007/1008-JAK2 and reprobing with JAK2 as indicated (n=3).  Proteins in aliquots of 
cell lysates were immunoblotted with pY416-Src and reprobed with Src as indicated 
(n=3).  The top 2 panels for (A) and (B) are the same as the top 2 panels in Figs. 4A and 4B, 
respectively.  C) 3T3-F442A preadipocytes stably expressing either control shRNA or JAK2 
shRNA were treated with either vehicle for 0 min or GH (500ng/ml) for the indicated time.  
Aliquots were immunoprecipitated with GHBP prior to blotting with pTyr.  Aliquots of cell 
lysates were immunoblotted with GHR (AL47) as indicated (n=3). 
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 GH activates JAK2, STATs 1, 3 and 5, ERKs 1 and 2, and Akt in cells lacking 
Src family members.  To provide genetic evidence that JAK2, but not Src family kinases, 
plays a direct and essential role in GH-induced activation of signaling molecules, mouse 
embryo fibroblasts (MEFs) derived from embryos from Src/yes/fyn (SYF) triple knock out 
mice (192) were tested for their responses to GH.  SYF MEF cells also lack Lyn expression.  
Thus, these cells lack all Src family members reported to be present in murine fibroblasts 
(192).  This absence of Src family members was confirmed by the absence of any 
detectable signal in Src or pY416 Src immunoblots of SYF MEF cells (Fig. 2.7, top 2 
panels, compare to wild-type MEFs shown in Fig. 2.8A, panels 5 and 6, lanes 1-5).  SYF 
MEFs were treated with vehicle alone or with GH (500 ng/ml) for various times.  
Immunoblots of lysates from these cells revealed that JAK2, STAT3, STAT5, ERK1, ERK2 
and Akt are all robustly phosphorylated in response to GH (Fig. 2.7).  These results provide 





Figure 2.7. GH activates JAK2, STATs 1, 3 and 5, Erks 1 and 2, and Akt in SYF MEF 
cells.  SYF MEF cells were treated with either vehicle (0 min) or with GH (500ng/ml) for the 
indicated time.  Proteins in cell lysates were blotted with pY416-Src (reprobed with Src), 
pY1007/1008-JAK2 (reprobed with JAK2), pY705-STAT3, STAT3, pY694-STAT5, 




 GH is unable to activate STAT5 in JAK2-/- MEFs.  The finding that in shRNA-JAK2 
3T3-F442A cells, GH stimulation of STAT5 phosphorylation was reduced to a lesser extent 
than levels of JAK2 (Fig. 2.4A) allows for the possibility that some other kinase contributes 
to that stimulation.  The SYF MEF and Src family inhibitor studies suggest members of the 
Src family of tyrosine kinases do not contribute.  However, those results do not allow us to 
rule out another, unidentified kinase.  To test the possibility that some kinase other than 
JAK2 mediates GH activation of STAT5, we examined to what degree deleting all JAK2 
would block GH activation of STAT5.  Wild-type and JAK2-/- MEFs were treated with vehicle 
alone or with GH (500 ng/ml) for various times.  Immunoblotting cell lysates with JAK2 
confirmed the complete loss of JAK2 expression in the JAK2-/- MEF cells (Fig. 2.8A, 2nd 
panel).  As predicted, blotting the lysates with pY1007/1008-JAK2 showed that, similar to 
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what we observed in 3T3-F442A and HEII4 cells, JAK2 was rapidly and transiently 
phosphorylated on Tyr1007/1008 in wild-type MEFs while no phosphorylated JAK2 was 
detectable in JAK2-/- MEFs (Fig 2.8A, top panel).  Similar to what we observed with lysates 
from SYF MEF cells, immunoblots of the wild-type MEF lysates with pY694-STAT5 
revealed a robust activation of STAT5 that was evident at 5 min and maximal at 10-15 min 
(Fig. 2.8A, lanes 1-5, 3rd panel).  However, there was no detectable phosphorylated STAT5 
in the lysate from JAK2-/- MEFs (Fig. 2.8A, lanes 6-10, 3rd panel), suggesting a total 
dependency on JAK2 of STAT5 activation.  Blotting the lysates with pY416-Src showed no 
difference in Src kinase phosphorylation following GH addition or between the wild-type and 
JAK2-/- MEFs (Fig. 2.8A, panels 5 and 6).  Levels of STAT5 and Src were similar in wild-type 
and JAK2-/- MEFs (Fig. 2.8A, panels 4 and 6).  Therefore, the loss of activation of STAT5 in 
JAK2-/- cells is most likely due to the lack of JAK2, and not indirectly to changes in the 
activity of Src family kinase activity or any other kinases.  Reintroducing wild-type JAK2 into 
JAK2-/- MEFs rescued GH-stimulated STAT5 activation, to a level commensurate with the 
level of reintroduced JAK2 (Fig. 2.8B), providing further support for the hypothesis that JAK2 




Figure 2.8.  GH is unable to activate STAT5 in MEFs lacking JAK2.  A) Wild-type MEFs 
or MEFs from JAK2-/- mice were treated with either vehicle (0 min) or with GH (500ng/ml) for 
the indicated times.  Cell lysates were immunoblotted with pY1007/1008-JAK2 (reprobed 
withJAK2), pY694-STAT5, STAT5, and pY416-Src (reprobed with Src) as indicated 
(n=3).  B) MEFs from JAK2-/- mice or the same MEFs in which JAK2 was stably reintroduced 
were treated with either vehicle (0 min) or with GH (500ng/ml) for the indicated times.  Cell 






 Because members of the cytokine family of receptors do not have intrinsic kinase 
activity, the signaling events initiated by cytokines are achieved through activation of 
receptor-associated tyrosine kinases, primarily members of the JAK family of tyrosine 
kinases (reviewed in (193)).  However, some cytokine receptors have been reported to bind 
to and activate members of the Src family of tyrosine kinases (165).  In the case of GH, 
JAK2 has classically been thought to be the major kinase responsible for initiating 
downstream signaling events although JAK1 and JAK3 have been shown to be minimally 
activated in some cells (26, 194).  Multiple studies have demonstrated an interaction 
between GH receptor and JAK2 and a robust activation of JAK2 following GH binding of GH 
receptor (4, 5, 25).  However, several studies have suggested that GH may also activate 
members of the Src family of tyrosine kinases and that activation of Src family members 
may contribute to activation of signaling molecules downstream of GH, including STAT5 and 
ERKs 1 and 2 (30, 32).   
 In this study, we sought to determine the relative contribution of Src family kinases to 
GH signaling by assessing the activation status of endogenous GH signaling proteins in cell 
lines that have been well characterized for GH signaling and GH responses.  Using an 
antibody to the phosphorylated form of the activating tyrosine in JAK2 to assess levels of 
activated JAK2, we found that JAK2 was inactive in both 3T3-F442A and H4IIE cells that 
had not seen GH.  Upon GH treatment, JAK2 was rapidly and transiently activated, as 
reported previously (5, 177).  In contrast, using an antibody that recognizes the 
phosphorylated form of the activating tyrosine in Src family kinases to assess levels of 
activated Src family kinases, we found that Src kinases are basally active in 3T3-F442A and 
H4IIE cells.  GH treatment did not appreciably enhance that activity at early time points (30 
sec and 2 min) (data not shown) or over an extended period of treatment (up to 60 min) (Fig. 
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2.1).  Thus, it seems unlikely that in these cell types, Src kinases can substitute for JAK2 as 
important mediators of GH action, unless GH activates only a small, undetectable, subset of 
the Src family kinases or increases Src kinase-substrate interactions (e.g. by altering the 
subcellular location of already active Src kinases or the availability of Src kinase substrates).  
Similarly, Yamauchi et al. (51) reported seeing no GH-induced increase in Src activity.  The 
reason why these results differ from those of the groups observing a GH-induced increase in 
the activity of Src family kinases is not clear.  Possible explanations include differences in 
culture conditions or cell type.  Relevant to the former, we observed no GH-induced 
increase in Src kinase activity in either subconfluent (70-80%) or confluent 3T3-F442A cells 
(data not shown).  Regarding the latter, all the different groups used different cell types.  Zhu 
et al. reported GH induced activity of Src kinases in CHO cells overexpressing GH receptor 
(c-Src and c-Fyn) (143) and in NIH-3T3 cells (c-Src) (30) while Manabe et al. (32) and 
Brown et al. (167) reported GH induction of Src using F-36P human leukemia cells (c-Src) 
and FDC-P1 myeloid cells (Lyn), respectively.  Circulating cells, such as the F-36P and 
FDC-P1 cells, in general seem to have a greater propensity for utilizing Src family kinases 
for cytokine signaling compared to non-circulating cell types (165), raising the question of 
whether the ratio of Src family kinases to JAK2 is higher in these cells or they have 
accessory proteins that enable or enhance cytokine activation of Src kinases.  It is 
interesting to note that even when GH was observed to activate Src family kinases, the 
degree of stimulation when assessed quantitatively, was quite modest, between 30-70% 
(143), in contrast to the degree of GH stimulation of JAK2 that generally shows a robust 
on/off type of response.  It is also important to note that we found the activity of Src family 
kinases to be unaffected by the level of JAK2 and vice-versa.  Thus, reducing levels of JAK2 
in 3T3-F442A and H4IIE cells by shRNA to JAK2 or in MEFs genetically deleted for JAK2 
did not decrease the level of activity of Src kinases, nor did reducing the activity of Src family 
kinases using PP1 and PP2 alter the ability of GH to activate JAK2.  This independence of 
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Src and JAK2 activity supports the previous findings of Zhu et al. (30) in NIH-3T3 cells using 
both pharmacological inhibitors (PP1, PP2 and AG490) and dominant negative constructs of 
Src and JAK2.  It also argues against Src being recruited to GH receptor-JAK2 complexes 
and being activated as a consequence of binding to tyrosines within JAK2 or GH receptor 
that are phosphorylated by JAK2 in response to GH. 
 The fact that GH did not appear to activate Src family kinases in our experiments 
does not a priori exclude them from being mediators of GH signaling, since it is possible that 
GH elicits a small, undetectable increase in the activity of one of more Src kinases, alters 
the subcellular location of already active Src kinases or alters the availability of Src kinase 
substrates.  However, our data using the Src family kinase inhibitors PP1 and PP2 reveal 
that blocking the activity of Src family kinases in 3T3-F442A preadipocytes and H4IIE 
hepatoma cells does not attenuate GH-mediated activation of STATs 1, 3 or 5, indicating 
that activation of these signaling molecules by GH is independent of Src in these cells.  The 
inability of PP1 and PP2 to block GH activation of STAT5 is consistent with the previous 
report of Guren et al. (195) showing no reduction in cultured rat hepatocytes of GH-
mediated STAT5 activation by a different Src kinase inhibitor, CGP77675.  It is also 
consistent with the finding that STAT5 is activated by GH in CHO cells stably expressing 
wild-type GH receptor but not in CHO cells stably expressing a mutated GH receptor lacking 
the binding site for JAK2 (28).  However, it contrasts with the finding of Manabe et al. (32), 
who showed a PP2-dependent, Src antisense oligonucleotide-sensitive, inhibition of GH-
mediated STAT5 phosphorylation in F-36P cells.  One explanation for the apparent 
discrepancy between these studies is a difference in cell type, with fibroblasts, 
preadipocytes and hepatocytes relying solely on JAK2 for GH activation of STAT5 and 
circulating cells being able to utilize Src family kinases in addition to or in place of JAK2.  
Unfortunately, in the latter study, the authors did not explore the relative contributions of 
JAK2 and Src kinases to the GH activation of STAT5, so that it is unclear whether in F-36P 
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cells, Src family kinases mediate or modulate GH activation of STAT5, and whether that 
action is independent of JAK2.  In further support of JAK2 and not Src kinases being 
responsible for GH activation of STAT5, we observed a robust activation of STAT5 by GH in 
SYF MEFs that are genetically deleted for SFKs and the absence of STAT5 activation in 
MEFs genetically deleted for JAK2.  The latter was rescued upon reintroduction of JAK2.  
GH activation of STAT5 was also significantly decreased in 3T3-F442A and H4IIE cells with 
reduced levels of JAK2 due to expression of shRNA to JAK2. 
 Similar to our results with STAT5, our findings with STATS 1 and 3 suggest that their 
activation by GH is highly dependent upon JAK2 and independent of Src family kinases. The 
independence from Src family kinases is supported by the findings that PP1 and PP2 
eliminated Src activity but had no effect on the ability of GH to activate STATs 1 and 3 in 
H4IIE and 3T3-F442A cells, respectively.  In addition, STAT3 was robustly activated by GH 
in SYF MEFs that are genetically deleted for SFKs.  In support of their activation being 
dependent upon JAK2, GH activation of STATs 1 and 3 above basal values was severely 
depressed in H4IIE and 3T3-F442A cells, respectively, in which JAK2 levels were reduced 
using shRNA to JAK2.  The dependence of GH activation of STATs 1 and 3 on JAK2 is 
consistent with the finding of Han et al. (196) that STATs 1 and 3 are activated by GH in 
wild-type H1080 cells but not in H1080 cells lacking intact JAK2.  
 Our Src family kinase chemical inhibitor and SYF MEF experiments also 
demonstrate that GH-mediated activation of ERKs 1 and 2 is not dependant on Src family 
kinases in 3T3-F442A, H4IIE or MEF cells.  This finding is consistent with the previous 
findings that Shc phosphorylation and MAP kinase activity are stimulated by GH in CHO-GH 
receptor cells but not in CHO cells stably expressing a mutated GH receptor lacking the 
binding site for JAK2 (48, 197).  It is also consistent with the report that Shc phosphorylation 
is stimulated by GH in wild-type H1080 cells but not in H1080 cells lacking JAK2 (196).  Zhu 
et al. (30, 31) proposed a JAK-independent, Src-dependent mechanism for activation of 
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ERKs 1 and 2 based on the observations that GH activates c-Src (as well as JAK2) in NIH-
3T3 cells, GH stimulates Ral A and Ral B, GH-activated RalA results in an increase in 
phospholipase D activity and the production of phosphatidic acid, and RalA, phospholipase 
D activity and phosphatidic acid are all required for GH-stimulated activation of ERKs 1 and 
2 as assessed using an Elk-1 reporter assay.  However, this group did not actually test 
directly the effects of decreasing levels of JAK2 or Src family kinase activity (by use of 
pharmacological inhibitors or decreasing levels of expression) on the ability of GH to 
activate ERKs 1 and 2.  Thus, the relative contributions of JAK2 and Src kinases to GH 
activation of ERKs 1 and 2 are not clear, nor is it clear from those studies whether Src is 
sufficient, or simply necessary, for GH activation of ERKs 1 and 2.  Finally, Gu et al. (198) 
raise the possibility of Src regulating GH-mediated activation of ERK2 by showing that 
overexpression of Csk (a protein that inactivates Src family kinases) in cardiac myocytes 
inhibits the ability of GH to activate overexpressed ERK2.  Unfortunately, Src family kinase 
and JAK2 activities were not assessed in the context of Csk overexpression, raising the 
possibility that this effect of Csk overexpression was not Src family kinase-specific.  
Furthermore, inhibitors of JAK2, EGF receptor and Src all blocked GH stimulation of ERKs 1 
and 2 in these cells, confounding the assessment of the role of Src kinases in the process. 
 In the case of Akt, we observed in both 3T3-F442A and H4IIE cells a PP1 and PP2-
dependent inhibition of GH-mediated phosphorylation on Ser473, raising the possibility that 
GH activation of Akt may require Src family kinases.  This would be consistent with studies 
in human neutrophils and BAF3 cells that suggest that the cytokines granulocyte-
macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor 
(G-CSF) may signal to STATs and MAP kinases through JAKs but signal to Akt through Src 
family kinases (199, 200).  However, we found that GH robustly stimulates the 
phosphorylation of Ser-473 in Akt in MEFs genetically deleted for Src family kinases.  
Furthermore, reduction of endogenous JAK2 levels by shRNA reduced GH-mediated Akt 
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activation to barely detectable levels in both 3T3-F442A and H4IIE cells, indicating that 
JAK2 is essential for GH-mediated Akt activation in these cells.  Consistent with Akt 
activation requiring JAK2, Yamauchi et al. (161) found in 2A-GHR cells lacking JAK2, that 
GH is unable to stimulate the tyrosyl phosphorylation of IRS-1, IRS-2, and IRS-3, their 
association with p85 subunit of PI3-kinase and the activation of PI3-kinase, events that are 
thought to link GH receptor to Akt activation.  Similarly, Argetsinger et al. (158, 164) found 
that GH stimulated tyrosyl phosphorylation of IRS 1 and 2 in CHO-GHR cells but not in CHO 
cells stably expressing a mutated GH receptor lacking the binding site for JAK2.  Thus, our 
finding that PP1 and PP2 inhibit GH-induced Ser473 phosphorylation of Akt raises the 
possibility that Src activity, rather than being a necessary component linking GH receptor to 
Akt, may be indirectly required for GH to activate Akt.   Supporting this hypothesis, the Qui 
group (201, 202) has described a potential mechanism whereby Src must phosphorylate Akt 
on Tyr315 and Tyr326 prior to growth factor-dependent phosphorylation of Thr308 and 
Ser473.  Consistent with this, our data show that both PP1 and PP2 inhibit basally active Akt 
(Fig. 2.3 A and B), raising the possibility that maximal phosphorylation of Akt Ser473 by any 
factor is unachievable when Src activity is decreased.  In support of this idea, we found that 
EGF is also unable to stimulate phosphorylation of Ser473 in Akt when 3T3-F442A 
preadipocytes are pretreated with PP1 or PP2 (data not shown).  Because PP3 at the 
concentrations used did not inhibit Src kinase activity, the finding that PP3 inhibits both 
basal and GH stimulated phosphorylation of Ser473 in Akt also raises the possibility that the 
effects of PP1 and PP2 are not mediated exclusively via Src family kinases.  PP1 and PP2 
have been reported to have significant off-target effects (189, 190).  
 An interesting byproduct of our studies is the observation that some signaling 
pathways are more tightly coupled to the level of activation of JAK2 than others.  Thus, 
when JAK2 levels were reduced by ~80% by shRNA against JAK2 in 3T3-F442A 
preadipocytes, the ability of GH to activate JAK2, ERKs 1 and 2, Akt, and STAT3 was 
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reduced to a similar extent.  In contrast, the ability of GH to stimulate the tyrosyl 
phosphorylation of STAT5 was reduced by only ~50%.  In JAK2 shRNA 3T3-F442A cells 
that exhibited only a 50-60% reduction of JAK2 (as quantified from all time points in two 
independent experiments), GH activation of ERKs 1 and 2 and Akt was again almost 
abolished, whereas GH stimulation of STAT5 activity was relatively unaffected (data not 
shown).  Although one could argue that this apparent discrepancy is because another 
kinase is necessary for maximal GH activation of STAT5, the MEF data argue that JAK2 is 
required for GH activation of STAT5 since we detected no GH stimulation of STAT5 when 
JAK2 was completely absent.  These results therefore suggest that in the case of ERKs 1 
and 2, Akt and STAT3, levels of activated JAK2 are rate-limiting, whereas they are not for 
STAT5. The MEF data also show that replacement of only a small amount of JAK2 is able to 
reconstitute substantial GH activation of STAT5.  That levels of STAT5 rather than levels of 
JAK2 appear to be rate-limiting in 3T3-F442A cells and MEFs is not so surprising, given that 
STAT5 is known to be recruited to multiple binding sites in the GH receptor (26), where it is 
rapidly phosphorylated by JAK2 and released from the GH receptor.  It then migrates to the 
nucleus where it is thought to undergo dephosphorylation and then recycle back to the GH 
receptor for reactivation (36).  The conclusion that levels of STAT5 rather than levels of 
JAK2 are sometimes rate-limiting for GH activation of STAT5 would be consistent with the 
finding of Yang et al. (6) using both 3T3-F442A cells and 2A cells expressing ectopic GH 
receptor and JAK2. When these cells were treated with a dimerized form of the GH 
antagonist G120R, GH activation of STAT5 was maintained at normal levels even though 
levels of JAK2 activation are greatly suppressed.  These results emphasize the need to 
consider the rate-limiting step in instances in which one GH signaling pathway (e.g. GH 
activation of STAT5) is inhibited to a lesser extent other GH signaling pathways.  We also 
noticed that in contrast to the 3T3-F442A cells, in H4IIE cells, GH’s ability to activate STAT5 
appears to be more closely linked to levels of JAK2. In JAK2 shRNA cells, the reduction in 
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levels of GH-activated STAT5 was similar to the reduction in levels of JAK2.  This finding 
suggests that the rate-limiting step for a particular GH signaling pathway may vary between 
cell types. 
 In conclusion, our results using pharmacological inhibitors of Src family kinases and 
cells with reduced levels of JAK2 using shRNA suggest that JAK2 and not a Src family 
kinase, is the primary kinase responsible for GH activation of STATs 1, 3, and 5, ERKs 1 
and 2, and Akt in the well characterized, highly GH-responsive 3T3-F442A preadipocytes 
and H4IIE hepatoma cells.  Studies using JAK2 and Src-deficient MEFs further support the 
hypothesis that GH is capable of activating STATs 3 and 5, ERKs 1 and 2, and Akt in the 
absence of Src family kinases and is incapable of activating STAT5 in the absence of JAK2.  
It is conceivable, however, that in different cell lines, perhaps where the ratio of Src family 
kinases to JAK2 is naturally or artificially high, Src family kinases are able to substitute for 
some or all of the actions of JAK2.  One can also envision the levels of some as yet 
unidentified accessory proteins shifting the balance between JAK2 and Src in ways that we 
do not yet understand.  Finally, our data provide a reminder that some signaling pathways 
are more tightly coupled to the level of activation of JAK2 than others and that this level of 
coupling is likely to vary between cell types.  Thus, titrating the level of JAK2 activity should 




Materials and Methods 
 
 Reagents: Recombinant 22,000-Da human GH was a kind gift from Eli Lilly & Co. 
(Indianapolis, IN). Dulbecco’s Modified Eagle Medium (DMEM) was from Cambrex.  Swims 
S-77 powder, L-cystine and L-glutamine were from United States Biological.  Fetal bovine 
serum (FBS) was from Hyclone. Calf serum was from Atlanta Biologica.  Sodium 
bicarbonate powder was from Mallinckrodt.  Calcium chloride dihydrate, puromycin and 
polybrene (hexadimethrine bromide) were from Sigma.  The antibiotic-antimycotic solution, 
trypsin-EDTA and Magic Mark XP western standards were from Invitrogen.  Aprotinin, 
leupeptin, and Triton X-100 were from Roche. Recombinant protein A-agarose was from 
Repligen.  Hybond-C Extra nitrocellulose was from Amersham Biosciences.  Src family 
kinase inhibitors PP1 and PP2 were from BioMol (Plymouth Meeting, PA).  PP3 was from 
Calbiochem.  The mammalian expression vector prk5 encoding wild-type murine JAK2 (GI: 
309463) was a generous gift from Dr. J. Ihle (St. Jude Children’s Hospital, Memphis, TN) 
(203). 
 Antibodies: Antibodies recognizing a peptide containing phosphorylated tyrosines 
1007 and 1008 of JAK2 (pY1007/1008, cat. #07-606); phosphotyrosines (PY) (4G10, cat. 
#05-321); and phospho STAT1 (pY701-STAT1, cat. #06-657) were from Upstate 
Biotechnology, Inc.  Antibody recognizing total STAT1 was from Transduction Laboratories 
(cat. # S21120).  Antibody recognizing both total STAT5b and total STAT5a (STAT5, cat. # 
sc-1656) was from Santa Cruz Biotechnology, Inc.  Antibody recognizing both 
phosphoSTAT5a and phospho STAT5b (pY694-STAT5, cat. #71-6900) was from Zymed 
Laboratories, Inc.  Antibodies recognizing phosphoSTAT3 (pY705-STAT3, cat. #9131), 
total STAT3 (STAT3, cat #4904), phosphoERKs 1 and 2 (pT202/pY204-ERK1/2, cat. 
#9106), total ERKs 1 and 2 (ERK1/2, cat. #4695), phosphoAkt (pS473-Akt, cat. #4058), 
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total Akt (Akt, cat. #9272) and phosphoSrc (pY416-Src, cat. #2113) were from Cell 
Signaling Technology. Mouse monoclonal antibody recognizing Src was from Dr. Tony 
Hunter (Salk Institute).  Mouse monoclonal antibody recognizing total JAK2 and used for 
immunoblotting was from BioSource International, Inc.  Polyclonal antibody used for JAK2 
immunoprecipitation was raised against a peptide corresponding to amino acids 758 to 776 
of murine JAK2 and prepared by our laboratory in conjunction with Pel-Freez Biologicals (5).  
Polyclonal GHBP antibody used for GH receptor immunoprecipitation was from Dr. William 
Baumbach (American Cyanamid Company, Princeton, N.J.).  Polyclonal antibody (AL47) 
used for GH receptor immunoblot was a kind gift from Dr. Stuart Frank (University of 
Alabama) (204).  IRDye 800 conjugated affinity purified anti-mouse IgG and anti-rabbit IgG 
were from Rockland.   
 Gene silencing by shRNA and retroviral infection:  The target sequences of 
murine and rat JAK2 were 5'- GGAGAGTATCTGAAGTTTC-3’ (205) and 5’ - 
GGAATGGCTTGCCTTACAA-3’ (206), respectively.  Oligonucleotides were annealed and 
subcloned into pSuperior.retro.puro (Oligoengine) at BglII and XhoI sites.  A control 
sequence of 5’- UUCUCCGAACGUGUCACGU-3’ with no known target (Qiagen-Xeragon, 
Germantown, MD) was also cloned into the same vector. Retroviral infection was performed 
according to Erickson et al. (207).  In brief, the recombinant plasmids were transfected into 
293T cells by calcium phosphate coprecipitation together with the viral packaging vectors 
SV-E-MLV-env and SV-E-MLV (208).  Virus-containing medium was collected 16 h after 
transfection and passed through a 0.45-µm syringe filter.  Polybrene was added to a final 
concentration of 8 µg/ml.  This medium was then applied to subconfluent (~30%) 3T3-F442 
cells or H4IIE cells.  The infection protocol was repeated twice with intervals of 8-16 h.  
When cells achieved ~ 80% confluence, they were trypsinized and cells expressing JAK2 
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shRNA were stably selected in medium containing 2 µg/ml (3T3-F442A cells) or 40 g/ml 
(H4IIE cells) puromycin.   
 Cell culture and transfection: The stock of murine 3T3-F442A preadipocytes was 
kindly provided by H. Green (Harvard University).  H4IIE rat hepatoma cells were a kind gift 
from J. Messina (University of Alabama Birmingham School of Medicine).  SYF (Src/yes/fyn) 
triple knock-out MEFs were kindly provide by P. Soriano (Univ. of Washington, Seattle)  
(192).  JAK2-/- MEFs were a kind gift of J. Ihle (St. Jude Children’s Hospital, Memphis, TN) 
(209).  3T3-F442A cells and 293T cells were grown in DMEM supplemented with 1 mM L-
glutamine, 100 U of penicillin per ml, 100 g of streptomycin per ml, 0.25 g of amphotericin 
per ml, and 8% calf serum.  H4IIE cells were grown in SWIMS 77 medium supplemented 
with 5% FBS, 26.2 mM sodium bicarbonate, 4 mM L-glutamine, 98 M L-cystine and 1.8 
mM calcium chloride dihydrate.  MEFs were grown in DMEM supplemented with 8% FBS, 
100 U of penicillin per ml, 100 g of streptomycin per ml, and 0.25 g of amphotericin per 
ml.  MEFs were transiently transfected using lipofectamine 2000 (Invitrogen, CA).  All cells 
were incubated overnight in serum-free medium containing 1% bovine serum albumin 
before treatment with 100 M PP1, PP2, or PP3 and/or GH (500 ng/ml).  All experiments 
were carried out at 37C. 
Immunoprecipitation and immunoblotting:  For all experiments, cells were grown in 10 
cm culture dishes. After GH treatment, cells were washed and solubilized in lysis buffer (50 
mM Tris [pH 7.5], 0.1% Triton X-100, 150 mM NaCl, 2 mM EGTA, 1 mM Na3VO4, [pH 7.5]), 
containing 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, and 10 g/ml leupeptin.  
1% Triton X-100 was used in place of 0.1% Triton X-100 to lyse cells for GH receptor 
studies.  The supernatant was collected.  For H4IIE cells, 50% of the supernatant was 
incubated with JAK2 on ice for 2 h followed by protein G-agarose beads (GE) rotating at 
4C for 1 h.  For GH receptor immunoprecipitation, 60% of the supernatant was incubated 
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with GHBP on ice for 2 h followed by protein G-agarose beads (GE) rotating at 4C for 1 h.  
The beads were washed three times with lysis buffer and boiled for 5 min in a mixture 
(80:20) of lysis buffer and SDS-PAGE sample buffer (250 mM Tris-HCl [pH 6.8], 10% SDS, 
10% ß-mercaptoethanol, 40% glycerol, 0.01% bromophenol blue).  Eluted proteins as well 
as proteins in cell lysates prepared in the same buffer were separated by SDS-PAGE, using 
10% polyacrylamide gels and an acrylamide:bis acrylamide ratio of 30:0.5. Bands on 
Western blots represent 12.5% of the total lysate from a 10 cm culture plate.   For 
immunoblotting, proteins in the gel were transferred to nitrocellulose and detected by 
immunoblotting with the indicated antibody using the ODYSSEY Infrared Imaging System 
(LI-COR Bio-sciences).  The intensity of the bands in immunoblots was quantified using Li-
Cor Odyssey 2.1 software.  Values for phosphorylated proteins were normalized for total 
levels of that protein.  For the shRNA experiments, JAK2 protein levels were normalized for 
total Src (H4IIE) or total ERK1/2 (3T3-F442A)  protein levels.  Every experiment was carried 
out at least twice with similar results.  Most were performed 3 or more times (number 
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Growth hormone induces SH2B1 and JAK2 to form a complex with the novel 




SH2B1 is a multifunctional adaptor protein that modulates processes involving 
regulation of the cytoskeleton such as cellular motility and differentiation. This raises the 
possibility that SH2B1 interacts with components of the cytoskeleton or proteins that 
regulate the cytoskeleton.  To identify novel SH2B1 interacting proteins, a yeast-two-
hybrid assay was performed. The C-terminal 158 amino acids of the cytoskeleton 
structural protein, II1-spectrin, were identified as interacting with the N-terminal 260 
amino acids of SH2B1.  Subsequent co-immunoprecipitation assays revealed that 
SH2B1 amino acids 105-150 interact with II1-spectrin amino acids 2200-2358, and 
confocal microscopy experiments showed that II1-spectrin co-localizes with both 
SH2B1 and the SH2B1-binding partner, JAK2, at the plasma membrane 
(pm)/cytoskeleton.  Phosphorylation of spectrins has previously been shown to regulate 
spectrin localization and/or function, prompting us to assess the possibility that JAK2 
phosphorylates II-spectrin.  Co-expression of JAK2 with II1-spectrin and the II1-
spectrin splice variant, II2-spectrin, resulted in tyrosyl phosphorylation of both II-
spectrin isoforms.  Interestingly, this phosphorylation was dependent on co-expression 
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of SH2B1.  Finally, growth hormone (GH) stimulation induced an SH2B1-dependent 
formation of a complex of endogenous II-spectrin, SH2B1 and JAK2 in 3T3-F442A cells 
and a redistribution of II2-spectrin from cell-cell contacts to the cytoplasm in H4IIE 
cells.  These results identify a novel interaction between SH2B1, II1-spectrin and 
JAK2, and uncover an SH2B1-dependent phosphorylation of II-spectrin by JAK2 that 





Adaptor proteins are generally characterized as proteins that lack intrinsic 
enzymatic activity yet serve as important modulators of signal transduction systems by 
recruiting and linking together additional signaling molecules.  Within the SH2B family of 
adaptor proteins, SH2B1 is known to modulate signaling induced by multiple hormones 
and growth factors (reviewed in (101)).  SH2B1 mRNA is alternatively spliced into four 
isoforms, resulting in four proteins (, , , ) that share an N-terminal dimerization 
domain (DD), nuclear localization sequence (NLS) and nuclear export sequence (NES), 
and a C-terminal pleckstrin homology (PH) and Src homology 2 (SH2) domain (see 
schematic in Fig. 1).  Each isoform contains unique sequences C-terminal to the SH2 
domain (105, 210).   
We and others have shown previously that SH2B1 modulates hormone and 
growth factor induced cellular responses that require regulation and/or modification of 
the actin-based cytoskeleton.  These responses include nerve growth factor (NGF)-
induced neurite outgrowth (109, 110); GH and platelet-derived growth factor (PDGF)-
induced cell ruffling and pinocytosis (132); GH-induced phagokinesis, lamellipodia 
activity and cell migration (112); and PDGF and insulin-like growth factor 1 (IGF-1)-
induced mitogenesis (105).  SH2B1 is also able to regulate actin-based bacterial 
motility (134). SH2B1 has been shown to localize with filamentous actin in ruffles (132), 
interact with the cytoskeleton remodeling proteins, Rac (112) and (bacterial) ActA (134), 
and cross-link actin filaments (113).  Interestingly, SH2B1 C-terminal truncation and 
point mutants act as dominant negative proteins in many of the above processes (110, 
112, 132), suggesting that the N-terminus of SH2B1 interacts with one or more proteins 
that are important regulators of the actin cytoskeleton. 
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Spectrins are large (>2000 amino acids) rod-like proteins that reside at the pm 
interface and act to cross-link actin filaments, transmembrane proteins and lipids either 
directly or indirectly through spectrin binding partners (reviewed in (131, 211).  In this 
way, spectrins are critical organizers and mediators of cellular signaling, adhesion, 
mechanical stability and polarity (reviewed in (130).  Cytoskeletal spectrins 
predominantly exist as  heterodimers that organize in a head-to-tail fashion to form 
heterotetramers (212, 213).   and  spectrins each contain PH domains as well as 
actin-binding calponin homology (CH) domains.  -spectrins contain an additional Src 
homology 3 (SH3) domain and a calmodulin-related domain.   and  spectrins also 
contain many (between 16 and 30) adjoining spectrin repeats, which typically consist of 
106 amino acid motifs (214) that form triple helical coiled coils (215, 216).  In humans, 
two -spectrin genes (I and II) have been identified along with 6 -spectrin genes (I, 
II, III, IV, V and golgi).  I, II and IV-spectrin mRNA each undergo alternative 
splicing to produce multiple protein isoforms (eg. II1, II2), potentially increasing the 
complexity of spectrin dimer and tetramer composition within the cytoskeleton (reviewed 
in (217)). 
Several groups have shown that both function and localization of  and  
spectrins can be regulated by phosphorylation.  The earliest report (performed prior to 
identification of differing spectrin isoforms) found that phosphorylation of spectrin 
dramatically increased its ability to bind actin and promote actin polymerization (218).  
More recently, TGF- has been found to induce serine phosphorylation and translocation 
of II2-spectrin (also named ELF for embryonic liver fodrin) from the plasma membrane 
into the nucleus in HepG2 cells (219).  II2-spectrin is also thought to be serine and 
threonine phosphorylated by protein kinase casein kinase 2 (PKCK2) and/or protein 
kinase A (PKA) in response to cAMP, which may decrease its affinity for II-spectrin and 
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be necessary for neuritogenesis in PC12 cells (220).  In addition, serine phosphorylation 
is correlated with a redistribution of II-spectrin from the membrane to the cytosol during 
mitosis in CHO and HeLa cells (221).    Casein kinase I-mediated I-spectrin 
phosphorylation has been shown to decrease mechanical stability of erythrocyte 
membranes (222). Finally, tyrosine phosphorylation of II-spectrin is thought to induce 
calpain-mediated cleavage (223).  
Here we identify II1-spectrin as a SH2B1 binding partner and show that JAK2 
is able to phosphorylate both II1 and II2-spectrin in an SH2B1-dependent manner.  
We also show that GH stimulation induces the formation of a II-spectrin/SH2B1/JAK2 
complex in 3T3-F442A cells and causes a shift in subcellular localization of BII spectrin 
in H4IIE hepatoma cells, raising the possibility that some of SH2B1’s regulatory effects 





Amino acids 105-150 of SH2B1 interact with amino acids 2200-2358 of 
II1-spectrin.  SH2B1 C-terminal truncation and point mutants act as dominant 
negative proteins in assays involving cytoskeletal reorganization (112, 132), suggesting 
that the N-terminus of SH2B1 may bind unknown proteins that are functionally relevant 
for this process.  To identify novel N-terminal SH2B1-interacting proteins, a yeast-2-
hybrid assay was utilized to screen a rat adipose cDNA library using amino acids 1-260 
of SH2B1 as bait (see Fig. 3.1 for SH2B1 schematic).  From 5.85 x 106 initial 
transformants, 22 LacZ+/Leu+ colonies were selected for further characterization.  One 
of these positives comprised amino acids 2200-2358 of the cytoskeletal protein, II1-
spectrin (Fig. 3.1).  To verify the yeast-two-hybrid assay interaction between the C-
terminus of II1-spectrin and the N-terminus of SH2B1, as well as to more precisely 
define the SH2B1 region of interaction, co-immunoprecipitation assays were 
performed.  Myc-tagged full-length and C-terminal SH2B1 truncation mutants were 
expressed with HA-tagged II1-spectrin (2200-2358) in 293T cells (Fig. 3.2A).  Myc-
tagged SH2B1 (1-670), (1-260), (1-200) and (1-150) all co-immunoprecipitated with 
HA-II1-spectrin (2200-2358) (Fig. 3.2A, lanes 2, 3, 4, and 5), while myc-SH2B1 (1-
105) failed to co-immunoprecipitate with HA-II1-spectrin (2200-2358) (lane 6).  These 
results indicate that the SH2B1-spectrin interaction is mediated through amino acids 




Figure 3.1.  Schematic representations of II1-spectrin and SH2B1.  
Abbreviations used are DD for dimerization domain, NLS for nuclear localization 
sequence, NES for nuclear export sequence, PH for pleckstrin homology domain, SH2 




We have previously characterized several SH2B1 domains as being crucial for 
the subcellular localization and/or function of SH2B1, including the polybasic NLS/pm-
localization region, the NES and the SH2 domain.  Mutation or deletion of the NLS/pm 
localization region inhibits SH2B1 from both binding the pm (Maures, et al. Manuscript 
in preparation) and cycling through the nucleus (107) and prevents SH2B1 from 
enhancing neurite outgrowth (106).  Mutation or deletion of the NES causes nuclear 
accumulation of SH2B1 and also prevents SH2B1 enhancement of NGF-induced 
neurite outgrowth (107).  Mutation and/or deletion of the SH2 domain results in a 
dominant negative phenotype for GH-induced cell ruffling (132), lamellipodia activity, 
phagokinesis and motility (112) and NGF-induced neurite outgrowth.  Each of the above 
processes require cytoskeletal remodeling, therefore, we sought to determine whether 
any of these mutations disrupt the interaction of SH2B1 with II1-spectrin (2200-
2358).  Co-immunoprecipitation experiments showed that myc-tagged II1-spectrin 
(2200-2358) interacts with GFP-tagged SH2B1 lacking the NLS/polybasic region 
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(148-198, Fig. 3.2B, lane 2), lacking a functional NES (mNES, Fig. 3.2, lane 3) or 
lacking a functional SH2 domain (R555E, Fig. 3.2B, lane 4).  
 
Figure 3.2.  Amino acids 105-150 of SH2B1 interact with amino acids 2200-2358 of 
II1-spectrin.  A) HA-tagged II1-spectin (2200-2358) was expressed with myc-
tagged WT SH2B1 or SH2B1 truncation mutants in 293T cells as indicated. Proteins 
from cell lysates were blotted with myc (right panel) or immunoprecipitated with HA 
and blotted with myc (left panel).  B) myc-tagged II1-spectrin (2200-2358) was 
expressed with GFP-tagged WT and mutant SH2B1 and WT SH2B1 in 293T cells.  
Proteins from cell lysates were blotted with GFP (bottom panel) or  immunoprecipitated 
with myc and blotted with GFP (top panel). 
 
 
These results indicate that the NLS, NES and SH2 domains of SH2B1 do not 
affect the ability of with SH2B1 to interact with aa 2200-2358 of II1-spectrin.  GFP-
SH2B1 also co-immunoprecipitated with myc-II1-spectrin (2200-2358) (Fig. 3.2B, 
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lane 5).  This latter finding suggests that II1-spectrin interacts with multiple SH2B1 
isoforms, consistent with the region of interaction lying within the region of SH2B1 
shared among all 4 SH2B1 isoforms.  However, the findings that II1-spectrin (2200-
2358) interacts with SH2B1 (148-198), (mNES), and SH2B1 were somewhat 
unexpected, given that II1-spectrin is characterized as a pm protein, while SH2B1 
primarily localizes to nucleoli (108).  SH2B1 (148-198) has been shown to be primarily 
cytoplasmic and mNES resides primarily in the nucleus.  We therefore wondered 
whether II1 spectrin 2200-2358 might be mislocalized. 
SH2B1 is able to alter II1-spectrin (2200-2358) subcellular localizaton. 
Using confocal microscopy to visualize II1-spectrin in living 293T cells, we found 
II1-spectrin (2200-2358) to localize to the cytoplasm and nucleus (Fig. 3.3A-C), 
revealing that II1-spectrin (2200-2358) is not properly targeted to the pm.  GFP-
SH2B1 localized to both the cytoplasm and pm (see Fig. 3.5B) consistent with previous 
reports (224), while GFP-SH2B1 appeared to localize primarily to nucleoli (Fig. 3.3D-F) 
as reported previously (108).  When co-expressed with GFP-SH2B1, mCherry-II1-
spectrin (2200-2358) remained predominantly in the cytoplasm and nucleus, although 
some pm localization was observed (Fig. 3.3G-I).  When co-expressed with GFP-
SH2B1, mCherry-II1-spectrin (2200-2358) was nearly completely localized to nucleoli 
(Fig. 3J-L).  These results indicate that SH2B1 is able to alter the subcellular localization 
of II1-spectrin (2200-2358), suggesting that the interaction between SH2B1 and II1-
spectrin is robust.  Interestingly, although spectrins are classically described as 
membrane/cytoskeletal proteins, several recent reports show that some spectrins are 
targeted to the nucleus (reviewed in (225)) and nucleoli (226, 227) raising the possibility 







Figure 3.3.  SH2B1 is able to alter the localization of II1-spectrin (2200-
2358).  mCherry-II1-spectrin (2200-2358), GFP-SH2B1 and GFP-SH2B1 were 
expressed alone or in combination in 293T cells as indicated.  Cells were fixed and 
imaged by confocal microscopy. Cells expressing mCherry-II1-spectrin (2200-2358) or 
GFP-SH2B1 alone were DAPI stained to visualize nuclei.  Arrows in H indicate co-




II1-spectrin (2165-2358) recruits cytosolic SH2B1 (148-198) to the pm.  
II1-spectrin is well characterized as a pm associated protein, indicating that the 
cytosolic/nuclear localization exhibited by II1-spectrin (2200-2358) is atypical.  
Spectrin is thought to participate in the polarization of cuboidal epithelial cells (228, 229) 
and, therefore, cuboidal epithelial cells, such as MDCK cells, are often used to assess 
II-spectrin localization and function. II1-spectrin (2200-2358) expressed in MDCK 
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cells also localized to both the cytoplasm and nucleus (Fig. 3.4C), indicating that this 
localization pattern was not an artifact of expression in 293T cells (Fig. 3.4A).  PH 
domains are known phospholipid and protein-protein interaction domains (reviewed in 
(230)), and the spectrin PH domain has been shown to bind phospholipids in vitro (231, 
232) and be targeted to the pm of COS7 cells (233).  II1-spectrin (2200-2358) consists 
of the extreme C-terminus of II-spectrin, and contains most, but not all, of the spectrin 
PH domain.  Addition of 35 amino acids to II1-spectrin (2200-2358) produced a II1-
spectrin C-terminal fragment that contains an intact PH domain [II1-spectrin (2165-
2358)]. Consistent with a previous report (233), and in contrast to II1-spectrin (2200-
2358) (Fig. 4A, 4C), II1-spectrin (2165-2358) localized almost entirely to the pm in 
both 293T cells (Fig. 3.4B) and MDCK cells (Fig. 3.4D).  
We next asked if, in addition to SH2B1 being able to alter C-terminal II1-
spectrin localization (Fig. 3.3), whether pm localized II1-spectrin (2165-2358) could 
recruit SH2B1 to the pm.  To this end, SH2B1 (148-198), which exhibits decreased 
pm and increased cytosolic localization (Maures, et al. Manuscript in preparation) 
compared to WT SH2B1, was expressed with or without II1-spectrin (2165-2358) in 
293T cells.  Cell lysates were separated into membrane and cytosolic fractions and the 
relative distribution of SH2B1 (148-198) was assessed (Fig. 3.4E).  When expressed 
with II1-spectrin (2165-2358), more SH2B1 (148-198) was found in the membrane 
fraction than when SH2B1 (148-198) was expressed alone (compare Fig. 3.4E, top 
panel, lanes 1 and 2).  Conversely, when expressed with II1-spectrin (2165-2358), 
less SH2B1 (148-198) was found in the cytosolic fraction than when SH2B1 (148-
198) was expressed alone (compare Fig. 3.4E, top panel, lanes 3 and 4).  Because -
spectrins are able to organize structural and signaling proteins to specific regions within 
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the pm (reviewed in (234)), these results suggest that II1-spectrin may be involved in 




Figure 3.4.  II1-spectrin (2165-2358) is targeted to the pm and is able to alter 
SH2B1 (148-198) localization.  GFP-II1-spectrin (2200-2358) was expressed in 
293T (A) or MDCK (C) cells.  GFP-II1-spectrin (2165-2358) was expressed in 293T 
(B) or MDCK (D) cells.  Cells were fixed and imaged by confocal microscopy.  E) GFP-
SH2B1 (148-198) was expressed alone or with II1-spectrin (2165-2358) in 293T 




II1-spectrin co-localizes with both SH2B1 and JAK2.  To determine if full-
length II1-spectrin co-localizes with full-length SH2B1, II1-spectrin and SH2B1 
were expressed alone or together in 293T cells (Fig. 3.5).  As expected, when expressed 
alone GFP-II1-spectrin (Fig. 3.5A) and GFP-SH2B1 (Fig. 3.5B) each localized 
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primarily to the pm.  To begin to explore a potential functional significance of the II1-
spectrin/SH2B1 interaction, we investigated the possibility that the SH2B1 binding 
partner, JAK2 ((100), reviewed in (101)), is also a component of this interaction.  
Consistent with previous reports demonstrating JAK2 localization at the pm in HEK293T 
and 2A cells (235, 236), GFP-JAK2 localized primarily to the pm in 293T cells (Fig. 5C).  
CFP-JAK2, GFP-II1-spectrin and mCherry-SH2B1 all co-localized at the pm when all 
three proteins were expressed in 293T cells (Fig. 3.5D-G).  These results raise the 
possibility that II1-spectrin exists in a complex with SH2B1 and JAK2 at the pm and 




Figure 3.5.  II1-spectrin co-localizes with SH2B1 and JAK2 at the plasma 
membrane.  Fluorescently tagged II1-spectrin, SH2B1 and JAK2 were expressed 
alone (Panels A-C) or together (Panels D-G) in 293T cells and image by live confocal 





SH2B1 is necessary JAK2-induced tyrosyl phosphorylation of II1-
spectrin and II2-spectrin.  II-spectrin is known to be tyrosyl phosphorylated by Src 
kinase in COS cells (237), and, although -spectrin can be tyrosyl phosphorylated by 
insulin receptor kinase (238, 239), Src kinase and epidermal growth factor receptor 
kinase (239) in vitro, no studies have yet shown -spectrins to be tyrosyl phosphorylated 
in vivo.  To determine if JAK2 is able to induce tyrosyl phosphorylation of II1-spectrin, 
GFP-II1-spectrin was expressed alone (Fig. 3.6A, lane 3) or with JAK2 (Fig. 3.6A, 
lane 2) in 293T cells.  Co-expression of II1-spectrin and JAK2 did not result in II1-
spectrin tyrosyl phosphorylation (compare Fig. 3.6A, top panel, lanes 2 and 3).  
However, when Flag-SH2B1 was co-expressed with GFP-II1-spectrin and JAK2, 
GFP-II1-spectrin was tyrosyl phosphorylated (Fig. 3.6A, top panel, lane 4).  The 
alternative splice variant of II1-spectrin, II2-spectrin, is ~92% identical to II1-
spectrin at the amino acid level, differing in sequence at the N and C-termini.  To 
determine if JAK2 is also able to mediate tyrosyl phosphorylation of II2-spectrin, myc-
II2-spectrin and JAK2 were expressed without (Fig. 3.6B, lane 1) or with (Fig. 3.6B, 
lane 2) myc-SH2B1.  As with II1-spectrin, JAK2 was only able to induce tyrosyl 




Figure 3.6.  JAK2 induces SH2B1-dependent tyrosyl phosphorylation of II1-
spectrin and II2-spectrin.  A) GFP-II1-spectrin, JAK2, and Flag-SH2B1 were 
expressed alone or in combination in 293T cells.  Cell lysates were blotted with 
phospho-tyrosine, GFP, JAK2 and Flag as indicated.  B) myc-II2-spectrin and 
JAK2 were expressed with or without myc-SH2B1 in 293T cells.  Cell lysates were 
blotted with phospho-tyrosine, II2-spectrin, JAK2 and myc as indicated. 
 
 
GH induces an SH2B1-dependant II-spectrin/SH2B1/JAK2 complex.  3T3-
F442A cells express SH2B1 (100) and GH stimulation of these cells results in JAK2 
activation (5, 240), making these cells a suitable model to test potential JAK2-mediated 
phosphorylation of II-spectrin in response to ligand activation using endogenous 
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proteins.  To determine if 3T3-F442A cells express II-spectrin, 3T3-F442A cells were 
separated into a cytoskeletal-enriched fraction and a soluble fraction (see materials and 
methods) and blotted with II-spectrin (an antibody that recognizes both II1-spectrin 
and II2-spectrin) and vinculin (Fig. 3.7A).  II-spectrin was found exclusively in the 
cytoskeletal fraction while vinculin was found in both the soluble and cytoskeletal 
fractions, consistent with previous reports (241). 
We have established 3T3-F442A cells that stably express either control shRNA 
(shControl) or shRNA against SH2B1 (shSH2B1) that results in a significant reduction 
of SH2B1 (Fig. 3.7B, bottom panel, compare lanes 1 and 3).  These cells allowed us to 
examine the necessity of SH2B1 for GH-induced JAK2-mediated phosphorylation of 
II-spectrin.  3T3-F442A shControl cells (Fig. 3.7B, lanes 1 and 2) or shSH2B1 cells 
(Fig. 3.7B, lanes 3 and 4) were stimulated with or without GH for 20 min, and proteins 
from cell lysates were immunoprecipitated with II-spectrin.  Western blot analysis 
showed that although II-spectrin was immunoprecipitated (Fig. 3.7B, panel 2), tyrosyl 
phosphorylated II-spectrin was not detected in either shControl or shSH2B1 cells (Fig. 
3.7B, panel 1).  However, GH stimulation induced a significant increase in the 
association between SH2B1 and II-spectrin in shControl cells (Fig. 3.7B, panel 8, 
compare lanes 1 and 2).  In addition, GH stimulation induced co-immunoprecipitation of 
JAK2 with II-spectrin in shControl cells (Fig. 3.7B, panel 4 compare lanes 1 and 2).  As 
expected, a lower amount of SH2B1 co-immunoprecipitated with II-spectrin in 
shSH2B1 cells due to reduced SH2B1 protein expression (Fig. 3.7B, panel 8 compare, 
lanes 3 and 4).  Interestingly, the amount of JAK2 co-immunoprecipitating with II-
spectrin in response to GH was also reduced in shSH2B1 cells (Fig. 3.7B, panel 4, 
compare lanes 3 and 4), compared to shControl cells (Fig. 3.7B, panel 4, compare lanes 
2 and 4).  This was not due to decreased activation of JAK2, as GH induced similar 
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levels of tyrosyl-phosphorylated JAK2 in shControl and shSH2B1 cells (Fig. 3.7B, panel 
7, compare lanes 2 and 4).  These results show that II-spectrin and SH2B1 interact in 
the basal state and that GH stimulation results in a significant increase in the II-
spectrin/SH2B1 interaction.  In addition, these results indicate that GH stimulation 
induces the formation of an II-spectrin/SH2B1/JAK2 complex, and suggest that the 




Figure 3.7.  GH induces the formation of an II1-spectrin/SH2B1/JAK2 complex.  
A) 3T3-F442A lysates were separated into a cytoskeletal enriched fraction and a soluble 
fraction and blotted with II-spectrin and vinculin antibodies.  B) 3T3-F442A cells 
were serum-deprived overnight and stimulated with or without GH for 20 min.  Proteins 
from cell lysates were immunoprecipitated with II-spectrin and lysates and 
immunoprecipitates were blotted with phospho-tyrosine, II-spectrin, JAK2, and 
SH2B1 as indicated. 
 
 
GH induces subcellular redistribution of II-spectrin.  Previous reports 
described above suggest that phosphorylation of spectrins can alter their subcellular 
distribution.  In HepG2 cells, TGF-induced phosphorylation of II2-spectrin is reported 
to cause II2-spectrin to leave the pm and translocate to the nucleus (219).  To 
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determine if GH causes II2 to translocate to the nucleus,  H4IIE hepatoma cells were 
stimulated with GH or TGF over 30 min.  Western blot analysis of II-spectrin and 
proteins that are phosphorylated downstream of TGF (Smad3) and GH (JAK2) 
indicated that H4IIE cells express II-spectrin and are responsive to both TGF and GH 
(Fig. 3.8A) (177).  Immunofluorescence staining using an II2-spectrin antibody 
revealed that GH, like TGF, stimulates a redistribution of II1-spectrin from cell-cell 




Figure 3.8.  GH induces a shift in II2-spectrin subcellular localization.  H4IIE 
hepatoma cells were serum-deprived overnight and stimulated with or without GH (500 
ng/ml) or TGF- (100 ng/ml).  A) Cells were lysed at the indicated times, and proteins 
from cell lysates were immunoprecipitated with II-spectrin or JAK2 and lysates and 
immunoprecipitates were immunoblotted with II-spectrin, phospho-tyrosine or JAK2 
as indicated (top panels).  Alternately, proteins from cell lysates were 
immunoprecipitated with Smad3 and immunoprecipitates and lysates were 
immunoblotted with phospho-Smad3 or Smad3 as indicated (bottom panels).  B) 
Cells were fixed at the indicated times, immunostained for II2-spectrin and visualized 






Here we have identified II1-spectrin as a novel SH2B1 binding partner.  The region 
of interaction lies within amino acids 105-150 of SH2B1 and 2200-2358 of II1-
spectrin.  The interaction between these proteins appears to be robust, as we have 
shown that SH2B1 isoforms that localize to the pm (SH2B1) recruit cytoplasmic and 
nuclear-localized II1-spectrin (2200-2358) to the pm (Fig. 3.3).  Conversely, we 
showed that pm localized II1-spectrin (2165-2358) recruits cytoplasmic localized 
SH2B1 (148-198) to the pm (Fig. 3.4).  These results suggest that SH2B1 and II1-
spectrin interact in the appropriate subcellular locations, and raise the possibility that the 
localization of each protein may be influenced by the localization of the other. In addition, 
it is possible that II1-spectrin recruits SH2B1 to functionally relevant domains within 
the pm as spectrins have been reported to do for other proteins (reviewed in (234)).  The 
region of interaction on SH2B1 is shared between all 4 SH2B1 isoforms, indicating that 
II1-spectrin is likely to interact with all 4 SH2B1 isoforms.  Indeed, we found that 
SH2B1, like SH2B1, co-immunoprecipitates and co-localizes with II1-spectrin 
(2200-2358) (Fig. 3.2).  The co-localization of SH2B1 and II1-spectrin (2200-2358) in 
nucleoli was particularly interesting as several groups have observed spectrin in the 
nucleus and nucleoli (226, 227).   
We and/or others have previously shown that II-spectrin, SH2B1 and JAK2 all 
localize to the pm.  Therefore, it was not surprising that we observed these three 
molecules to co-localize at the pm in 293T cells (Fig. 3.5).  However, we present the 
novel finding that JAK2 induces tyrosine phosphorylation of II1-spectrin and II2-
spectrin, and that this phosphorylation is dependent on SH2B1 (Fig. 3.6).  These data 
raise several questions, including whether JAK2 directly phosphorylates II-spectrins, 
 
 96 
whether JAK2 can induce phosphorylation of II-spectrins when co-expressed with 
SH2B1 lacking the spectrin-interaction region, and whether SH2B1 physically induces 
a JAK2-II-spectrin interaction or, alternatively, enhances JAK2 activation to a level that 
is necessary for II-spectrin phosphorylation.  Some of these questions can be 
answered by our finding of a GH-induced formation of an endogenous II-
spectrin/SH2B1/JAK2 complex (Fig. 3.7).  We show that co-immunoprecipitation of 
JAK2 with II-spectrin is dependent on the presence of SH2B1, and that GH induces 
JAK2 activation to similar levels in both shControl and shSH2B1 cells.  These results 
suggest that SH2B1 physically brings II-spectrin and JAK2 together rather than 
enhancing JAK2 to a level needed to phosphorylate II-spectrin.  However, we were 
unable to observe GH-induced II-spectrin tyrosyl phosphorylation in this experiment, 
suggesting that although GH induces the formation of a II-spectrin/SH2B1/JAK2 
complex in 3T3-F442A cells, JAK2 may not phosphorylate II-spectrin under these 
conditions.  Alternatively, it is possible that under these conditions, not enough II-
spectrin was tyrosyl-phosphorylated to be observed by immunoblotting with phospho-
tyrosine or that GH induces tyrosyl-phosphorylation of II-spectrin at a time point other 
than 20 min.  Future experiments similar to those performed for Figure 3.7 should clarify 
these remaining questions. 
Historically, spectrins have been known as important structural molecules for the 
cytoskeleton.  Regulated localization of spectrins into or out of the cytoskeleton has 
been thought to be an important event in cytoskeletal reorganization (220, 221, 242).  
Spectrins have also been implicated as central nodes that serve to recruit multiple 
signaling molecules into specialized membrane regions (234).  The SH2B1-II1-
spectrin interaction may fit both models.  II-spectrin is able to bind both JAK2 and 
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SH2B1, and therefore may serve as a node to maintain two signaling molecules in 
close proximity that are important for several ligands, perhaps facilitating more efficient 
signaling.  On the other hand, data demonstrating JAK2-mediated phosphorylation of II-
spectrin and GH-induced redistribution of II2-spectrin out of cell-cell contacts and into 
the cytoplasm support spectrin being a regulated cytoskeletal structural protein.  In 
addition, SH2B1 mutants that are unable to bind the plasma membrane act as 
dominant negatives in the neuronal differentiation of PC12 cells, a process that is also 
regulated by phosphorylation of II2-spectrin (220). 
In summary, we have demonstrated that II1-spectrin is a novel SH2B1 
binding protein and that SH2B1 is required for JAK2-induced tyrosyl phosphorylation of 
both II1-spectrin and II2-spectrin.  In addition, we have shown that in 3T3-F442A 
cells, GH stimulation induces the formation of an endogenous II-spectrin/SH2B1/JAK2 
complex.  Finally, we have shown that GH induces II2-spectrin redistribution from cell-
cell contacts into the cytoplasm.  Taken together, we propose a model wherein SH2B1 
binds II-spectrin at the plasma membrane, and that upon GH stimulation, active JAK2 
recruits the II-spectrin/SH2B1 complex via the SH2 domain of SH2B1, forming a 
tertiary complex.  Active JAK2 then phosphorylates II-spectrin, resulting in the 
translocation of II-spectrin out of the pm allowing for reorganization of the cytoskeleton.  
While the functional relevance of this model is beyond the scope of this study, the 
previously demonstrated importance of II-spectrin, SH2B1 and GH in processes that 
require restructuring of the pm provide grounds for further investigation into this novel 
relationship.  Future studies assessing the impact of the II1-spectrin/SH2B1/JAK2 
interaction in cell motility, ruffling and neuronal differentiation assays will provide further 
clarification of the functional importance of this interaction. 
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Materials and Methods 
 
Antibodies:  The following antibodies were used for Western blotting at a 
dilution of 1:1000:  Anti-myc mouse monoclonal antibody (myc) (Santa Cruz 
Biotechnology, Inc.), anti-HA mouse monoclonal antibody (HA) (Covance), anti-JAK2 
(JAK2) and anti-phosphotyrosine (PY) (4G10) mouse monoclonal antibodies 
(Millipore), anti-Flag M2 mouse monoclonal antibody (Flag) (Sigma), anti-II-spectrin 
rabbit polyclonal antibody (II spectrin) (Bethyl Laboratories, Inc.), anti-Smad3 
(Smad3) and anti-phospho-Smad3 (Ser423/425) (pSmad3) rabbit polyclonal 
antibodies (Cell Signaling Technology), anti-SH2B1 [kind gift of Dr. Liangyou Rui 
(University of Michigan) (243)] (SH2B1) and anti-II2-spectrin {(ELF2), kind gift of 
Dr. Lopa Mishra (Georgetown University)}.  For immunoprecipitation, myc and HA 
were used at a dilution of 1:100, and II-spectrin was used at a dilution of 1:75.  IRDye 
800- and IRDye 700-conjugated affinity-purified anti-mouse IgG and anti-rabbit IgG 
(Rockland Immunochemicals Inc.) were used at a dilution of 1:20,000.  Anti-GFP IRDye 
800-conjugated goat polyclonal antibody (Rockland) (GFP) was used at a dilution of 
1:5000 for Western blotting.  Anti-GFP mouse monoclonal antibody (GFP mab) for 
immunoprecipitation (1:100 dilution) was from Clontech (Mountain View, CA).  -II2-
spectrin was used at a dilution of 1:100 for immunofluorescence.  Alexa Fluor 594 
secondary antibodies (dilution 1:1000) used for immunofluorescence were from 
Invitrogen. 
Reagents:  Recombinant 22,000-Da human GH was a kind gift from Eli Lilly & 
Co.  Dulbecco’s Modified Eagle Medium (DMEM) was from Cambrex.  Fetal bovine 
serum (FBS) was from Hyclone.  Calf serum was from Atlanta Biologicals.  The 
antibiotic-antimycotic solution, trypsin-EDTA and Magic Mark XP western standards 
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were from Invitrogen.  Aprotinin, leupeptin, and Triton X-100 were from Roche. 
Recombinant protein A-agarose was from Repligen.  Hybond-C Extra nitrocellulose was 
from Amersham Biosciences.  Paraformaldehyde was from Electron Microscopy 
Sciences.  
Cell Culture, Transfection and Stimulation:  The stock of murine 3T3-F442A 
fibroblasts was kindly provided by Dr. H. Green (Harvard University), 293T cells were 
from ATCC, MDCK cells were kindly provided by Dr. B. Margolis (University of Michigan, 
Ann Arbor) and H4IIE hepatoma cells were kindly provided by Dr. J. Messina (University 
of Alabama, Birmingham).  3T3-F442A and 293T cells were grown in DMEM 
supplemented with 1 mM L-glutamine, 100 U of penicillin per ml, 100 g of streptomycin 
per ml, 0.25 g of amphotericin per ml, and 8% calf serum.  MDCK cells were grown in 
Messina (University of Alabama, Birmingham).  3T3-F442A and 293T cells were grown 
in DMEM supplemented with 1 mM L-glutamine, 100 U of penicillin per ml, 100 g of 
streptomycin per ml, 0.25 g of amphotericin per ml, and 8% fetal bovine serum.  H4IIE 
cells were grown in SWIMS 77 medium supplemented with 5% FBS, 26.2 mM sodium 
bicarbonate, 4 mM L-glutamine, 98 M L-cystine and 1.8 mM calcium chloride dihydrate. 
293T cells were transiently transfected by calcium phosphate precipitation.  3T3-F442A 
and H4IIE cells were incubated overnight in serum-free medium before treatment with 
GH. 
Plasmids: GFP-tagged SH2B1, SH2B1 (R555E), SH2B1 (148-198) and 
SH2B1 mNES were cloned as described previously (106, 107, 110).  GFP-II1-
spectrin was a kind gift from Dr. Vann Bennett (Duke University) and myc-II1-spectrin 
was a kind gift from Dr. Lopa Mishra (Georgetown University). 
Immunofluorescence:  For fixed-cell imaging, cells were fixed in 4% 
parformaldehyde in PBS, gently washed 3 times in PBS, permeabilized in 0.1% TritonX-
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100 in phosphate buffered saline (PBS) and blocked for 30 min in PBS containing 5% 
normal serum from the species used for secondary antibody production.  Cells were then 
incubated with primary antibody diluted in blocking solution for one hour.  Cells were 
gently washed 3 times in PBS, and then incubated for 1 h with secondary antibody 
diluted in PBS.  Cells were gently washed 3 times in ddH2O, and then mounted on 
Fisherfinest Premium Microscope Slides (Fisher Scientific) using Prolong Gold Antifade 
mounting reagent (Invitrogen).  For live cell imaging, cells were grown on no. 1.5 glass 
bottom dishes (MatTek Corp. Ashland, MA) and imaged in Ringer’s buffer (155 mM 
NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2 6H2O, 2 mM NaH2PO4 H2O, 10 mM HEPES, 
10 mM glucose).  Confocal laser scanning microscopy images were obtained with an 
Olympus FluoView 500 Laser Scanning Confocal Microscope.  Widefield fluorescence 
microscopy images were obtained using a Nikon Eclipse TE200 inverted fluorescence 
microscope. 
 Immunoprecipitation and Immunoblotting:  Cells were grown in 10 cm culture 
dishes, washed and solubilized in lysis buffer (50 mM Tris [pH 7.5], 1% Triton X-100, 150 
mM NaCl, 2 mM EGTA, 1 mM Na3VO4, [pH 7.5]), containing 1 mM phenylmethylsulfonyl 
fluoride, 10 g/ml aprotinin, and 10 g/ml leupeptin. For immunoprecipitation, 60% of the 
supernatant was incubated with antibody on ice for 2 h followed by incubation with protein 
A-agarose beads rotating at 4C for 1 h.  The beads were washed three times with lysis 
buffer and boiled for 5 min in a mixture (80:20) of lysis buffer and SDS-PAGE sample buffer 
(250 mM Tris-HCl [pH 6.8], 10% SDS, 10% ß-mercaptoethanol, 40% glycerol, 0.01% 
bromophenol blue).  Eluted proteins as well as proteins in cell lysates prepared in the same 
buffer were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, using 
10% polyacrylamide gels and an acrylamide:bis acrylamide ratio of 30:0.5.  For 
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immunoblotting, proteins in the gel were transferred to nitrocellulose and detected by 
immunoblotting with the indicated antibody. 
 Cell Fractionation: Membrane and cytosolic fractionation: Cells from a 10 cm dish 
were collected in 1.0 ml ice-cold phosphate-buffered saline containing 2 mM Na3(VO)4 
(PBSV) and pelletted by centrifugation at 1000 RPM for 2 min.  PBSV was aspirated, and 
the pellet was resuspended in 500 l extraction buffer, (50 mM Tris-HCl pH 7.5, 50 mM 
beta-mercaptoethanol, 2 mM EGTA, 0.1 mM EDTA, 0.1 mM NaF, 1 mM 
phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, and 10 g/ml leupeptin).  Samples were 
incubated on ice for 10 min with occasional 10 s vortexing.  Samples were then pelleted by 
centrifugation at 1000 RPM for 1 min.  The supernatant was collected and the pellet was 
discarded.  The supernatant was centrifuged at 120,000 x g for 2 h.  The supernatant was 
designated the cytosolic fraction and was transferred to a new tube.  The pellet was 
designated the membrane fraction and was washed once in extraction buffer and then 
resuspended in 100 l lysis buffer (50 mM Tris pH 7.5, 0.1% Triton X-100, 150 mM NaCl, 2 
mM EGTA, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, and 10 
g/ml leupeptin). 
Cytoskeletal enrichment fractionation (241):  Cells were washed with cell solubilization buffer 
(10 mM PIPES, 50 mM KCl, 20 mM EGTA, 3 mM MgCl2, 2 M glycerol, 2 mM NaF, 2 mM 
Na3(VO)4, 10 g/ml aprotinin, and 10 g/ml leupeptin), then incubated on ice in CSB 
containing 1% TritonX-100 for exactly 5 min.  The buffer containing solubilized proteins was 
removed and designated the soluble fraction.  Plates were then washed with CSB and the 
remaining cytoskeletal fraction was collected with extraction buffer (20 mM Tris-HCl, 300 
mM NaCl, 30 mM MgCl2, 1 mM DTT, 10 g/ml aprotinin, and 10 g/ml leupeptin) and 
passed through a 28-gauge syringe 10 times.  Proteins in each fraction were quantified 
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using the bicinchoninic acid protein assay (Pierce Biotechnology), and 50 g of protein was 
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The multifunctional adaptor protein, SH2B1, regulates diverse cellular functions, 
including cell motility.  To gain further insight into the ability of SH2B1 to regulate the 
cytoskeleton and cell motility, we assessed the subcellular localization of GFP-SH2B1 
in fibroblast and epithelial cells.  We found GFP-SH2B1 to localize to focal adhesions 
via its SH2 domain.  Focal adhesions are cell adhesion sites, critical nodes of cell-
extracellular matrix communication and important facilitators of cell motility.  Multiple 
protein kinase C (PKC) isoforms are found in focal adhesions and PKC activation 
induces the formation of focal adhesions and promotes cell motility.  We provide 
evidence that SH2B1 is phosphorylated in response to phorbol 12-myristate 13-acetate 
(PMA)-induced PKC activation and show that PMA stimulation induces a rapid 
redistribution of SH2B1 out of focal adhesions.  Multiple serines in SH2B1 lie within 
PKC consensus substrate phosphorylation motifs.  Mutation to alanine of two of these 
serines (Ser 161 and 165) abrogates the ability of PMA stimulation to induce this 
redistribution.  These mutations also significantly decrease the dynamic cycling of 
SH2B1 into and out of focal adhesions as analyzed by fluorescence recovery after 
photobleaching (FRAP) analysis.  Mutation of Ser 165 to glutamate (mimicking 
phosphorylation) reduces the amount of SH2B1 at focal adhesions, increases the rate 
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of SH2B1 turnover at focal adhesions and significantly increases the number of focal 
adhesions per cell.  Taken together, these results show that SH2B1 localizes to focal 
adhesions through its SH2 domain.  They also provide evidence that PKC activation 
regulates SH2B1 focal adhesion localization through phosphorylation of SH2B1 
serines 161 and/or 165 and that PKC-mediated phosphorylation of SH2B1 at serine165 





SH2B1 is a member of the SH2B family of adaptor proteins that includes SH2B1 
(formerly SH2-B/PSM), SH2B2 (formerly APS) and SH2B3 (formerly Lnk).  SH2B1 
mRNA is alternatively spliced to produce SH2B1, ,  and  isoforms (105, 210).  The 
translated products share a dimerization domain (DD), a nuclear localization signal 
(NLS) a nuclear export signal (NES), a pleckstrin homology (PH) domain and a Src 
homology 2 (SH2) domain (see schematic in Fig. 1), but differ at the extreme C-terminus 
of each protein.  SH2B1 is recruited, via its SH2 domain, to multiple activated receptor 
tyrosine kinases and receptor-associated tyrosine kinases, enabling it to serve as an 
adaptor/scaffolding protein for multiple hormones and growth factors, including growth 
hormone (GH) (100), leptin (111), nerve growth factor (100, 109), brain derived 
neurotrophic factor (109), glial derived neurotrophic factor (244), insulin (210, 245), 
insulin-like growth factor I (246), fibroblast growth factor (247), platelet-derived growth 
factor (248) and hepatocyte growth factor (249).  Within the context of these signaling 
systems, SH2B1 has been shown to enhance kinase activity, regulate gene 
transcription and/or modulate cytoskeletal dynamics (reviewed in (101)).  These cellular 
effects contribute to the ability of SH2B1 to promote neuronal differentiation and 
maintenance of a differentiated phenotype (109, 110), regulate energy and glucose 
homeostasis (111), and promote cell motility (112, 113).  All of these effects require 
either regulated intracellular transport or alterations in cell morphology, processes that 
rely on regulation of the actin-based cytoskeleton (reviewed in (121, 122)).  SH2B1 
localizes to the plasma membrane/cytoskeleton (224) and membrane ruffles (132), 
suggesting that SH2B1 localization to cytoskeletal structures may be important for its 
function.  SH2B1 has been shown to regulate cytoskeletal dynamics by enhancing GH, 
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PDGF and prolactin-induced cell ruffling and lamellipodia formation (113, 132), and by 
enhancing GH-dependent cell motility (112).  In addition, SH2B1 has been shown to 
bind activated Rac (112), cross-link actin filaments in vitro (113), and interact with the 
Listeria monocytogenes actin nucleating protein, ActA, to enhance bacterial actin-based 
motility (134).  Other SH2B family members have also been implicated in regulation of 
the cytoskeleton.  SH2B2 co-localizes with actin in B cells (135), is thought to modulate 
actin dynamics in mast cells (136), and interacts with the cytoskeleton regulatory 
proteins, Vav3 (137) and Enigma (138).  SH2B3 is a binding partner of the actin binding 
and focal adhesion protein, filamin, although this interaction was not shown to be 
present in focal adhesions (139).   
Focal adhesions are large integrin-based macromolecular complexes that 
mediate cell-extracellular matrix (ECM) attachment, facilitate direct signaling between 
the extracellular matrix and the cell, and facilitate cell anchorage and motility (reviewed 
in (128)).  The number of proteins identified as localizing to focal adhesions is vast, and 
the number and regulation of interactions between focal adhesion proteins make these 
structures among the most dynamic and complex structures within a cell (see (128)for 
review}).  Individual proteins within focal adhesions contribute to focal adhesion function 
through a number of mechanisms.  Many proteins, such as vinculin, provide structural 
support for focal adhesion complexes and are generally associated with reduced cellular 
motility (250).  Other scaffolding/adaptor proteins, such as paxillin, are generally 
associated with promoting migration by recruiting and assembling critical focal adhesion 
signaling components (251).  All focal adhesion proteins are dynamically regulated so 
that they continually cycle in and out of focal adhesions (focal adhesion protein 
turnover).  Modulation of this focal adhesion protein turnover can directly affect the 
strength and turnover of focal adhesions themselves (252), and thus cell motility.  
Phosphorylation of focal adhesion proteins is a major mechanism by which turnover is 
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regulated.  Several kinases are localized to focal adhesions [e.g. focal adhesion kinase 
(FAK), Src family kinases, ERKs and protein kinase C (PKC)]; when activated, they 
phosphorylate nearby focal adhesion proteins, serving to regulate focal adhesion 
stability, turnover, and cell motility (129, 253).  Several PKC isoforms exist, some of 
which (, , ) have been identified as focal adhesion proteins (254-256).  Active PKC is 
known to phosphorylate focal adhesion proteins (257-259), regulate focal adhesion 
formation (260) leading to an increase in the overall number of focal adhesions per cell 
(253), and promote focal adhesion-dependant processes such as cell adhesion, 
spreading and migration ((261, 262) reviewed in (263)). 
In this study, we identify SH2B1 as a novel focal adhesion protein.  We show 
that SH2B1 localizes to focal adhesions through its SH2 domain, and provide evidence 
that PKC may regulate SH2B1 focal adhesion localization through phosphorylation of 
SH2B1 serines 161 and/or 165.  In addition, we present evidence that phosphorylation 
of serines 161 and/or 165 has a profound effect on overall focal adhesion number which 





SH2B1 is a novel focal adhesion protein.  Our previous studies have 
implicated SH2B1 in the control of cytoskeletal dynamics by enhancing GH and PDGF-
dependent cell ruffling and lamellipodia formation and GH-induced cell motility (112, 
132).  To gain further insight into the role of SH2B1 in cytoskeletal dynamics and cell 
motility, GFP-SH2B1 was visualized in 3T3-F442A fibroblasts.  Initial experiments 
revealed GFP-SH2B1 co-localization with the termini of actin filaments in a pattern 
characteristic of focal adhesion proteins (Fig. 4.2A).  To confirm that SH2B1 is localized 
to focal adhesions, GFP or GFP-SH2B1-expressing 3T3-F442A fibroblasts were fixed 
and stained for the focal adhesion markers, vinculin and FAK.  GFP-SH2B1 co-
localized with both endogenous vinculin (Fig. 4.2B) and endogenous FAK (Fig. 4.2C).  
GFP-SH2B1 also co-localized with mCherry-vinculin when both proteins were 
expressed and visualized in living HeLa cells (Fig. 4.2D), indicating that SH2B1 




Figure 4.1.  Schematic representations of SH2B1 truncation, deletion and point 
mutations.  Red lines indicate point mutations that render the respective domains 
nonfunctional (107, 248).  Schematics are represented in the same order as depicted in 
Figure 4.3.  Abbreviations are: DD, dimerization domain; NLS, nuclear localization 
sequence; NES, nuclear export sequence; PH, pleckstrin homology domain; SH2, Src 





Figure 4.2.  SH2B1 localizes to focal adhesions.  (A) 3T3-F442A cells expressing 
GFP (top panel) or GFP-SH2B1 (bottom panel), were fixed and stained with phalloidin 
to visualize F-actin.  (B) 3T3-F442A cells expressing GFP (top panel) or GFP-SH2B1 
(bottom panel), were fixed and stained for vinculin to visualize focal adhesions.  (C) 3T3-
F442A cells expressing GFP (top panel) or GFP-SH2B1 (bottom panel) were fixed and 
stained for FAK to visualize focal adhesions.  (D) HeLa cells expressing GFP and 
mCherry-vinculin (top panel) or GFP-SH2B1 and mCherry-vinculin (bottom panel) were 
imaged live.  All images were obtained by confocal microscopy.  Insets in the overlay 
images are magnifications of the boxed areas.  Scale bar = 10 m. 
 
 
The SH2 domain of SH2B1 is necessary and sufficient for focal adhesion 
localization.  To determine the region of SH2B1 responsible for focal adhesion 
localization, a series of GFP-tagged SH2B1 truncation, deletion and point mutants that 
disrupt SH2B1 signaling domains were co-expressed with mCherry-vinculin in 3T3-
F442A fibroblasts (see schematics in Fig. 4.1) and visualized by live confocal 
microscopy (Fig. 4.3).  As expected, GFP-SH2B1 (Fig. 4.3B) but not GFP alone (Fig. 
4.3A) localized to focal adhesions.  Deletion of the dimerization domain [SH2B1 (118-
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670), Fig. 4.3C] or NLS (SH2B1 148-198, Fig. 4.3D) or mutation of the NES (SH2B1 
mNES, Fig. 4.3E) did not prevent GFP-SH2B1 from localizating to focal adhesions.  
GFP-SH2B1 (269-670), which lacks all three of these domains, also retained its ability 
to localize to focal adhesions (Fig. 4.3F).  In contrast, GFP-SH2B1 (1-260), which lacks 
both the PH and SH2 signaling domains, was unable to localize to focal adhesions (Fig. 
4.3G), implicating the PH and/or SH2 domain in SH2B1 focal adhesion localization.  
GFP-SH2B1 (1-555), which contains the PH domain but lacks an intact SH2 domain, 
was also unable to localize to focal adhesions (Fig. 4.3H), indicating that the SH2 
domain is necessary for focal adhesion localization.  GFP-SH2B1 (R555E) lacks a 
functional SH2 domain due to a single point mutation (248). The inability of this mutant 
to localize to focal adhesions (Fig. 4.3I) indicates that the SH2 domain alone, and not the 
region C-terminal to the SH2 domain, is necessary for focal adhesion localization.  
Finally, GFP-SH2B1 (505-670), which includes primarily the SH2 domain, was able to 
localize to focal adhesions (Fig. 4.3J), indicating that the SH2 domain is both necessary 




Figure 4.3.  The SH2 domain of SH2B1 is necessary and sufficient for focal 
adhesion localization.  (A-J) Live 3T3-F442A cells co-expressing mCherry-vinculin with 
GFP, GFP-SH2B1 or the indicated mutant GFP-SH2B1 were visualized by confocal 
microscopy. Insets in the overlay images are magnifications of the boxed areas.  Scale 
bar = 10 m. 
 
 
Growth hormone stimulation increases SH2B1 turnover dynamics at focal 
adhesions.  Tyrosyl and serine phosphorylation is known to alter the rates at which 
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proteins cycle into and out of focal adhesions (focal adhesion protein turnover dynamics) 
(129).  GH stimulation induces JAK2-mediated tyrosyl-phosphorylation of SH2B1 in 
3T3-F442A cells (100).  Therefore, we asked whether GH stimulation alters SH2B1 
turnover dynamics in focal adhesions.  We assessed GFP-SH2B1 turnover dynamics at 
focal adhesions using fluorescence recovery after photobleaching (FRAP) (Fig. 4.4).  
Normalized recovery was substantially increased for GFP-SH2B1 at focal adhesions in 
cells treated with GH compared to control cells (Fig. 4.4A).  While the fraction of mobile 
GFP-SH2B1 calculated for each condition was similar (Fig. 4.4A, left inset), the t1/2, or 
time need to recover to 50% of the maximum (Fig. 4.4A, right inset), was significantly 
reduced in GH-treated cells, indicating that GH treatment significantly increases the rate 
at which SH2B1 cycles in and out of focal adhesions. 
 
 
Figure 4.4.  GH stimulation increases GFP-SH2B1 turnover dynamics at focal 
adhesions. 3T3-F442A cells expressing GFP-SH2B1 were incubated in serum-free 
medium overnight.  During the photobleaching scans, cells were treated with (n=5) or 
without (n=8) 500 ng/ml GH.  FRAP analysis was carried out for 400 seconds.  FRAP 
values were obtained using Fluoview software.  Curves were fit to normalized data using 
SigmaPlot software.  Mobile fraction (left insets) and 1/2 (right insets) values were 




PKC mediates PMA-induced SH2B1 phosphorylation.  We have previously 
shown that SH2B1 is serine phosphorylated in response to the PKC agonist, phorbol 
12-myristate 13-acetate (PMA), in the PC12 neuronal cell line (110).  Our present 
identification of SH2B1 as a focal adhesion protein combined with the previous 
observations that several PKC isoforms localize to focal adhesions raise the possibility 
that PKC regulates SH2B1 at focal adhesions.  We first confirmed that SH2B1 is 
phosphorylated in response to PMA in 3T3-F442A fibroblasts.  PMA stimulation 
activated ERK1/2 (Fig 4.5A, middle panel), consistent with previous studies showing 
PKC-mediated activation of the Raf/MEK/ERK pathway (264-266).  PMA stimulation also 
caused a significant upward shift in SH2B1 mobility in Western blots (Fig. 4.5A, top 
panel), an event that we have previously shown to be indicative of increased 
serine/threonine phosphorylation of SH2B1 (100, 224).  Dose and time course 
experiments revealed PMA stimulation to result in maximal SH2B1 phosphorylation at 
100 nm PMA after 15-30 min (Fig. 4.5B).  Pre-treating cells with the PKC-specific 
inhibitor, bisindolylmaleimide I (bis I), but not its inactive analogue, bisindolylmaleimide V 
(bis V), prior to PMA stimulation inhibited SH2B1 phosphorylation (Fig. 4.5C), indicating 
that PKC or a kinase downstream of PKC mediates the PMA-induced SH2B1 
phosphorylation in 3T3-F442A fibroblasts.  Treatment of 3T3-F442A fibroblasts 
expressing GFP-SH2B1 with PMA also resulted in an upward shift in migration of GFP-
SH2B1 (Fig. 4.5D) consistent with exogenously expressed SH2B1 also being 




Figure 4.5.  PMA induces SH2B1 phosphorylation.  (A) 3T3-F442A cells were 
stimulated with vehicle or 100 nm PMA for 15 min.  Lysates were blotted for total SH2B1 
(top panel), phospho-ERK1/2 (middle panel) or total ERK1/2 (bottom panel).  (B) 3T3-
F442A cells were stimulated with increasing concentrations of PMA for 15 min (top 
panel) or with 100 nm PMA for increasing time periods (bottom panel).  Lysates were 
blotted with SH2B1.  (C) 3T3-F442A cells were pretreated with DMSO, bis I or bis V for 
1 hr, then stimulated with vehicle or 100 nm PMA for 15 min.  Lysates were blotted with 
SH2B1, phospho-ERK1/2 or ERK 1/2.  (D) 3T3-F442A cells expressing GFP-
SH2B1 were stimulated with vehicle or 100 nm PMA for 15 minutes.  Lysates were 
immunoprecipitated with GFP.  Immunoprecipitates (top panel) and lysates (bottom 
panel) were blotted with GFP. 
 
 
Phosphorylation of Serines 161/165 regulates localization of SH2B1 in 
focal adhesions.  We have shown previously by mass spectrometry that serine 161 in 
SH2B1 is phosphorylated and have indirectly implicated phosphorylation of serine 165 
in PMA-stimulated 293T cells (Maures, et al. Manuscript in preparation).  Both serines lie 
within the classic PKC-substrate motif, X(S/T)X(R/K) (Center for Biological Sequence 
Analysis, http://www.cbs.dtu.dk/index.shtml) (Fig. 4.6A).  To investigate the potential for 
phosphorylation of these Ser to regulate SH2B1 at focal adhesions, GFP-SH2B1, 
GFP-SH2B1 (S161,165A) (which lacks these two serines) and GFP-SH2B1 (S165E), 
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(in which Ser 165 has been mutated to glutamate, mimicking phosphorylation) were 
expressed in 3T3-F442A fibroblasts (Fig. 4.6B).  Whereas GFP-SH2B1 localizes to 
focal adhesions and the cytoplasm, GFP-SH2B1 (S161,165A) localized almost 
exclusively to focal adhesions.  Conversely, GFP-SH2B1 (S165E) localized less to 
focal adhesions and more to the cytoplasm.  Additionally, on average, GFP-SH2B1 
(S161,165A)-positive focal adhesions appeared larger than GFP-SH2B1-positive focal 
adhesions.  These results suggest that phosphorylation of Ser 161 and/or 165 regulates 
SH2B1 localization at focal adhesions, and possibly the size of focal adhesions. 
 
 
Figure 4.6.  Serines 161 and 165 regulate SH2B1 localization within focal adhesions.  
(A) Schematic representation of serines 161 and 165 in SH2B1.  Abbreviations are: 
DD, dimerization domain; NLS, nuclear localization sequence; NES, nuclear export 
sequence; PH, pleckstrin homology domain; SH2, Src homology 2 domain.  (B) Live 
3T3-F442A cells expressing WT or mutant GFP-SH2B1 were imaged by confocal 
microscopy.  Scale bar = 10 m. 
 
 
To determine if PKC activation influences SH2B1 localization at focal adhesions 
and whether phosphorylation of Ser 161/165 mediates this potential PKC regulation, 
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3T3-F442A fibroblasts expressing GFP-SH2B1 or GFP-SH2B1 (S161,165A) were 
stimulated with PMA.  While PMA stimulation resulted in a significant upward shift in 
mobility for GFP-SH2B1, GFP-SH2B1 (S161,165A) exhibited a minimal upward shift, 
consistent with PKC inducing phosphorylation of Ser 161 and/or 165 (Fig. 4.7A). 
Interestingly, serines 161 and 165 lie within a 30 amino acid stretch of SH2B1 
that contains 13 serines and threonines.  Ten of these serines and threonines (S137, 
S141, T142, T143, S144, S145, S154, S157, S161, S165) lie within the classic PKC-
substrate motif, X(S/T)X(R/K) (Center for Biological Sequence Analysis, 
http://www.cbs.dtu.dk/index.shtml).  3T3-F442A cells expressing GFP-vinculin, WT GFP-
SH2B1 or GFP-SH2B1 (13SA) (in which all 13 serines and threonines were mutated 
to alanine) were also imaged by confocal microscopy before and after PMA stimulation.  
Confocal images were taken every 5 min for 30 min (Fig. 4.7B) and the fluorescence 
intensity of individual focal adhesions was measured and quantified at each time-point 
(Fig. 4.7C).  PMA stimulation resulted in a significant reduction (> 50%) of GFP-SH2B1 
at focal adhesions over 30 min.  Mutating Ser 161/165 to alanine substantially reduced 
the degree of PMA-mediated depletion of GFP-SH2B1 from focal adhesions (to <20%).  
Interestingly, PMA stimulation of GFP-SH2B1(13SA) resulted in phenotype almost 
identical to that of GFP-SH2B1 (S161,165A) (data not shown).  PMA stimulation only 
significantly reduced GFP-vinculin localization at focal adhesions at the 25 min time 
point, indicating that PMA stimulation does not induce general focal adhesion 
dissolution.  These data suggest that PMA-mediated PKC activation and subsequent 





Figure 4.7.  PMA stimulation induces a loss of GFP-SH2B1, but not GFP-SH2B1 
(S161,165A), from focal adhesions.  (A) 3T3-F442A cells expressing WT or mutant GFP-
SH2B1 were stimulated with vehicle or 100 nm PMA for 15 min.  Lysates were blotted 
with GFP.  (B) 3T3-F442A cells expressing GFP-SH2B1 were imaged by confocal 
microscopy before and after 100 nm PMA stimulation for up to 30 min.  (C) Metamorph 
imaging software was used to quantify the fluorescence intensity of individual focal 
adhesions.  Three independent experiments assessing focal adhesions from 2-4 cells 
were performed for WT and mutant GFP-SH2B1 and two independent experiments 
assessing focal adhesions from 2-4 were performed for GFP-vinculin.  Error bars 
indicate s.e.m.  *P<0.05 by Student’s t-test. 
 
 120 
Serines 161/165 regulate SH2B1 focal adhesion dynamics.  The observed 
differences in mutant SH2B1 localization and response to PMA stimulation compared 
to WT SH2B1 suggest that phosphorylation of Ser 161 and/or 165 modulate SH2B1 
turnover dynamics at focal adhesions.  To assess the turnover dynamics of focal 
adhesion-localized SH2B1, and determine whether phosphorylation of Ser 161 and/or 
165 are likely to regulate this turnover, FRAP experiments were performed on focal 
adhesion-localized GFP-SH2B1, GFP-SH2B1 (S161,165A) and GFP-SH2B1 
(S165E) in 3T3-F442A fibroblasts (Fig. 4.8A).  Normalized recovery was substantially 
delayed for GFP-SH2B1 (S161,165A) and slightly accelerated for GFP-SH2B1 
(S165E) compared to WT GFP-SH2B1 (Fig. 4.8B).  The fraction of mobile SH2B1 
(mobile fraction, Fig. 4.8C) and time needed for SH2B1 to recover 50% fluorescence 
intensity (1/2, Fig. 4.8D) were also determined.  While the mobile fraction of both 
mutants was similar to WT, the 1/2 of GFP-SH2B1 (S161,165) was significantly 
increased compared to WT GFP-SH2B1, and the 1/2 of GFP-SH2B1 (S165E) 
appeared to be decreased (although statistical significance was not achieved, p = .09) 
compared to WT GFP-SH2B1 (Fig. 4.8C).  Interestingly, GFP-SH2B1 (13SA) again 
displayed an almost identical phenotype to GFP-SH2B1 (S161,165A) (data not shown).  
These data indicate that while the total fraction of SH2B1 able to dynamically cycle in 
and out of focal adhesions is not affected by mutating Ser 161/165, the rate of turnover 
is significantly decreased when Ser 161 and 165 cannot be phosphorylated.  This 
provides further evidence that phosphorylation of one or both of these residues regulates 




Figure 4.8.  Serines 161 and/or 165 regulate SH2B1 focal adhesion dynamics.  (A) 
Confocal microscopy images of focal adhesion-localized WT and mutant GFP-SH2B1 
in 3T3-F442A cells before and after photobleaching. Scale bare = 2 m.  (B) FRAP 
values were obtained using Fluoview software.  Curves were fit to normalized data using 
SigmaPlot software.  Mobile fraction (C) and 1/2 (D) values were calculated from the 
curve fit equations. n=9 (WT and S161,165A); n=10 (S165E). Error bars indicate s.e.m. 
*P <0.01 by Student’s t-test. 
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GFP-SH2B1 (S165E) increases focal adhesion number.  PKC activation is 
associated with increased focal adhesion formation (253).  Intriguingly, expression of 
GFP-SH2B1 (S165E) alone also appeared to produce an increased number of focal 
adhesions per cell as well as smaller focal adhesions compared to cells expressing WT 
GFP-SH2B1 (Fig. 4.9A.)  Quantification of focal adhesions per cell showed that 
expression of GFP-SH2B1 (S165E) resulted in a significant increase in the number of 
focal adhesions per cell compared to cells expressing GFP alone, WT GFP-SH2B1 or 
GFP-SH2B1 (S161,165A) (Fig. 4.9B).  This raises the exciting possibility that in 
addition to regulating focal adhesion-localized SH2B1 turnover, phosphorylation of 





Figure 4.9.  SH2B1 (S165E) increases the number of focal adhesions per cell.  (A) 
3T3-F442A cells expressing WT or mutant GFP-SH2B1 were fixed, stained for vinculin 
and imaged by confocal microscopy.  Scale bar = 10 m.  (B) Quantification of number 
of focal adhesions per cell. Three independent experiments assessing focal adhesions 
from at least 10 cells were performed for each condition.  Error bars indicate s.e.m.  *P 





Here, we have identified SH2B1 as a novel focal adhesion protein that is 
targeted to focal adhesions through its SH2 domain.  We further provide evidence that 
SH2B1 localization at focal adhesions is regulated by PMA-induced phosphorylation, 
most likely of serines 161 and/or 165, and that this phosphorylation regulates overall 
focal adhesion number.  That the SH2 domain of SH2B1 is necessary and sufficient for 
focal adhesion localization indicates that SH2B1 binds a tyrosyl phosphorylated protein 
within the focal adhesion complex.  Focal adhesions are known to contain several 
tyrosyl-phosphorylated proteins, including paxillin (267), vinculin (268, 269), talin (270) 
p130Cas (271), tensin (272), and FAK (267).  The SH2 domains of other focal adhesion 
proteins have been identified as important for focal adhesion localization (273, 274) and 
overall tyrosine phosphorylation of focal adhesion proteins is thought to be an important 
regulatory mechanism of focal adhesion formation, stability and maturation (reviewed in 
(275)).  Therefore, in addition to the regulation of SH2B1 focal adhesion localization by 
PKC activation, it seems likely that mechanisms regulating overall focal adhesion protein 
tyrosyl phosphorylation (eg. Src and FAK activation) also regulate the recruitment of 
SH2B1 to focal adhesion.  In addition to SH2B1, we found SH2B1 and SH2B1 to 
localize to focal adhesions (data not shown), and we predict that SH2B1 also localizes 
to focal adhesions as SH2B1 contains the same SH2 domain as ,  and  isoforms.  
SH2B2 and SH2B3 both contain SH2 domains similar to SH2B1, and all three family 
members have been shown to bind phospho-Tyr813 in JAK2 through their SH2 domains 
(22, 23, 276).  This suggests that SH2B family members may be recruited to similar 
targets through their SH2 domains, and therefore it is possible that SH2B2 and SH2B3, 
like SH2B1, are localized to focal adhesions.  SH2B3 has also been described as a 
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binding partner of the focal adhesion protein, filamin (139),  although this interaction was 
not mediated through the SH2 domain of SH2B3 and not observed at focal adhesions.   
It has recently been shown that the rates at which individual proteins cycle into 
and out of focal adhesions can directly affect the rates of focal adhesion assembly and 
disassembly (129, 252) as well as cell motility.  Therefore, our finding that GH 
stimulation can directly and significantly regulate the turnover dynamics of a focal 
adhesion protein (i.e. SH2B1) (Fig. 4.4A) provides one possible mechanism by which 
GH regulates cell motility.  Consequently, it will be of interest in the future to determine 
the effect that altered rates of SH2B1 turnover dynamics at focal adhesions have on 
cell motility.  
Previous studies have shown that PKC may directly phosphorylate several focal 
adhesion proteins including vinculin (257), talin (258), filamin (259) and integrin (277).  In 
addition, PKC is an important factor in integrin-mediated signaling (reviewed in (263)) 
and is able to induce activation of ERK1/2 (253, 278, 279), RhoA (280), and FAK (281), 
events which lead to an increase in focal adhesion number, cell adhesion and/or cell 
migration.  Our recent work suggests that PKC regulates SH2B1 localization at the 
plasma membrane (PM) in PC-12 neuronal cells and 293T cells through phosphorylation 
at Ser 161 and/or 165 (Maures, et al. Manuscript in preparation).  These data combined 
with the data presented in the present study suggest the existence of an intriguing model 
whereby PKC regulates SH2B1 at multiple levels (ie. at the PM and focal adhesions).  
Interestingly, several studies have shown that different PKC family members are 
localized to distinct subcellular locations including the PM and focal adhesions (reviewed 
in (282)), raising the possibility that specific PKC family members regulate SH2B1 at 
different subcellular locations.  In the PC-12 model, it is thought that positively charged 
amino acids within the NLS recruit SH2B1 to the negatively charged PM.  The negative 
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charge from phosphorylation of Ser 161/165 (which lie adjacent to the positively charged 
NLS) counteracts this positive charge, leading to dissociation of SH2B1 from the PM.  
Here, we show that the NLS is dispensable for SH2B1 focal adhesion localization (Fig. 
4.3), indicating that phosphorylation of Ser 161/165 causes SH2B1 dissociation from 
focal adhesions by some other mechanism (e.g. a phosphorylation-induced 
conformational change leading to a decreased affinity of SH2B1 for a binding partner).  
Precedence exists for serine phosphorylation-mediated regulation of focal adhesion 
protein localization.  Serine phosphorylation of vinculin (283) and paxillin (284) is known 
to cause dissociation of these molecules from focal adhesions.  Serine phosphorylation 
of paxillin has also been shown to regulate paxillin dynamic turnover at focal adhesions 
(129).  Inhibiting Ser 161/165 phosphorylation or mimicking constitutive Ser 165 
phosphorylation similarly altered SH2B1 turnover dynamics at focal adhesions, 
providing further evidence that regulated phosphorylation at these sites is important for 
SH2B1 function at focal adhesions.   
Our surprising finding that focal adhesion numbers per cell were significantly 
increased by mimicking Ser 165 phosphorylation by mutation to Glu suggests that 
phosphorylation of SH2B1 at Ser 165 may be a key step in the formation of new focal 
adhesions.  In addition, cells expressing SH2B1 (S165E) appeared to harbor smaller 
focal adhesions than cells expressing GFP or WT GFP-SH2B1 (Fig. 4.9 and data not 
shown).  Interestingly, FAK null fibroblasts also display increased numbers of focal 
adhesions compared to WT cells (285) and vinculin null fibroblasts display focal 
adhesions that are smaller in size (250).  However FAK null fibroblasts are less motile 
than their WT counterparts while vinculin null fibroblasts are more motile than WT cells 
but have a decreased number of focal adhesions per cell.  SH2B1 (S165E) appears to 
incorporate aspects of both of these opposing phenotypes as we have also found 
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SH2B1 (S165E) to potently increase cell migration (HWS paper}.  Perhaps the 
phenotype that most closely resembles that of SH2B1 (S165E) is that of PMA-induced 
PKC activation in glioma cells, which results in both an increase in focal adhesion 
number and cell migration (253).   
One mechanism by which SH2B1 may regulate focal adhesion number is by 
modulating the dynamic turnover of other focal adhesion proteins.  There is evidence 
indicating that turnover of individual focal adhesion proteins may be directly related to 
the turnover of focal adhesions themselves (252), a process that is linked to the 
formation of new focal adhesions.  After localizing to focal adhesions through its SH2 
domain, SH2B1 may bind and stabilize other focal adhesion proteins through its other 
signaling domains, thus providing additional integrity to the focal adhesion complex.  In 
addition, cells expressing GFP-SH2B1 (S161,165A) appeared to harbor large focal 
adhesions with many fibrillar adhesions (Fig. 4.9 and data not shown) suggesting that 
focal adhesions in GFP-SH2B1 (S161,165A)-expressing cells either mature more 
rapidly or turn over less rapidly than in cells expressing WT GFP-SH2B1.  Taken 
together, these observations suggest that PKC-mediated phosphorylation of SH2B1 
and subsequent redistribution out of focal adhesions may initiate partial destabilization of 
focal adhesions, leading to smaller and increased number of focal adhesions, resulting 
in increased cell motility.  
The regulation of cell signaling, cytoskeletal dynamics and cell motility through 
focal adhesions is crucial for numerous physiological and pathophysiological processes.  
A growing number of studies also implicate SH2B family members in an array of 
physiological processes that are dependent on cytoskeletal dynamics and/or cell motility.  
Our finding of SH2B1 as a novel focal adhesion protein whose phosphorylation 
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dynamically regulates focal adhesion number provides the grounds for further study into 
the precise function and regulation of SH2B1 in focal adhesions. 
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MATERIALS AND METHODS 
 
 Antibodies:  Anti-vinculin mouse monoclonal antibody (-vinculin) was from Sigma-
Aldrich (Cat. # V9131) and anti-FAK mouse monoclonal antibody (-FAK) was from 
Transduction Laboratories (Cat. # F15020).  Both were used at a dilution of 1:100 for 
immunofluorescence. Polyclonal antibody to rat SH2B1 {(SH2B1), kind gift of Dr. Liangyou 
Rui (University of Michigan)}, was raised against an SH2B1β glutathione S-transferase 
fusion protein and used at a dilution of 1:1000 for Western blotting (243).  Anti-phospho-
44/42 MAPK antibody that recognizes both ERK1 and ERK2 that are doubly phosphorylated 
on T202/Y204 (pERK1/2; E10) and anti-total ERK (ERK1/2) were from Cell Signaling 
Technology and were used at a dilution of 1:1000 for Western blotting. IRDye 800- and 
IRDye 700-conjugated affinity-purified antimouse IgG and antirabbit IgG (Rockland 
Immunochemicals Inc.) were used at a dilution of 1:20,000. Anti-GFP IRDye 800-congujated 
goat polyclonal antibody (Rockland) was used at a dilution of 1:5000 for Western blotting.  
Anti-GFP mouse monoclonal antibody (GFP) for immunoprecipitation (1:100 dilution) was 
from Clontech. Alexa Fluor 568-conjugated phalloidin (dilution 1:100) and anti-mouse Alexa 
Fluor 405 and 594 secondary antibodies (dilution 1:1000) for confocal immunofluorescence 
were from Invitrogen.   
 Reagents:  Recombinant 22,000-Da human GH was a kind gift from Eli Lilly & Co.  
PMA (Sigma) was diluted in DMSO.  Dulbecco’s Modified Eagle Medium (DMEM) was from 
Cambrex.  Fetal bovine serum (FBS) was from Hyclone.  Calf serum was from Atlanta 
Biologicals.  The antibiotic-antimycotic solution, trypsin-EDTA and Magic Mark XP western 
standards were from Invitrogen.  Aprotinin, leupeptin, and Triton X-100 were from Roche. 
Recombinant protein A-agarose was from Repligen.  Hybond-C Extra nitrocellulose was 
from Amersham Biosciences.  Bisindolylmaleimide I and bisindolylmaleimide V were from 
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Calbiochem.  Human fibronectin was from BD Biosciences.  Paraformaldehyde was from 
Electron Microscopy Sciences. 
 Cell Culture, Transfection and Stimulation:  The stock of murine 3T3-F442A 
fibroblasts was kindly provided by H. Green (Harvard University).  HeLa cells were from 
ATCC.  3T3-F442A cells were grown in DMEM supplemented with 1 mM L-glutamine, 100 U 
of penicillin per ml, 100 g of streptomycin per ml, 0.25 g of amphotericin per ml, and 8% 
calf serum.  HeLa cells were grown in DMEM supplemented with 100 U of penicillin per ml, 
100 g of streptomycin per ml, 0.25 g of amphotericin per ml, and 10% fetal bovine serum. 
3T3-F442A fibroblasts were transiently transfected using Amaxa nucleofector technology 
from Lonza (Colonge, Germany) using solution V and setting U24.  HeLa cells were 
transiently transfected using FuGene HD from Roche (Indianapolis, IN).  All cells were 
incubated overnight in serum-free medium containing 1% bovine serum albumin before 
treatment with PMA or GH. 
Plasmids, Cloning and Mutagenesis:  All cDNAs encoding GFP-tagged 
SH2B1 and SH2B1 point, deletion and truncation mutants were described previously 
(106, 107, 110, 112, 132) (Maures, et al. Manuscript in preparation).  GFP-vinculin was a 
kind gift from Dr. Kenneth Yamada (National Institutes of Health). 
Immunofluorescence:  For fixed-cell imaging cells were fixed in 4% 
paraformaldehyde in phosphate buffered saline (PBS), gently washed 3X in PBS, 
permeabilized in 0.1% TritonX-100 in PBS, blocked for 30 minutes in PBS containing 5% 
normal serum from the species used for secondary antibody production.  Cells were then 
incubated with primary antibody diluted 1:100 in blocking solution for one hour.  Cells 
were gently washed 3X in PBS, and then incubated for 1 h with secondary antibody 
diluted 1:1000 in PBS or alexa fluor-conjugated phalloidin diluted 1:100 in PBS.  Cells 
were gently washed 3X in ddH2O, and then mounted on Fisherfinest Premium 
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Microscope Slides using Prolong Gold Antifade mounting reagent (Invitrogen).  For live 
cell imaging, cells were grown on no. 1.5 glass bottom dishes (MatTek Corp.) and 
imaged in Ringer’s buffer (155 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2 6H2O, 2 
mM NaH2PO4 H2O, 10 mM HEPES, 10 mM glucose).  All images were obtained with an 
Olympus FluoView 500 Laser Scanning Confocal Microscope.  For focal adhesion 
counting, cells were fixed and stained for vinculin.  15-20 random images were obtained 
in each of three independent experiments for each condition, and vinculin-positive focal 
adhesions in each cell were counted. 
Fluorescence Recovery After Photobleaching:  GFP-SH2B1β, GFP-SH2B1 
(S161,165A) or GFP-SH2B1 (S165E) were transiently expressed in 3T3-F442A 
fibroblasts.  The GFP signal in individual focal adhesions was bleached by 3 iterations of 
100% laser power. Fluorescent intensity measurements were taken every 6 or 10 sec.  
Data were normalized to unbleached sections of cytosol after background subtraction. 
SigmaPlot 11.0 was used to fit curves to FRAP data by applying the nonlinear 
regression of exponential rise to maximum and the double fours best fit equation, y = 
a*(1–e–b*x)+c*(1– e–d*x).  The fraction of mobile SH2B1β and τ1/2 (time needed to recover 
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Su.  James Herrington made the initial observations that SH2B1 is a focal adhesion 
protein and that the SH2 domain was necessary for focal adhesion localization, Travis J. 
Maures cloned many of the GFP-SH2B1 mutants used in these studies, and I provided 










The overall goal of my thesis research was to answer some of the important remaining 
questions in GH signal transduction.  In particular, I wanted to identify the primary 
kinase(s) responsible for transducing the GH signal in 3T3-F442A and H4IIE cells and 
then more fully characterize the role of SH2B1 in GH-induced regulation of the actin 
cytoskeleton.  While JAK2 and Src family kinases have both been shown to function 
within the GH signaling pathway, the relative contributions of each to GH signaling in the 
frequently used models of GH signaling, 3T3-F442A preadipocytes and H4IIE hepatoma 
cells, remained unclear.  The interpretation and application of dozens of previous studies 
along with the design of future studies utilizing these cell lines rely on the answer to this 
question.  Additionally, many GH-induced responses such as differentiation, proliferation 
and migration require regulation of the actin cytoskeleton, yet few studies have probed 
the molecular mechanisms of these actions.  From the few studies attempting to identify 
these mechanisms, SH2B1 has clearly emerged as an important modulator of GH-
induced cytoskeletal regulation.   
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JAK2, but not Src family kinases, regulate Stat, ERK1/2 and PI3-kinase activation 
in 3T3-F442A preadipocytes and H4IIE hepatoma cells 
 The results presented in Chapter 2 collectively indicate that JAK2 is primarily 
responsible for GH activation of Stat1, Stat3, Stat5, ERK1/2 and Akt in 3T3-F442A 
fibroblasts, H4IIE hepatoma cells and murine embryonic fibroblasts (MEFs).  While the 
overall interpretation of the results in Chapter 2 is fairly straight forward, there are 
instances where further discussion is warranted.  Prior to the study described in Chapter 
2, JAK2 had been classically thought of as the primary kinase responsible for 
transducing the GH signal (5).  However, in recent years, several reports have surfaced 
indicating that, like other members of the cytokine family, GH also activated members of 
the Src family of kinases (these reports are described in detail in the Introduction section 
of this thesis).  Like JAK2, Src family kinases are able to induce the activation of Stat, 
ERK1/2 and Akt proteins (reviewed in (286)) raising the possibility that GH activation of 
Src family kinases may contribute to some GH signaling events.  Therefore, we sought 
to determine the relative contribution of JAK2 and Src family kinases to GH signaling in 
two highly GH responsive cell types: 3T3-F442A preadipocytes and H4IIE hepatoma 
cells.  3T3-F442A preadipocytes require GH in order to mature into adipocytes (168).  
GH has also been shown to regulate the actin cytoskeleton in these cells (132, 169).  In 
differentiated 3T3-F442A adipocytes, GH regulates the transcription of multiple genes 
(172), as well as lipolysis, hormone-sensitive lipase (170) and rates of glucose transport 
(171).   Hepatocytes are a major target of GH-mediated transcriptional regulation 
(reviewed in (39)), and H4IIE hepatoma cells have been used to study the effect of GH 
on protein synthesis (180) and insulin responsiveness (179, 181, 182).  Therefore, we 
sought to determine the relative contribution of the aforementioned kinases to GH 
signaling in these cells. 
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Src family kinases were not found to be activated in response to GH in either of 
these cell lines.   In data not included in Chapter 2, we were able to identify by molecular 
weight the active forms of all six Src family kinases present in 3T3-F442A and H4IIE 
cells, indicating that the method that we chose to assess Src family kinase activity (i.e. 
blotting with a phospho-specific antibody specific to the activating tyrosine) did not 
overlook activation of any Src family kinase members.  Additionally, as described in 
Chapter 2, we found EGF stimulation of 3T3-F442A cells to significantly further activate 
Src family kinases.  Thus Src family kinases were not maximally activated in the basal 
state, and were capable further activated by physiologically relevant ligands.  
Pretreatment with Src family kinase pharmacological inhibitors reduced the activity of all 
six Src family kinases to levels below detection.  However, the inhibitors had no effect on 
GH-induced activation of JAK2, ERK1/2, Stat1, Stat3, or Stat5.  Collectively, these 
results showed that in 3T3-F442A and H4IIE cells, GH-induced activation of JAK2, 
ERK1/2 and Stat proteins is not dependent on Src family kinase activity.  We cannot rule 
out the possibility that Src family kinases account for a fraction of GH activation of these 
proteins that is too small to be detected by this established method of Src family kinase 
activation detection. However, we hypothesize that any such contributions by Src family 
kinases to the physiological actions of GH in these cells would be negligible.  In addition, 
these results argue against the possibility that GH treatment results in the recruitment of 
basally active Src family kinases to a cellular compartment where they can then activate 
ERKs and Stats. 
 Pharmacological inhibition of Src family kinases did, however, result in a 
significant reduction in GH-induced Akt activation in both cell lines.  However, the 
inhibitors also significantly reduced basal Akt activity, raising the possibility that the Src 
inhibitor-induced reduction in GH-induced Akt activation was not specific to GH-induced 
activation, but was instead related to decreased basal Akt activity. One group has 
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proposed that Src must phosphorylate Akt on Tyr315 and Tyr326 before growth factors 
can activate Akt by stimulating its phosphorylation on Thr308 and Ser473 (201, 202). 
Thus, while Src phosphorylation of Akt may be necessary for GH to induce Akt 
activation, Src may not directly mediate that activation.  In support of this, we found that 
in 3T3-F442A cells pretreated with Src family kinase inhibitors, epidermal growth factor 
was, like GH, unable to activate Akt (data not shown).  Further, we found that reducing 
JAK2 levels by RNAi almost abolished GH-induced activation of Akt, and that GH was 
able to substantially activate Akt in Src family kinase null fibroblasts.  These data 
indicate that GH is able to activate Akt without Src family kinases, but seems unable to 
activate Akt without JAK2.  Additionally, PP3, the inactive analogue of the Src family 
kinase inhibitors, PP1 and PP2, inhibited both basal and GH-stimulated Akt activation.  
This raises the additional possibility that the inhibitory effects of the active Src family 
kinase inhibitors, PP1 and PP2, are not mediated exclusively via Src family kinases, but 
rather have off-target effects as has been previously documented (189, 190). 
The overall results of our study are in direct opposition to those generated by the 
Lobie, Tanaka, and Waters groups who found GH to activate at least one Src family 
kinase in CHO cells, NIH 3T3 cells, F-36P human leukemia cells, FDC-P1 hematopoietic 
progenitor cells, or murine liver tissue (30, 32, 34, 287). The simplest explanation for this 
apparent discrepancy is that different cell types activate different kinases in response to 
GH. For example, cells of hematopoietic origin appear to utilize Src family kinases for 
cytokine signaling to a greater extent than cells of non-hematopoietic origin (165). 
However, the reason why different cell types utilize different kinases for signal 
transduction remains unknown.  One hypothesis is that different cell types express 
different relative amounts of particular kinases.  In a situation in which two kinases are 
able to transduce the same signal, the relative amount of one kinase compared to 
another will determine which kinase is used (i.e. if there are more JAK2 molecules than 
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Src family kinase molecules, JAK2 will transduce the GH signal).  This explanation may 
be satisfactory for the example of F-36P and FDC-P1 cells compared to 3T3-F442A and 
H4IIE cells as F-36P and FDC-P1 cells are of hematopoietic origin, and thus may have 
higher levels of Src family kinases compared to JAK2 than fibroblasts and hepatoma 
cells.  However, this explanation does not seem to explain the differences in results 
between our 3T3-F442A and MEF cells (derived from three separate mice) and those 
obtained by the Lobie group who used NIH 3T3 cells.  All of these cells are derived from 
mouse fibroblasts, and therefore might be expected to contain similar relative levels of 
JAK2 and Src family kinases.  An alternative explanation for the differences between our 
results and those of the Lobie group relates to the method of assessing Src activation.  
We relied on a phospho-specific antibody that detects phosphorylated tyrosine 416 in c-
Src and analogous tyrosines in other Src family kinases as an indication of SFK activity.  
Although the Lobie group relied on analogous phospho-specific antibodies to assess 
JAK2 and ERK1/2 activation, they utilized an in vitro kinase assay to detect GH-
activated Src. In this assay, Src was immunoprecipitated with a polyclonal antibody 
(from Santa Cruz Biotechnology, Inc.) from GH-treated cells, then incubated with a Src 
substrate in the presence of [32-P]ATP (30). We attempted to use a Src polyclonal 
antibody from Santa Cruz Biotechnology, Inc. for detection of total Src but found that 
there were too many non-specific bands present on Western blots to identify c-Src or 
other Src family kinases.  While it is possible that when the Lobie group used this 
antibody for immunoprecipitations and subsequent in vitro kinase assays, a relatively 
pure Src immunoprecipitate was obtained, controls assessing the efficiency of these 
immunoprecipitations were not shown, leaving questions regarding the specificity of 
these results. 
More recently, the Waters group has reported GH activation of Src in mouse liver 
tissues (34, 35). This is in seeming contrast with our H4IIE cells, which are derived from 
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a rat hepatoma.  In their animal studies, the Waters group specifically tested GH-induced 
responses in liver tissue to implicate Src in the activation of ERK, and JAK2 in the 
activation of Stat5, Stat3 and Akt.  These studies were conducted on mice harboring a 
GHR knock-in that contained proline to alanine mutations within the Box 1 region of the 
GHR.  These point mutations disrupt the ability of JAK2 to bind GHR and, therefore, the 
ability of GH to activate JAK2.  In their data using liver from mutant mice, GH clearly 
activates Src.  Additionally, while JAK2, Stat5 and Akt are not activated in these 
experiments, ERK1/2 is activated, indicating that GH can activate ERK1/2 in the 
absence of JAK2 activation.  This finding raises the possibility that JAK2 is responsible 
for GH activation of Stats and Akt in liver tissue while Src is responsible for GH 
activation of ERK1/2.  However, while the two papers characterizing these mutant mice 
(34, 35) both assert that GH induces Src activation in WT mice, there are no convincing 
data to substantiate these claims.  This raises the possibility that GH is only able to 
activate Src in the mutant mice due to the fact that JAK2 is unable to be activated.  If this 
is true, this mouse model of GH-induced Src activation may be an artifact of an inability 
to activate JAK2. 
Future Directions 
  Because GH-mediated activation of Stat, ERK and Akt proteins in 3T3-F442A and 
H4IIE cells appears to be dependent on JAK2, it would be interesting to determine whether 
JAK2 is required for more downstream actions of GH.  GH is necessary for 3T3-F442A 
preadipocyte differentiation into mature adipocytes (168).  Thus, testing the ability of JAK2 
shRNA expressing-3T3-F442A preadipocytes to mature into adipocytes is a logical future 
experiment.  Likewise, assessing the ability of GH to regulate lipolysis, hormone-sensitive 
lipase and glucose transport rates in JAK2 knockdown 3T3-F442A adipocytes would shed 
light on the importance of JAK2 to these previously described actions of GH in 3T3-F442A 
adipocytes (170, 171).  H4IIE cells have been used to study the effect of GH on protein 
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synthesis (180) and insulin responsiveness (179, 181, 182), and therefore repeating these 
experiments with H4IIE JAK2 knockdown cells would clarify the importance of JAK2 to these 
GH-induced actions.  
 Perhaps the most outstanding question stemming from this study is why our study 
identified JAk2 as the primary upstream kinase in GH signaling while other groups report Src 
family kinases playing a prominent role in GH signaling.  We have hypothesized that cell 
type and relative kinase abundance may account for these differences.  Others have 
proffered this hypothesis too (35).  Future experiments comparing relative levels of JAK2 
and Src family kinases in 3T3-F442A, H4IIE, NIH 3T3, CHO, F-36P and FDC-P1 cells are a 
logical first step to answering this question.  If our hypothesis is true, I would expect to 
observe significantly higher levels of JAK2 relative to levels of Src family kinases in 3T3-
F442A and H4IIE cells than in NIH 3T3, CHO F-36P and FDC-P1 cells and mouse liver 
tissue. 
 
Growth hormone induces SH2B1 and JAK2 to form a complex with the novel 
SH2B1-interacting partner, II-spectrin, and induces II-spectrin re-localization 
 In Chapter 3, the relationship of SH2B1 to GH-mediated regulation of the actin 
cytoskeleton was investigated by characterizing the novel interaction between SH2B1 
and the cytoskeleton protein, II1-spectrin.  At the time this study was undertaken, Rac 
had previously been identified as an SH2B1-binding protein, providing one mechanism 
whereby SH2B1 could modulate GH-induced changes in the actin cytoskeleton {e.g. 
recruitment of Rac to the actin cytoskeleton via plasma membrane-localized and/or 
JAK2 associated SH2B1) {Diakonova, 2002 #3497}. However, in a yeast 2-hybrid 
screen for novel SH2B1 interacting proteins, the C-terminus of II1-spectrin was 
identified.  The importance of spectrins to the regulation and function of the actin 
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cytoskeleton is well established.  Thus, its binding to SH2B1 raised the possibility of an 
added mechanism whereby SH2B1 is able to mediate or modulate GH-induced 
changes in the actin cytoskeleton.  Subsequent co-immunoprecipitation experiments 
identified amino acids 2200-2358 of II1-spectrin as interacting with amino acids 105-
150 of SH2B1 in a mammalian expression system.  In data not shown, the SH2B1 
region of interaction was further refined to amino acids 118-150.   While amino acids 
2200-2358 include 97% (102 out of 111 amino acids) of II1-spectrin’s PH domain, no 
functional domains are known to lie within amino acids 118-150 of SH2B1, raising the 
possibility of a previously undefined PH domain-interacting region in SH2B1.  
Alternatively, it is possible that the PH domain of II1-spectrin does not mediate the 
interaction with SH2B1, but that the 55 amino acids C-terminal to the PH domain are 
responsible for the interaction.  Like the region of interaction within SH2B1, amino acids 
2304-2358 of II1-spectrin do not contain any known functional domains. 
 Interestingly, the extreme N- and C-terminal domains of II1- and II2-spectrin 
share no sequence commonality, and II1-spectrin amino acids 2200-2358 largely 
consists of almost the entire C-terminal region of dissimilarity between these splice 
variants.  Therefore, I predicted that II2-spectrin will not interact with SH2B1.  In data 
not shown, immunoprecipitation experiments were performed on lysates from 293T cells 
expressing full-length II2-spectrin and SH2B1.  In these experiments, GFP-SH2B1 
was not found to co-immunoprecipitate with myc-II2-spectrin, seemingly verifying the 
hypothesis that SH2B1 binds II1- but not II2-spectrin.  However, it must be noted 
that these experiments were performed with full-length II2-spectrin.  In fact, when the 
same experiment was repeated with full-length II1-spectrin, I found that full-length 
II1-spectrin also failed to co-immunoprecipitate with SH2B1.  Further, II1-spectrin 
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(2165-2358), which contains an intact PH domain, also failed to co-immunoprecipitate 
with SH2B1 in similar experiments.  In summary, II1-spectrin (2200-2358) 
consistently co-immunoprecipitates with SH2B1, while II1-spectrin (2165-2358), full-
length II1-spectrin and full length II2-spectrin all fail to co-immunoprecipitate with 
SH2B1 when exogenously expressed in 293T cells.   
The simplest explanation for these apparent discrepancies takes into account the 
fact that II1-spectrin (2200-2358) is localized to the cytoplasm and nucleus while the 
other spectrins are tightly associated with the plasma membrane (see Figs. 3.4 and 3.7).  
Spectrins that are tightly associated with the plasma membrane have a high likelihood of 
remaining in the insoluble fraction of cell lysates, and therefore remaining unavailable for 
co-immunoprecipitation.  On the other hand, a large percentage of II1-spectrin (2200-
2358) is present in the cytoplasm, and is thus available for co-immunoprecipitation with 
SH2B1.  All of these co-immunoprecipitation experiments were performed under 
conditions using lysis buffer containing 0.1% TritonX-100.  In the 3T3-F442A model that 
revealed a GH-induced complex formation between endogenous II-spectrin, SH2B1 
and JAK2, 1% TritonX-100 lysis buffer was used.  The more powerful 1% TritonX-100 
lysis buffer may account for the positive results observed in the latter experiment. 
In the overexpression co-immunoprecipitation and confocal microscopy 
experiments, II1-spectrin (2200-2358) and SH2B1 appeared to interact constitutively. 
In the co-immunoprecipitation experiment assessing endogenous proteins, a low level of 
interaction was present in the serum-deprived condition and the level of interaction was 
significantly increased with GH stimulation.  Therefore, in the endogenous system, GH-
stimulation (or possibly other ligand stimulation) appears to be necessary for the robust 
interaction between SH2B1 and II-spectrin.  GH and other ligands are present in 
serum, providing a possible explanation for the constitutive nature of the interaction in 
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the overexpression systems.  An alternative explanation is that II1-spectrin (2200-
2358) lacks a region that negatively regulates the interaction with SH2B1, allowing for 
constitutive interaction.  Further insight into a possible mechanism for this interaction 
may be gleaned from the facts that co-expression of JAK2 with both full-length spectrin 
isoforms resulted in tyrosyl phosphorylation of both spectrins, and that GH induced an 
increase in the interaction between II-spectrin and SH2B1. Therefore, it is possible that 
in the basal state, a lower affinity interaction exists between amino acids 2200-2358 of 
II1-spectrin and amino acids 118-150 of SH2B1.  Upon GH stimulation, the 
SH2B1/II1-spectrin complex is recruited to JAK2, resulting in tyrosyl-phosphorylation 
of II1-spectrin by JAK2, thereby creating higher-affinity binding sites for SH2B1’s 
SH2 domain.  Alternatively, JAK2 phosphorylation of II1-spectrin alters its 
conformation, making amino acids 2200-2358 more readily accessible to SH2B1. 
Notice that this model provides for a direct interaction only between II1-
spectrin, but not II2-spectrin (II2-spectrin does not contain amino acids 2200-2358 
of II1-spectrin).  It is possible that a yet undiscovered site of SH2B1 interaction is 
present on II2-spectrin.  It is also possible that II2-spectrin is present in a 
heterotetramer with II1-spectrin and is co-recruited to JAK2 with II1-spectrin, thus 
allowing for phosphorylation by JAK2. 
Interestingly, we found that JAK2 does not phosphorylate amino acids 2200-2358 
of II1-spectrin (data not shown), which is one of the regions of difference between the 
splice variants.  Thus it seems likely that JAK2 phosphorylates II1- and II2-spectrin 
on the same sites.  Finally, all identified metazoan spectrins share 50-60% amino acid 
sequence similarity, with some regions sharing 70-80% sequence similarity (217).  If 
JAK2 phosphorylates II1- and II2-spectrin within these regions of homology 
between all spectrins, it is possible that JAK2-mediated phosphorylation of spectrin 
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repeat-containing proteins is a common and major mode of regulation of the 
cytoskeleton.   
 The functional significance of JAK2-mediated phosphorylation of II-spectrin is 
yet to be established.  Phosphorylation of spectrins is thought to increase their ability to 
bind actin (218), induce their re-localization from the plasma membrane into the 
cytoplasm and/or nucleus (219, 221), decrease their affinity for other spectrins (220), 
decrease their affinity for the plasma membrane (222) and induce their cleavage by 
proteases (237).  Insulin receptor (IR) and epidermal growth factor receptor (EGFR) 
have both been shown to directly tyrosyl phosphorylate -spectrin in in vitro kinase 
assays (238, 239).  However, these assays were used to assess the relative kinase 
activities of IR and EGFR and did not link the phosphorylation of -spectrin with a 
function.  With the exception of tyrosyl-phosphorylation-induced calpain cleavage of II-
spectrin, all known spectrin phosphorylation events linked to a function are induced by 
serine/threonine phosphorylation of spectrin.  This raises the question of whether the 
GH-induced subcellular redistribution of II2-spectrin that we observed in H4IIE cells is 
directly linked to JAK2-mediated tyrosyl-phosphorylation of II2-spectrin or indirectly 
linked via serine/threonine phosphorylation of II2-spectrin by some kinase 
downstream of JAK2 (e.g. ERK1/2).  
One mechanism whereby GH may induce tyrosyl-phosphorylation and 
subsequent subcellular redistribution of II-spectrin is through GH stimulation inducing 
the formation of a complex of II-spectrin, SH2B1 and JAK2.  We observed GH 
treatment to induce the formation of this complex in 3T3-F442A cells.  However, we did 
not observe tyrosyl phosphorylation of II-spectrin at the 20 min time point tested.  One 
explanation for the apparent discrepancies between this result and the ability of JAK2 to 
phosphorylate II-spectrin in the 239T cell overexpression system is that GH induces II-
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spectrin phosphorylation at a time point prior to or after 20 min. This is a possibility that 
can be addressed by performing time courses of GH treatment.  Alternatively, the anti-
phospho-tyrosine antibody used in this experiment may not have been sensitive enough 
to identify GH-induced phosphorylation of endogenous spectrin, or II-spectrin may not 
be tyrosyl phosphorylated in response to GH treatment.  Future studies are required to 
determine if II-spectrin is phosphorylated in response to GH treatment.   
 Dissociation of spectrins from the plasma membrane is thought to be an event 
that precedes proliferation (221). Therefore, JAK2-mediated phosphorylation of spectrin 
and subsequent dissociation of spectrin from the plasma membrane may be a 
mechanism whereby GH can induce proliferation.  Autocrine GH signaling has recently 
been implicated in several cancer-associated phenotypes including enhanced 
proliferation of MCF-7 cells (288).  Accordingly, it is possible that GH-induced 
redistribution of II-spectrin may contribute to the proliferative actions of GH in MCF-7 
cells.  Another example where JAK2 phosphorylation of -spectrins may contribute to 
proliferative disorders may be in the case of the constitutively active JAK2 mutant, JAK2 
V617F, which drives several myeloproliferative disorders, including polycythemia vera, 
essential thrombocythaemia, and myelofibrosis (reviewed in (289)).   
In addition to promoting proliferation, dissociation of spectrin from the plasma 
membrane has been connected to other mechanisms of neoplasia. E-cadherin is a 
critical component of cell-cell contacts, and mislocalization or down-regulation of E-
cadherin is often associated with epithelial to mesenchymal transition (EMT) and 
metastasis (reviewed in (290)).  Proper localization of both II1 and II2-spectrin has 
been demonstrated to be necessary for proper E-cadherin localization (228, 229, 291).  
Autocrine GH has recently been shown to induce relocalization of E-cadherin from 
adherens junctions into the cytoplasm resulting in EMT in MCF-7 cells (292). Based on 
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these combined findings, it is reasonable to hypothesize that GH-induced, JAK2-
mediated phosphorylation of II-spectrin leads to mis-localization of E-cadherin, 
contributing to the autocrine GH-induced EMT phenotype in MCF-7 cells.  It is interesting 
to note that I have also found SH2B1 to be localized to adherens junctions in MCF-7 
cells (data not shown), raising the possibility that the II-spectrin/SH2B1 interaction 
plays a role in this potential mechanism. 
 Overall, the results presented in Chapter 3 establish the basis for additional 
studies investigating the functional significance of the SH2B1-dependent, JAK2-
mediated tyrosyl phosphorylation of II-spectrin and the GH-induced formation of a II-
spectrin/SH2B1/JAK2 complex, as well as the physiological relevance of the GH-induced 
shift in II-spectrin localization. 
Future Directions 
 As mentioned above, my inability to co-immunoprecipitate full length II1- and 
II2-spectrin with SH2B1 may have been due to insufficient solublization of plasma-
membrane associated II-spectrin.  Therefore, I will repeat these co-immunoprecipitation 
experiments with SH2B1 and full-length II1- and II2-spectrin using 1% TritonX-100 
as opposed to 0.1% TritonX-100.  Based on the co-immunoprecipitation results in 3T3-
F442A cells using the 1% TritonX-100 lysis buffer, I predict that both full-length II-
spectrin isoforms will co-immunoprecipitate with SH2B1. 
 One model that can be constructed based on my results in Chapter 3 is that a 
small fraction of SH2B1 and II-spectrin exist in a complex in the cytoskeleton prior to 
GH treatment.  Upon GH stimulation, II-spectrin is recruited with SH2B1 to active 
JAK2.  Active JAK2 phosphorylates II-spectrin, creating additional binding sites for 
SH2B1, and thus increasing the interaction between II-spectrin and SH2B1.  JAK2-
mediated phosphorylation of II-spectrin additionally results in the translocation of II-
 
 146 
spectrin out of the plasma membrane and into the cytosol.  From the studies by other 
groups described above that assess the functional consequences of altering spectrin 
localization, the functional consequences of this model may include GH-induced 
proliferation, migration or subcellular redistribution of E-cadherin. 
I would like to first determine the mechanism of GH-induced formation of the II-
spectrin/SH2B1/JAK2 complex.  Previous studies showed that GH stimulation 
increases the interaction between SH2B1 and JAK2 (100).  My results showed that 
SH2B1 knockdown decreases the GH-induced interaction between II-spectrin and 
JAK2.  Taken together, these results suggest that GH may induce SH2B1 to recruit II-
spectrin to JAK2.  Figure 3.7 shows that II-spectrin resides almost completely in the 
cytoskeletal fraction.  In contrast, SH2B1 mostly resides in the soluble fraction in this 
experiment, while a small portion resides in the cytoskeletal fraction (data not shown).  It 
is important to note that the membrane fraction is included in the soluble fraction in these 
experiments, as previous reports have shown the majority of SH2B1 to reside in the 
membrane (132).  To determine if GH stimulation induces II-spectrin redistribution out 
of the cytoskeletal fraction and into the membrane fraction (where SH2B1 and JAK2 
are present), parallel cytoskeleton/non-cytoskeleton and membrane/cytosol fractionation 
experiments will be performed in 3T3-F442A and H4IIE cells stimulated with GH from 0-
60 min.  In Fig. 3.8, I showed that GH induced redistribution of II2-spectrin out of cell-
cell contacts and into the cytoplasm starting at 15 min, with almost complete II2-
spectrin cytoplasmic localization by 30 minutes.  Therefore I predict that GH 
administration will recruit II-spectrin out of the cytoskeletal fraction and into the plasma 
membrane fraction by 15 min following GH stimulation.  By 30 min following GH 
stimulation, I expect the majority of II-spectrin to be present in the cytoplasm. 
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To determine the importance of SH2B1 to this proposed subcellular 
redistribution of II-spectrin, I will also perform these experiments in SH2B1 knockdown 
3T3-F442A cells (shSH2B1 3T3-F442A cells).  My results in Fig 3.7 showed reduced 
complex formation between II-spectrin, SH2B1 and JAK2 in shSH2B1 cells 
compared to shControl cells. Therefore, I predict that GH will induce less II-spectrin to 
be redistributed into membrane and cytoplasmic fractions in shSH2B1 cells compared 
to shControl cells.   
Finally, the model proposed above predicts that JAK2-mediated phosphorylation 
of II-spectrin is necessary for GH to induce II-spectrin to redistribute into the 
cytoplasm.  To test this, tyrosine phosphorylation of II-spectrin will also be monitored in 
the different subcellular fractions over the GH time course.  Additionally, if the tyrosine(s) 
phosphorylated by JAK2 are identified (see below), I will express II-spectrin tyrosine to 
phenylalanine mutants in this system.  I expect that GH stimulation will not elicit 
redistribution of II-spectrin tyrosine to phenylalanine mutants into the cytoplasm.  
To identify the tyrosine(s) phosphorylated by JAK2, I will create II1- or II2-
spectrin truncation mutants.  These mutants will be expressed in 293T cells with 
SH2B1 and JAK2 to identify the region of II-spectrin that is tyrosyl phosphorylated.  
Following identification of the region of II-spectrin that is tyrosyl-phosphorylated by 
JAK2, I will create tyrosine to phenylalanine point mutants to identify the individual 
tyrosine(s) on II-spectrin that are phosphorylated by JAK2.  Assuming positive results 
are achieved in these experiments, in vitro kinase assays will be employed to determine 
if JAK2 directly phosphorylates II-spectrin on tyrosines.  The model predicts that tyrosyl 
phosphorylation of II-spectrin creates additional binding sites for SH2B1.  Therefore, 
these tyrosine to phenylalanine point mutants will be utilized in co-immunoprecipitation 
 
 148 
assays with SH2B1.  I predict that less SH2B1 will co-immunoprecipitate with mutant 
II-spectrin compared to wild type II-spectrin. 
I would like to characterize the functional consequence of GH-induced II-
spectrin-containing complexes, potential II-spectrin tyrosyl phosphorylation and II-
spectrin subcellular re-distribution.  I will create and express SH2B1 truncation mutants 
lacking the II-spectrin binding domain, or II-spectrin mutants lacking the SH2B1 
binding domain or lacking tyrosines phosphorylated by JAK2 in 3T3-F442A, H4IIE or 
autocrine GH-expressing MCF-7 cells.  If II-spectrin phosphorylation or subcellular 
redistribution is necessary for GH-induced proliferation or migration, I predict that 
expression of these mutants will act as dominant negative proteins in assays of GH-
induced proliferation and/or migration. 
 
Identification and characterization of SH2B1 as a novel focal adhesion protein 
In Chapter 4, I further solidify the role of SH2B1 as a component and/or 
regulator of the actin cytoskeleton by the identification of SH2B1 as a focal adhesion 
protein.  Fluorescently tagged SH2B1 consistently localized to focal adhesions in 3T3-
F442A and NIH 3T3 fibroblasts as well as MCF-7 and HeLa epithelial-derived cells, 
indicating that SH2B1 is a component of focal adhesions in multiple cell types. Focal 
adhesions are integrin-based macromolecular complexes that mediate cell-extracellular 
matrix (ECM) attachment and allow direct signaling between the extracellular matrix and 
the cell (reviewed in (128)).   
The finding that the SH2 domain of SH2B1 is necessary and sufficient for focal 
adhesion localization leads to the hypothesis that SH2B1 binds a tyrosyl 
phosphorylated protein within the focal adhesion complex.  Focal adhesions are known 
to contain multiple tyrosyl-phosphorylated proteins (including paxillin (267), vinculin (268, 
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269), talin (270) p130Cas (271), tensin (272), and FAK (267)).  Additionally, the SH2 
domains of other focal adhesion proteins have been identified as important for focal 
adhesion localization (273, 274) and overall tyrosine phosphorylation of focal adhesion 
proteins is thought to be an important regulatory mechanism of focal adhesion formation, 
stability and maturation (reviewed in (275)).  Therefore, it is possible that mechanisms 
regulating overall focal adhesion protein tyrosyl phosphorylation (eg. Src and FAK 
activation) also regulate the recruitment of SH2B1 to focal adhesions.  However, I have 
eliminated both FAK and paxillin as potential SH2B1 interacting molecules.  We have 
identified two additional focal adhesion proteins, vinculin and talin, whose sites of tyrosyl 
phosphorylation make them attractive candidates for SH2B1 binding proteins.  SH2B1 
is known to bind phosphotyrosines that lie within a YXXL motif (12).  Vinculin tyrosine 
822 and talin tyrosines 270 and 2530 are all reported to be phosphorylated and all reside 
within a YXXL motif (269, 293).  Future experiments will explore the possibility that 
SH2B1 interacts with one or both of these proteins within the context of tyrosine 
phosphorylation.  
All SH2 domain-containing SH2B1 mutants were able to localize to focal 
adhesions.  GFP-SH2B1 (118-670), lacking the dimerization domain, GFP-SH2B1 
(150-200), lacking the NLS, and GFP-SH2B1 mNES all displayed focal adhesion 
localization similar to WT.  However, GFP-SH2B1 (269-670), which contains an intact 
SH2 domain but lacks the dimerization domain, NLS and NES, appeared to display 
reduced focal adhesion localization compared to WT GFP-SH2B1 (Fig. 4.3).  These 
data indicate that while individual disruption of the dimerization domain, NLS or NES by 
deletion or point mutation does not affect focal adhesion localization, collective 
disruption of these regions does have an effect.  Alternatively, deleting amino acids 1-
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268 may produce a conformational change in the remaining SH2B1 protein that results 
in atypical protein localization.   
In addition to SH2B1, I found SH2B1 and SH2B1 to localize to focal 
adhesions.  I predict that localization of these SH2B1 isoforms is also mediated through 
the SH2 domain of SH2B1, and I therefore expect that SH2B1 will also localize to focal 
adhesions through its SH2 domain when tested in future experiments.  SH2B2 and 
SH2B3 both contain SH2 domains similar to SH2B1, and are known to bind at least 
some of the same partners as SH2B1 (22, 276, 294). Therefore it is possible that the 
other SH2B family members are also focal adhesion proteins.  Interestingly SH2B3 has 
been described as a binding partner of the focal adhesion protein, filamin (139). 
However, this interaction was not mediated through the SH2 domain of SH2B3.  
Therefore, it is possible that different SH2B family members are targeted to focal 
adhesions through differing mechanisms. 
There are currently greater than 150 proteins identified as focal adhesion 
proteins and almost 700 identified interactions between focal adhesion proteins, making 
these structures among the most complex assembly of proteins within a cell (see (275) 
and (128) for reviews}.  Although the term “focal adhesion” is generally used to denote 
these structures, at least three distinct cell-ECM adhesion complexes have been defined 
in motile cells based on their temporal formation and protein composition (reviewed in 
(295)).  Focal complexes are the earliest integrin-based adhesions to form, can be seen 
underneath the leading edge of lamellipodia, are highly vinculin and paxillin positive and 
contain a high concentration of tyrosyl-phosphorylated proteins (296-298).  These focal 
complexes are the initial sites of attachment at the leading edge of lamellipodia.  They 
have been hypothesized to tether the actin meshwork at the leading edge of lamellipodia 
to a solid substrate, and thus act to direct the force of actin polymerization towards the 
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leading edge.  Some focal complexes mature into focal adhesions, which are located at 
the edges of the cell and dispersed underneath the body of the cell.  Like focal 
complexes, focal adhesions are highly vinculin and paxillin positive and contain many 
tyrosyl-phosphorylated proteins.  However, unlike focal complexes, focal adhesions are 
also zyxin and tensin positive and incorporate actin bundles into the adhesion site (297).  
Focal adhesions can further mature into fibrillar adhesions, which are typically located 
more centrally within the cell and are elongated, rather than punctate adhesion sites.  
While fibrillar adhesions are composed largely of the same proteins that make up focal 
adhesions, fibrillar adhesions display a higher concentration of tensin than focal 
adhesions and contain little or no tyrosyl-phosphorylated proteins (298).  Both focal 
adhesions and fibrillar adhesions are thought to provide traction, monitor mechanical 
forces and monitor the composition of the ECM to facilitate and regulate cell motility.  
Therefore, while motile cells contain three major types of adhesions sites that perform 
varying functions, there are currently only a few known differences in protein 
composition between focal complexes, focal adhesions and fibrillar adhesions.   
Interestingly, I found SH2B1 to constitutively localize to both focal adhesions 
and fibrillar adhesions, but I was unable to conclusively find SH2B1 present in vinculin 
positive focal complexes (Figure 4.1B, bottom left image, punctate dots are focal 
adhesions and slashes are fibrillar adhesions; data not shown).  This raises the 
possibility that, like zyxin and tensin, SH2B1 is specifically a component of more 
mature adhesion sites.  While the functional consequences of zyxin and tensin 
incorporation into mature adhesion sites is unknown, it has been hypothesized that 
these proteins add structural stability to adhesion sites (297).  Focal adhesions have 
half-lives of 10-30 min while focal complexes have half-lives of only a few minutes 
(reviewed in (295)).  The turnover of these adhesion complexes may be related to the 
 
 152 
dynamic cycling of focal adhesion proteins into and out of focal adhesions themselves 
(called focal adhesion protein turnover dynamics) (252).  Therefore, proteins that exhibit 
reduced turnover dynamics or reduce the turnover dynamics of other focal adhesion 
proteins may in turn reduce the overall turnover of cell adhesion sites.  It is possible that 
SH2B1 functions in a similar fashion to add stability to these adhesion sites.  The 
dynamic turnover of vinculin and paxillin are often monitored to assess the overall 
turnover rates of focal adhesions (129).  I found that co-expression of SH2B1 with 
vinculin does not alter vinculin focal adhesion turnover dynamics compared to vinculin 
expressed alone (data not shown), possibly excluding this hypothesis.  Alternative 
potential functions of SH2B1 in focal adhesions are discussed in greater detail below. 
The data presented in Chapter 4 show that SH2B1 is present in focal adhesions 
prior to stimulation by GH or other stimuli such as serum.  However, GH stimulation 
increases the dynamic cycling of SH2B1 into and out of focal adhesions (SH2B1 focal 
adhesion turnover) (Fig. 4.4).  In additional experiments, I found that SH2B1 focal 
adhesion turnover was increased in cells cultured in serum-containing medium 
compared to cells cultured in serum-free medium.  These observations raise the 
question of how GH and other stimuli act on focal adhesion-localized SH2B1.  Although 
several growth factor receptors have been reported to localize to focal adhesions, GHR 
has not been reported in focal adhesions and in additional experiments, I was unable to 
detect GFP-GHR in focal adhesions.  This seems to rule out the possibility that SH2B1 
associates with and is regulated by a GHR/JAK2 complex at focal adhesions.  It is 
possible that GH and other stimuli induce JAK2 or other regulators to translocate to focal 
adhesions to modify SH2B1, thus altering its focal adhesion turnover dynamics.  
However, I did not observe JAK2 to localize to focal adhesions under serum-deprived, 
GH-stimulated or serum-stimulated conditions.  Alternatively, GH or other stimuli modify 
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SH2B1 at the plasma membrane (e.g. JAK2 phosphorylates SH2B1 at the activated 
GHR/JAK2 complex).  This modified SH2B1 may then be incorporated into focal 
adhesions through the normal process of focal adhesion protein turnover.  As the 
concentration of modified SH2B1 in the cell increases, the concentration of modified 
SH2B1 within focal adhesions will also increase, thus altering SH2B1 turnover 
dynamics at focal adhesions.  Future experiments described below will test these 
hypotheses. 
The fact that rates at which individual proteins cycle into and out of focal 
adhesions can directly affect the rates of focal adhesion turnover (129, 252) and cell 
motility raises the possibility that one mechanism whereby GH induces cell motility is 
through altering the focal adhesion turnover dynamics of SH2B1.  Therefore, it will be 
of interest to determine whether inhibiting the ability of GH to alter SH2B1 turnover 
dynamics also inhibits GH-induced cell motility. GH stimulation induces phosphorylation 
of SH2B1 at tyrosines 439 and 494, and phosphorylation of these tyrosines is thought 
to be required for SH2B1 enhancement of GH-induced cell motility (116).  I found that 
mutation of both tyrosines 439 and 494 in combination does not affect basal focal 
adhesion turnover rates of SH2B1 in 3T3-F442A cells cultured in the presence of 
serum (data not shown).  However, to assess the effect of phosphorylation of tyrosines 
439 and 494 on the ability of GH to increase the turnover rate of SH2B1 at focal 
adhesions, these experiments need to be repeated in cells treated with GH following a 
period of serum deprivation.  
Although GH stimulation is primarily thought to result in tyrosyl phosphorylation of 
SH2B1, NGF and PMA stimulation is thought to result in SH2B1 becoming highly 
serine/threonine phosphorylated (224). In Fig. 4.5, I show that PKC mediates a PMA-
induced upward shift in endogenous SH2B1 mobility, as assessed by Western blot.  This 
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upward shift is consistent with SH2B1 being serine/threonine phosphorylated since it is 
reversed by incubation with a phosphatase (224). Recent work in the Carter-Su 
laboratory has identified at least two serines, serine 161 and serine 165, as playing an 
important role in the regulation of SH2B1 at the plasma membrane in response to PMA 
in neuronal PC12 cells (Maures, et al. Manuscript in preparation). Mass spectroscopy 
identified serine 161 as being phosphorylated in cells stimulated with PMA.  Whether 
serine 165 is also phosphorylated is unknown.  Both of these serines lie within classic 
PKC substrate phosphorylation motifs [X(S/T)X(R/K)], and therefore, may be 
phosphorylated by PKC.  I found that PMA stimulation resulted in less of an upward 
mobility shift of GFP-SH2B1 (S161,165A) than WT GFP-SH2B1 in 3T3-F442A cells.  
These results suggest the possibility that PMA stimulates a PKC-mediated 
phosphorylation of SH2B1 at serines 161 and/or 165 in 3T3-F442A cells. 
In Chapter 4, I also show that PMA stimulation causes WT SH2B1, but not 
SH2B1 (S161,165A), to leave focal adhesions.  PKC ,  and  are found in focal 
adhesions (254-256) and PKC is thought to directly phosphorylate vinculin (257), talin 
(258), filamin (259) and integrin (277) at focal adhesions.  Taking these results into 
account, I hypothesize that PMA induces PKC to phosphorylate SH2B1 at serines 161 
and/or 165, which causes SH2B1 to leave focal adhesions.  Adding PMA in the 
presence of PKC-specific inhibitors and examining whether PMA causes SH1B1 to 
leave focal adhesions would lend additional support for PKC in this mechanism.  
Serines 161 and 165 lie within a 30 amino acid stretch of SH2B1 that contains 
13 serines and threonines.  Ten of these serines and threonines (S137, S141, T142, 
T143, S144, S145, S154, S157, S161, S165) lie within the classic PKC-substrate motif, 
X(S/T)X(R/K) (Center for Biological Sequence Analysis, 
http://www.cbs.dtu.dk/index.shtml).  Of these many potential PKC phosphorylation sites, 
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serines 161 and 165 appear particularly important for SH2B1 movement out of focal 
adhesions due to several additional experiments that I have recently performed.  First, 
experiments with SH2B1 containing mutation of 11 additional serines and threonines in 
combination with serines 161 and 165 [SH2B1 (13SA)] gave the same results as 
SH2B1 (S161,165A).  Second, when these experiments were performed on SH2B1 
(13SA) with alanine 165 mutated back to serine [SH2B1 (13SA,A165S)], the results 
were almost identical to WT SH2B1.  This raised the possibility that serine 165 alone 
was responsible for the PMA-induced redistribution out of focal adhesions.  However, 
when these experiments were performed with SH2B1 (S165A), the results were again 
almost identical to WT SH2B1.  Together, these results suggest that PMA-induced 
phosphorylation of either serine 161 or 165 is sufficient for SH2B1 to leave focal 
adhesions.  This comes from the fact that WT SH2B1, SH2B1 (13SA,A165S), and 
SH2B1 (S165A) all have the same phenotype (ie. PMA induces their dissociation from 
focal adhesions), and that SH2B1 (S161,165A) and SH2B1 (13SA) have the same 
phenotype (ie. PMA does not induce their dissociation from focal adhesions). I predict 
that future experiments using SH2B1 (S161A) will also result in a phenotype similar to 
that of WT SH2B1. 
In the PC-12 model, it is thought that the negatively charged plasma membrane 
recruits SH2B1 through its positively charged amino acids within the NLS.  
Phosphorylation of Ser 161/165 (which lie adjacent to the positively charged NLS) would 
add a negative charge to the vicinity of the NLS, counteracting its positive charge, and 
acting as an electrostatic switch.  This is thought to induce dissociation of SH2B1 from 
the PM.  In Fig. 4.3, I show that the NLS is dispensable for SH2B1 focal adhesion 
localization.  This indicates that it is not necessary for SH2B1 to be localized to the 
plasma membrane in order to localize to focal adhesions.  It also indicates that the 
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proposed phosphorylation of Ser 161/165 causes SH2B1 dissociation from focal 
adhesions by some mechanism other than that of an electrostatic switch.  For example, 
a phosphorylation-induced conformational change could lead to a decreased affinity of 
SH2B1 for some binding partner.  Serine phosphorylation of vinculin (283) and paxillin 
(284) induces dissociation of these proteins from focal adhesions, although the 
mechanism of dissociation is also unknown.  Therefore, future investigation into the 
precise mechanism of PMA-induced SH2B1 release from focal adhesions is warranted, 
and may shed light on a general mechanism whereby serine phosphorylation regulates 
localization of focal adhesion proteins. 
The results suggesting a phosphorylation-induced release of SH2B1 from focal 
adhesions are supported by the SH2B1 turnover experiments in Chapter 4 that show 
that compared to WT SH2B1, SH2B1 (S161,165A) has reduced turnover dynamics 
and SH2B1 (S165E) has increased turnover dynamics.  I found that SH2B1 (13SA) 
displayed turnover dynamics almost identical to SH2B1 (S161,165A) in both serum-
deprived and serum-fed conditions.  I predict the turnover dynamics of SH2B1 (S161E) 
will be found to be similar to those of SH2B1 (S165E).  These experiments suggest that 
phosphorylation of SH2B1 at serine 161 and/or 165 regulates the dynamic turnover of 
SH2B1 at focal adhesions.  Serine phosphorylation of paxillin has been shown to 
regulate the dynamic turnover of paxillin at focal adhesions (129), indicating that 
phosphorylation of focal adhesion proteins may be a general mechanism regulating focal 
adhesion protein turnover.   
These differences in SH2B1 turnover dynamics due to mutation of serines 
161/165 are likely to be related to the PMA-induced dissociation of SH2B1 from focal 
adhesions.  PMA stimulation induces strong activation of several PKC isoforms.  Cells 
are not normally exposed to conditions such as this, but rather are exposed to lower 
 
 157 
levels of PKC activation in response to various cytokines, growth factors and other 
external and internal stimuli.  Therefore, rather than the all or nothing localization 
response observed in the PMA stimulation experiments, a cell will more likely be 
exposed to conditions that either increase or decrease the dynamic cycling SH2B1 into 
and out of focal adhesions.  I hypothesize that conditions that induce the proposed 
phosphorylation of serines 161 and 165 will push the balance of SH2B1 focal adhesion 
dynamics towards increased cycling into and out of focal adhesions (i.e. less SH2B1 in 
focal adhesions and/or SH2B1 remaining in focal adhesions for a shorter period of 
time). Conversely, I hypothesize that conditions that promote dephosphorylation of 
serines 161 and 165 will push the balance of SH2B1 focal adhesion dynamics towards 
decreased cycling into focal adhesions (i.e. more SH2B1 in focal adhesions for a longer 
period of time). 
The functional consequences of changes in SH2B1 focal adhesion turnover 
dynamics seem to support this hypothesis.  Although the data were not quantified in 
Chapter 4, it appeared that focal adhesions in cells expressing GFP-SH2B1 
(S161,165A) were brighter (more intense fluorescence) than focal adhesions in cells 
expressing WT SH2B1.  Conversely, focal adhesions in cells expressing GFP-SH2B1 
(S165E) appeared dimmer (less intense fluorescence) than focal adhesions in cells 
expressing WT GFP-SH2B1.  As described above, a slower SH2B1 (S161,165A) 
turnover rate would lead to more SH2B1 in focal adhesions and vice versa for SH2B1 
(S165E).  The dynamic turnover of SH2B1 at focal adhesions also appeared to affect 
focal adhesion size, as cells expressing GFP-SH2B1 and GFP appeared to have focal 
adhesions of the same size, whereas focal adhesions in cells expressing GFP-SH2B1 
(S161,165A) were larger and those in cells expressing GFP-SH2B1 (S165E) were 
smaller. A finding that these differences in focal adhesion size are statistically significant 
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would implicate the regulation of SH2B1 focal adhesion turnover dynamics as an 
important mediator of overall focal adhesion characteristics.   
The final piece of data presented in Chapter 4 revealed the surprising fact that 
expression of SH2B1 (S165E) alone resulted in a significant increase in the overall 
number of focal adhesions per cell.  Increased dynamic cycling of SH2B1 (S165E) 
appears necessary for this phenotype as opposed to decreased levels of SH2B1 
(S165E) in focal adhesions.  This conclusion is based on the observation that SH2B1 
truncation mutants that do not localize to focal adhesions [e.g. SH2B1 (1-555), SH2B1 
(1-260)] or that appear to exhibit reduced focal adhesion localization [e.g. SH2B1 (269-
670) do not increase the overall number of focal adhesions per cell.  Interestingly, PKC 
activation is able to recruit activated ERK1/2 to focal adhesions (253) as well as activate 
Rho-A (280), events which lead to an increase in the focal adhesion number.  It is 
tempting to hypothesize that PKC-mediated phosphorylation of SH2B1 at serine 161 
and/or 165 plays a role in PKC-mediated recruitment of ERK1/2 to focal adhesions 
and/or activation of RhoA. 
 As discussed above, the functional consequences of the differences between 
composition of focal complexes and more mature adhesions sites have not been 
elucidated. However, the signals that initiate the formation of focal complexes and focal 
adhesions have been characterized.  Rac-1 activity is well known to initiate focal 
complex formation (reviewed in (299)) while focal adhesion formation is dependent on 
Rac-1 inactivation and Rho-A activation (300).  In relation to these mechanisms of 
adhesion formation, it is worth noting that SH2B1 has been found to constitutively bind 
Rac (112).  However, I predict that focal adhesion-localized SH2B1 does not bind Rac, 
as this would inhibit the actual formation of focal adhesions.  Because SH2B1 is 
already known to bind one small GTPase (Rac-1), it may be worthwhile for future studies 
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to investigate the possibility that SH2B1 interacts with additional small GTPases such 
as Rho-A.  Alternatively, SH2B1 may recruit GTPase regulator or effector molecules to 
focal adhesions.  In unpublished data, the Carter-Su lab has identified Vav1 and Vav2 as 
SH2B1 binding partners.  Vav proteins are guanine nucleotide exchange factors 
(GEFs) for small GTPases (301-304).  Vav2 has been shown to localize to focal 
adhesions (305), and expression of constitutively active Vav has been shown to induce 
focal adhesion formation in a manner similar to constitutively active Rho-A (306).  
Therefore, it is possible that SH2B1 regulates focal adhesion dynamics by recruiting 
Vav proteins to focal adhesions.  In support of this hypothesis, in preliminary 
experiments, I found GH stimulation of 3T3-F442A cells expressing GFP-Vav2 to result 
in the recruitment of GFP-Vav2 into the region of focal adhesions, but only when 
mCherry-SH2B1 was co-expressed.  Additionally, focal adhesions in GH-stimulated 
cells co-expressing Vav2 and SH2B1 appeared smaller and finer than in unstimulated 
cells or cells expressing SH2B1 alone.  Khosravi-Far et. al reported a similar phenotype 
when they expressed constitutively active Vav or Rho-A in NIH 3T3 cells (306).   
Taking these observations together, I hypothesize that stimuli that induce 
phosphorylation of SH2B1 on serines 161 and/or 165 increase the rate of SH2B1 
turnover dynamics at focal adhesions.  This, in turn, could allow for increased Vav 
targeting to focal adhesions as SH2B1 quickly cycles into and out of focal adhesions.  
Alternatively, phosphorylation of SH2B1 at serines 161/165 may increase the affinity of 
Vav for SH2B1.  In either case, the interaction between SH2B1 and Vav may result in 
Rho-A activation which would be predicted to promote the formation of new focal 
adhesions.  In support of this hypothesis, as described above, cells expressing GFP-
SH2B1 (S165E) (mimicking phosphorylation of S165) alone exhibit smaller and more 
focal adhesions that appear strikingly similar to focal adhesions in GH-treated cells 
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expressing both Vav2 and SH2B1.  Clearly, additional experiments are needed to 
establish that PKC mediates phosphorylation of SH2B1 at serines 161/165 and 
elucidate the mechanism whereby that modification alters SH2B1 focal adhesion 
turnover dynamics and increases overall focal adhesion number.   
Currently, no fractionation protocols exist to allow complete isolation of focal 
adhesions proteins, and therefore, it is impossible to determine with complete 
confidence whether PKC directly phosphorylates SH2B1 in focal adhesions.  However, 
in vitro kinase assays assessing direct phosphorylation of SH2B1 by specific PKC 
isoforms, PKC-specific inhibitor assays testing the necessity of PKC to regulate SH2B1 
at focal adhesions, and RNAi experiments evaluating the effect of reducing specific PKC 
isoforms can all be employed in future studies to more completely investigate the role of 
PKC in regulating SH2B1 at focal adhesions. 
One final additional mechanism by which SH2B1 may be involved in focal 
adhesion function relates to the emerging role of focal adhesion proteins in the nucleus.  
Intriguingly, proteins (e.g. Vav, VASP, paxillin and the zyxin family of proteins (reviewed 
in (307)) have recently been observed to shuttle between focal adhesion complexes and 
the nucleus.  The mechanism of nuclear translocation for most of these proteins is 
unknown, as most do not contain an NLS.  The Carter-Su lab has shown that SH2B1 
contains both an NLS and NES, undergoes nucleocytoplasmic shuttling (106, 107) and 
binds at least one focal adhesion protein (Vav).  In preliminary experiments, I observed 
accumulation of SH2B1 in the nucleus of 3T3-F442A cells when co-expressed with 
Vav2.  It is possible, therefore, that SH2B1 translocates to the nucleus with, or alters 
the nuclear dynamics of, one or more focal adhesion proteins.  Future experiments 
utilizing photoactivatable-tagged SH2B1 can assess the ability of stimuli such as GH or 
PMA to induce SH2B1 shuttling between focal adhesions and the nucleus.  In addition, 
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blocking SH2B1 nuclear import may reveal SH2B1 as a shuttling protein for one or 
more focal adhesion proteins.  
Future Experiments 
 While I have demonstrated that the SH2 domain of SH2B1 is necessary and 
sufficient for focal adhesion localization, I have not yet determined what the SH2 domain 
binds within focal adhesions.  As mentioned above, the focal adhesion proteins talin and 
vinculin, are both phosphorylated on tyrosines lying within YXXL motifs.  Because 
SH2B1 is known to bind pYXXL, I plan to perform co-immunoprecipitation experiments 
with SH2B1 and talin or vinculin.  I have obtained cDNA encoding these proteins and 
have performed preliminary experiments.  Unfortunately, I have run into several 
technical difficulties in these preliminary experiments.  Both talin and vinculin are GFP-
tagged, and I have currently co-expressed GFP-vinculin with Flag-tagged SH2B1 in 
HeLa and 293T cells.  In each case, our anti-Flag conjugated agarose beads efficiently 
pulled down Flag-SH2B1 as well as GFP-vinculin.  However, GFP alone was also 
pulled down, indicating that the anti-Flag beads non-specifically bind GFP.  I 
subsequently expressed GFP-vinculin or GFP-talin with myc-SH2B1 in 293T cells and 
immunoprecipitated with anti-myc antibody.  In this experiment, GFP-vinculin co-
immunoprecipitated with myc-SH2B1, but also with the empty myc-vector control, again 
indicating non-specific co-immunoprecipitation.  Although it appeared that a small 
amount of GFP-talin might have co-immunoprecipitated with myc-SH2B1, the band was 
too faint to draw any conclusions.  I subsequently found by confocal microscopy that 
293T cells do not appear to have any distinguishable focal adhesions, making this cell 
line a poor choice for detecting interactions between focal adhesion proteins.  In future 
experiments, I plan to express GFP-talin or GFP-vinculin in 3T3-F442A cells with myc-
SH2B1 and perform parallel myc and GFP immunoprecipitations.  Michael Doche, a 
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fellow graduate student in the Carter-Su laboratory, is performing a tandem affinity 
purification (TAP)-tagged SH2B1 immunoprecipitation assay using 3T3-F442A cells.  It 
is possible that his experiment will also yield an SH2B1-interacting focal adhesion 
protein. 
 I am also interested in whether other SH2B family members are focal adhesion 
proteins, and therefore plan to express GFP-tagged SH2B2 and SH2B3 in 3T3-F442A 
cells and visualize them by confocal microscopy.  Because of their shared SH2 domains 
and shared ability of their SH2 domains to bind phosphorylated tyrosine 813 in JAK2, I 
expect that both proteins will localize to focal adhesions.  Also, because SH2B3 has 
been shown to interact with the focal adhesion protein, filamin, it would be interesting to 
perform co-immunoprecipitation experiments with each SH2B family member and 
filamin.   
 In Fig. 4.4, I showed that GH stimulation increases SH2B1 focal adhesion 
turnover.  I would like to determine if this effect is due to GH-induced tyrosyl 
phosphorylation of SH2B1.  Therefore, I plan to perform additional FRAP experiments 
on focal adhesions in 3T3-F442A cells expressing WT GFP-SH2B1 or GFP-SH2B1 
(Y439,494F) in serum-deprived and GH-stimulated conditions.  If GH-induced tyrosyl 
phosphorylation of SH2B1 is required for GH-induced increases in SH2B1 focal 
adhesion turnover rates, I predict that GH stimulation will be unable to increase GFP-
SH2B1 (Y439,Y494) focal adhesion turnover rates.  A positive finding would suggest 
that the SH2B1 in focal adhesions after GH stimulation has been phosphorylated by 
JAK2.  This raises the question of whether JAK2 phosphorylates SH2B1 at focal 
adhesions or whether SH2B1 that was associated with the GHR/JAK2 complex at the 
plasma membrane translocates to focal adhesions.  To address this question, SH2B1 
could be tagged with a photoactivatable tag.  Immediately prior to, or during GH 
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stimulation, the tag of either focal adhesion-localized or plasma membrane localized 
SH2B1 could be photoactivated and then traced over a period of time.  Because I have 
not been able to identify JAK2 in focal adhesions, I expect that SH2B1 that is 
associated with JAK2 at the plasma membrane will translocate to focal adhesions, thus 
accounting for the increased SH2B1 focal adhesion turnover observed upon GH 
stimulation. 
 I believe that establishing the functional significance of SH2B1 in focal 
adhesions is among the most important issues remaining for this project.  In initial 
experiments, I found 3T3-F442A cells stably overexpressing GFP-SH2B1 to spread 
significantly faster than cells stably expressing GFP alone.  Conversely, I found SH2B1 
knockout MEFs to spread significantly slower than their WT MEF counterparts.  These 
data suggest that levels of SH2B1 in focal adhesions have a general effect on focal 
adhesion function (cell spreading assays are commonly used to assess the effect of 
increasing or decreasing focal adhesion protein levels).  I attempted to repeat these 
experiments with 3T3-F442A cells transiently expressing GFP-SH2B1 (S161,165A) or 
GFP-SH2B1 (S165E).  However, I observed no differences between these cells and 
cells transiently expressing WT GFP-SH2B1 or GFP alone.  It is possible that stable 
cell lines are needed for this assay to succeed.  
 To more directly assess the contribution of focal adhesion localized SH2B1 to 
GH-induced responses, I will test the effect of WT, (S161,165A) and (S165E) SH2B1 
on GH-induced cell migration.  In unpublished data, Dr. Hsiao-Wen Su, a postdoctoral 
fellow in the Carter-Su laboratory, has recently shown WT SH2B1 to enhance GH-
induced cell motility in RAW 264.7 macrophages.  In addition, she found that SH2B1 
(S161,165A) inhibits GH-induced motility while SH2B1 (S165E) enhances basal motility 
to levels above that of GH inducement in these same cells.  These results are consistent 
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with what I would predict based on my characterization of SH2B1 as a focal adhesion 
protein.  However, focal adhesions are difficult to visualize in RAW 264.7 macrophages, 
and therefore, characterization of SH2B1 focal adhesion dynamics in these cells may 
not be possible.  I have attempted to repeat these experiments in 3T3-F442A cells using 
transwell migration assays.  However, I have been unable to observe GH-induced 
motility in this model.  In fact, using live cell confocal microscopy, I failed to detect any 
motility in 3T3-F442A cells in response to GH, EGF or FGF stimulation over a period of 1 
hour.  This indicates that 3T3-F442A cells are not the optimal model to assess effects of 
SH2B1 on cell motility. However, while performing the live cell confocal microscopy 
experiments, I observed GH, EGF and FGF to induce lamellipodia extension and 
retraction as well as changes in overall cell morphology. Formation and dissolution of 
focal adhesions accompanied these processes.  Cells expressing GFP, WT GFP-
SH2B1 and GFP-SH2B1 (S165E) appeared to all respond similarly. However, cells 
expressing GFP-SH2B1 (S161,165A) appeared to be unable to extend lamellipodia or 
change their morphology as fluidly as the other cells.  In fact, I commonly observed 
GFP-SH2B1 (S161,165A) expressing cells attempting to retract a cellular extension, 
and in the process, tear themselves apart.  Interestingly, focal adhesions remained at 
the ends of where the extension had been before the cells were torn.  This raises the 
possibility that these cells were unable to properly dissolve focal adhesions, a function 
that is necessary for cellular motility.  I would like to repeat the transwell assays in the 
MCF-7 model that stably expressed GH.  These cells are known have increased motility 
compared to control MCF-7 cells (308).  I predict that results in these cells will be similar 
to those in the RAW 264.7 macrophage model in part based on some results that I did 





The overall goal of my thesis research was to answer some of the important 
remaining questions in GH signal transduction.  In particular, I wanted to identify the 
primary kinase(s) responsible for transducing the GH signal in 3T3-F442A and H4IIE 
cells and then more fully characterize the role of the adaptor protein, SH2B1, in GH-
induced regulation of the actin cytoskeleton.  I have shown that JAK2 is primarily 
responsible for GH-induced activation of Stat1, Stat3, Stat5, ERK1/2 and Akt in both 
3T3-F442A and H4IIE cells.  I have additionally shown that a major component of the 
actin cytoskeleton, II1-spectrin, is a novel SH2B1 binding partner that is 
phosphorylated by JAK2 in an SH2B1-dependent manner.  I have further demonstrated 
that GH stimulation of 3T3-F442A cells induces the formation of a II-
spectrin/SH2B1/JAK2 complex, and show that GH stimulation of H4IIE cells results in a 
redistribution of II2-spectrin from cell-cell contacts to the cytoplasm.  Finally, I have 
identified SH2B1 as a novel focal adhesion protein whose focal adhesion turnover 
dynamics are regulated by GH stimulation in 3T3-F442A cells.  I have also demonstrated 
that PMA stimulation of 3T3-F442A cells induces a rapid redistribution of SH2B1 out of 
focal adhesions.  I have provided evidence suggesting that phosphorylation of two 
serines within SH2B1 regulates both this PMA-mediated event, SH2B1 turnover at 
focal adhesions, and overall focal adhesion number.  SH2B1 is an adaptor protein in 
several signal transduction pathways, and therefore we predict that SH2B1 localization 
to focal adhesions and the SH2B1/II-spectrin interaction are relevant to many other 
ligands.  In addition, because SH2B1 localizes to focal adhesions in the absence of any 
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